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RESUM 
La hipertensió arterial es considera un dels problemes de salut pública 
més importants en la nostra societat. El tractament d’aquesta patologia 
es basa en una combinació de canvis en l’estil de vida i tractament 
farmacològic. No obstant, per aquells pacients en fases de 
desenvolupament de la malaltia i que encara no necessiten tractament 
farmacològic, l’ús de nutracèutics o aliments funcionals amb propietats 
antihipertensives està rebent molta atenció ja que podria ser una bona 
estratègia per evitar el desenvolupament de la hipertensió.   
En aquest sentit, aquesta tesi té com a objectiu principal l’obtenció de 
pèptids antihipertensius a partir de la hidròlisi de proteïnes de pota de 
pollastre, un subproducte de la indústria avícola. Així, mitjançant la 
hidròlisi de la proteïnes de pota de pollastre sota condicions d’hidròlisi 
optimitzades, es va obtenir un hidrolitzat, Hpp11, que mostrava efecte 
antihipertensiu després d’una administració aguda i crònica. 
L’hidrolitzat Hpp11 administrat agudament produïa l’efecte 
antihipertensiu mitjançant la reducció de l’activitat de l’enzim 
convertidor d’angiotensina, mentre que després d’una administració 
crònica, l’efecte antihipertensiu estava mediat per una millora en la 
funció endotelial. Addicionalment es van caracteritzar els pèptids 
presents en l’Hpp11 i dos d’ells, AVFQHNCQE i QVGPLIGRYCG van 
mostrar efecte antihipertensiu. En particular, el pèptid AVFQHNCQE 
no era absorbit i produïa el seu efecte antihipertensiu mitjançant la 
interacció amb receptors opioides presents en el tracte 
gastrointestinal. La interacció amb aquests receptors desencadenava 
un efecte antihipertensiu mediat pel vasodilatador òxid nítric, del qual 
se’n veia augmentada la seva biodisponibilitat gràcies a l’efecte 
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antioxidant i de millora de la funció endotelial que també mostrava el 
pèptid.  
Els resultats d’aquesta tesi obren les portes a l’ús del l’hidrolitzat i dels 
pèptids antihipertensius obtinguts en nutracèutics o aliments 
funcionals que permetrien el control i prevenció del desenvolupament 
de la hipertensió.  
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RESUMEN 
La hipertensión arterial se considera uno de los problemas de salud 
pública más importante de nuestra sociedad. El tratamiento de esta 
patología se basa en una combinación de cambios en el estilo de vida y 
tratamiento farmacológico. No obstante, para esos pacientes que se 
encuentran en fase de desarrollo de la enfermedad y que aún no 
requieren de tratamiento farmacológico, el uso de nutracéuticos o 
alimentos funcionales con propiedades antihipertensivas está 
recibiendo mucha atención ya que podrían ser una buena estrategia 
para evitar el desarrollo de la hipertensión.  
En este sentido, esta tesis tiene como objetivo principal la obtención 
de péptidos antihipertensivos a partir de la hidrólisis de proteínas de la 
pata de pollo, un subproducto de la industria avícola. Así, mediante la 
hidrólisis de las proteínas de la pata de pollo bajo condiciones de 
hidrólisis optimizadas se obtuvo un hidrolizado, Hpp11, que mostró 
efecto antihipertensivo después de una administración aguda y 
crónica. El hidrolizado Hpp11 administrado agudamente producía el 
efecto antihipertensivo mediante la reducción de la actividad de la 
enzima convertidora de angiotensina, mientras que después de su 
administración crónica, el efecto antihipertensivo estaba mediado por 
una mejora en la función endotelial. Adicionalmente se caracterizaron 
los péptidos presentes en Hpp11 y dos de ellos AVFQHNCQE y 
QVGPLIGRYCG mostraron efecto antihipertensivo. En particular, el 
péptido AVFQHNCQE no era absorbido y producía su efecto 
antihipertensivo mediante la interacción con receptores opioides 
presentes en el tracto gastrointestinal. La interacción con estos 
receptores desencadenaba  un efecto antihipertensivo mediado por el 
vasodilatador óxido nítrico, del cual se veía aumentada su 
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biodisponibilidad gracias al efecto antioxidante y de mejora de la 
función endotelial que también mostró el péptido.   
Los resultados de esta tesis abren las puertas al uso del hidrolizado y 
de los péptidos antihipertensivos obtenidos en nutracéuticos o 
alimentos funcionales que permitirían el control y prevención del 
desarrollo de la hipertensión.  
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SUMMARY 
Hypertension is considered one of the most important public health 
problems in our society. The treatment of this pathology is based on 
lifestyle modifications and pharmacology treatment. However, for 
those patients developing hypertension, whose blood pressure is not 
high enough to warrant pharmacology treatment, the use 
nutraceuticals or functional foods with antihypertensive properties 
have attracted considerable interest. These antihypertensive natural 
agents could be a good strategy to avoid the development of 
hypertension. 
In this regard, this thesis aims to obtain antihypertensive peptides 
through the hydrolysis of chicken foot proteins, a by-product from 
poultry industries. Thus, through the hydrolysis of chicken foot 
proteins, it was obtained the hydrolysate Hpp11, exerting 
antihypertensive effect after acute and chronic administration. Hpp11 
administered acutely produced its antihypertensive effect by reducing 
the activity of angiotensin converting enzyme, while when 
administered chronically its antihypertensive effect was mediated by 
an improvement in the endothelial function. Additionally, the peptides 
present in Hpp11 were characterised and two of them, AVFQHNCQE 
and QVGPLIGRYCG, showed antihypertensive effect. In particular, the 
peptide AVFQHNCQE was not absorbed and produced its 
antihypertensive effect through the interaction with opioid receptors 
from the gastrointestinal tract. The interaction with these receptors 
leaded to a nitric oxide-mediated antihypertensive effect. Moreover, 
the peptide contributed to enhance nitric oxide by exhibiting 
antioxidant effect and improving endothelial function.  
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The results of this thesis open the doors to the use of the 
antihypertensive hydrolysate and peptides in nutraceuticals or 
functional foods for the control and prevention of hypertension. 
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LIST OF ABBREVIATIONS 
 
ACE   Angiotensin converting enzyme 
ACE2  Angiotensin converting enzyme 2 
ACEI                 Angiotensin converting enzyme inhibitory 
Ang  Angiotensin 
Arg-1  Arginase 1 
AT1   Angiotensin II type 1 receptor 
AT2  Angiotensin II type 2 receptor 
BK  Bradykinin 
BP  Blood pressure 
BW  Body weight 
CAF  Cafeteria 
cAMP  Cyclic adenosine monophosphate 
cGMP  Cyclic guanosine monophosphate 
COX  Cyclooxygenase 
CV  Cardiovascular 
CVD  Cardiovascular disease 
DBP  Diastolic blood pressure 
EC  Endothelial cells 
ECE              Endothelin converting enzyme  
eNOS  Endothelial nitric synthase 
ET  Endothelin 
ETA  Endothelin-1 receptor A 
ETB  Endothelin-1 receptor B 
FAD  Flavin adenine dinucleotide 
FMN  Flavin mononucleotide 
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GI  Gastrointestinal 
GIT  Gastrointestinal tract 
GSH  Reduced glutathione 
HPLC  High performance liquid chromatography 
HTN  Hypertension 
Klf-2  Krupple like factor 2 
L-NAME N(ω)-monomethyl-L-arginine 
MetS  Metabolic syndrome 
NADPH Nicotinamide adenine dinucleotide phosphate 
NO  Nitric oxide 
NOS  Nitric oxide synthase 
O2-  Superoxide 
PGI2  Prostaglandin I2 or prostacyclin 
RAAS  Renin-angiotensin-aldosterone system 
ROS  Reactive oxygen species 
SBP  Systolic blood pressure 
SD  Sprague-Dawley  
SHR  Spontaneously hypertensive rats 
Sirt-1  Silent information regulator factor 2 related enzyme 1 
VSMC  Vascular smooth muscle cell 
WKY  Wistar Kyoto  
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Hypertension (HTN) is the major modifiable risk factor for all-
increased risk of cardiovascular disease (CVD) (1). This pathology has no 
identifiable specific cause and is currently understood as a 
multifactorial disease comprising genetic, environmental and 
behavioural factors (2). In this sense, HTN usually clusters with other 
cardiovascular (CV) risk factors such as obesity, insulin resistance, 
diabetes and hyperlipidaemia (3), which all coexist in metabolic 
syndrome (MetS). The effective HTN preventive approaches include 
lifestyle changes, primarily weight loss, diet, and exercise, and the 
treatment comprises the appropriate use of pharmacological agents (4). 
In recent years, bioactive peptides from proteins have emerged as a 
potential alternative in the prevention and management of HTN (5). 
These bioactive peptides, administered as functional foods and 
nutraceuticals, have attracted considerable interest as a potential 
alternative treatment for prehypertensive patients, whose blood 
pressure (BP) is mildly high but not high enough to warrant the 
prescription of BP-lowering medications (6).  
1. BLOOD PRESSURE 
Blood pressure (BP) is the pressure that is exerted by the blood 
upon the walls of the blood vessels, especially arteries, and that varies 
depending on the muscular efficiency of the heart, the blood volume 
and viscosity, the state of the vascular wall and the age and health of 
the individual. BP is conventionally measured by systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) determinations. SBP 
is defined as the maximum BP during contraction of the ventricles 
                                                              INTRODUCTION 
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while the minimum BP is DBP, recorded just prior the next contraction. 
The World Health Organization- International Society of Hypertension 
the European Society of Hypertension and the European Society of 
Cardiology guidelines for adults class optimal BP as less than 120 
mmHg for SBP and 80 mmHg for DBP, while recordings over 120/80 
mmHg and up to 139/89 mmHg are ranged as normal to high normal 
BP or prehypertension, depending on the coexisting medical 
conditions. High or elevated BP increases the risk to suffer from a CV 
event (7,8). In this sense, HTN or long term high BP is defined as BP 
values equal or over 140/90 mmHg and is considered one of the main 
risk factors for CVD (Figure1) (9).  
 
Figure 1.  Classification of hypertension based in the European Society of Hypertension 
and the European Society of Cardiology (8). 
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1.1. CARDIOVASCULAR SYSTEM  
The CV system conveys blood through vessels to the different 
parts of the body carrying nutrients and oxygen and removing carbon 
dioxide and other wastes. The blood is pumped by the heart into and 
through the vascular system to and from all parts of the body.  The 
vascular system consists of arterial, capillary and venous components, 
that, as in any biologic system, their structure and function are closely 
related (7).  
 
Figure 2. Schematic representation of the vascular system. Adapted from Sandoo et al. 
2010 (10). 
The blood is conducted by the conductance arteries from the heart to 
muscular or distribution arteries. The heart forces blood into these 
vessels in pulsating waves. Then, blood flows to the arterioles, or 
resistance small arteries, which have the distinction to contribute the 
most to BP and act as a control valves through which blood is released 
into the capillaries (Figure 2) (11). In the capillaries is where oxygen, 
nutrients and wastes are exchanged between the blood and the 
tissues. Thus, capillaries are the ultimate destination of arterial blood 
from the heart and the starting point for flow of venous blood back to 
the heart.  
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As mentioned above, in the CV system the heart pumps blood into the 
vessels in pulsating waves. In consequence, these vessels possess 
strong and elastic walls to guarantee fast and efficient flow to the 
target organs. The wall of blood vessels consists of three layers: tunica 
intima, tunica media and tunica adventitia (Figure 3).  
The tunica intima is the most inner layer, in contact with the blood. It is 
the thinnest layer of the vascular wall and consists of a single sheet of 
endothelial cells (EC) or the endothelium covered by a surface of 
elastic tissues, relevant for the exchange of molecules in capillaries. 
The endothelium is the main structure in tunica intima, which not only 
acts as a physical barrier to separate the blood from the surrounding 
tissue but also participates in the regulation of coagulation, 
inflammation and vessel tone (12). Then it is found the tunica media, 
which consists of smooth muscle cells (VSMC) intermingled with 
elastic fibres. VSMC are controlled by sympathetic vasomotor nerve 
fibres of the autonomic nervous system and by endothelial vasodilator 
molecules such as nitric oxide (NO) or prostacyclin (PGI2), and by 
vasoconstrictors, including endothelin-1 (ET-1) or angiotensin II (Ang II). 
Interestingly, the tunica media in conducting arteries is relatively thin 
and that allows the tunica intima to move independently from the other 
layers. The elastic fibres that compose tunica media expand with the 
increase of SBP and contract when the ventricles relax, pushing the 
blood forward. Surrounding the tunica media, there is an elastic layer 
and immediately after the tunica adventitia, the outermost layer, is 
found. The tunica adventitia is composed by collagenous and elastic 
fibres and protects the vessels from overexpansion. It is also 
characteristic of this layer the presence of small blood vessel, the vasa 
vasorum, which supply nutrients to the interior layers of the walls of 
arteries and veins. In veins, which function is to conduct blood from 
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the peripheral tissues to the heart, the tunica adventitia is the biggest 
layer conferring more distension to expand and contract due to 
changes in volume and BP (7).  
 
Figure 3. Transverse section of an artery. Adapted from Encyclopaedia Britannica  (13). 
 
1.2 BLOOD PRESSURE REGULATION 
The maintenance of physiological BP values is crucial. While a 
decrease in BP could decrease blood flow and oxygen delivery to the 
peripheral tissues, an increase in BP could induce devastating end-
organ damage (14).   
 
BP is influenced by several parameters of the CV system and their 
maintenance involves a complex interaction of various elements. 
Among these, it is found the renin-angiotensin-aldosterone system 
(RAAS) and the natriuretic peptides, which induce the excretion of 
sodium from the kidneys regulating the vascular tone. Furthermore, 
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the endothelium, which release vasoactive substances controlling the 
vascular tone or the sympathetic nervous system, inducing Na+ 
reabsorption, and the immune system which may contribute to reduce 
or increase BP depending on released type of inflammatory molecule 
(1), are demonstrated to be involved in BP control (Figure 4).  
 
Figure 4. The major neuroendocrine systems involved in the regulation of blood 
pressure. Neurohumoral, immune and organ systems involved in the maintenance of 
blood pressure. Na+, sodium; RAAS, renin–angiotensin–aldosterone system; SNS, 
sympathetic nervous system; Treg, regulatory T. Extracted from Oparil et al. 2018 (1). 
 
1.2.1. THE RENIN–ANGIOTENSIN–ALDOSTERONE SYSTEM  
The RAAS plays a fundamental role in the homeostatic control of BP, 
tissue perfusion and extracellular volume. This hormonal cascade 
system begins with the synthesis of pro-renin (inactive) by 
juxtaglomerular cells in the kidney and mature renin (active) is formed 
by proteolytic removal of a 43-amino acid pro-segment peptide from 
the N-terminus of pro-renin. Renin is released from the granules of 
juxtaglomerular cells into the systemic circulation in response to 
various stimuli including changes in renal perfusion pressure, changes 
in delivery of NaCl, sympathetic nerve stimulation or negative 
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feedback by Ang II (15). Renin regulates the initial, rate-limiting step of 
the RAAS by cleaving the N-terminal portion of angiotensinogen (16), a 
protein hormone released mainly by the liver, to form angiotensin I 
(Ang I). Inactive decapeptide Ang I is hydrolysed by angiotensin-
converting enzyme (ACE), which removes the C-terminal dipeptide 
His-Leu to form the octapeptide Ang II, a biologically active potent 
vasoconstrictor. ACE is mainly produce and found in high 
concentrations in the lung. However, it has also been described in 
kidneys, the heart, some segments of the digestive tract, the adipose 
tissue and the brain (17–20).  
Besides of Ang I breakdown into Ang II, ACE metabolizes other 
peptides, including the vasodilator peptides bradykinin (BK) and 
kallidin, to inactive metabolites (15). Thus, the enzymatic activity of 
ACE results in increased vasoconstriction and decreased vasodilation.  
 
Regarding to Ang II, it is considered the primary effector hormone of 
the RAAS. This hormone can act either as a systemic hormone or as 
locally produced factor stimulating the adrenals to produce 
aldosterone, which affects BP through regulating the amount of 
sodium  by increasing or decreasing the total amount of volume in the 
extracellular fluid (21). In addition, Ang II contributes to the regulation 
of BP by influencing VSMC and sodium and volume homeostasis (16). 
The Ang II effects are mediated via two G-protein-coupled receptors, 
Ang receptor type 1 (AT1) and Ang receptor type 2 (AT2) that act in 
opposite directions mainly resulting in vasoconstriction when AT1 is 
activated and in vasodilation when Ang II binds to AT2 (22). As 
mentioned, the AT1 receptor has been shown to mediate most of the 
physiological and pathophysiological actions of Ang II, and this 
subtype is predominantly expressed in CV cells, such as VSMC. The 
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interaction of Ang II with this receptor results in the activation of a 
number of cytoplasmic signalling pathways, which can contribute to 
vasoconstriction, sodium reabsorption and aldosterone secretion in 
kidney and adrenal glands, sympathetic activation and cell growth, 
among others (23,24). On the other hand, AT2 stimulation results in 
vasodilation of vessels and regulates many processes implicated in 
vascular pathophysiology, including the inhibition of cell growth or the 
apoptosis of vascular cells (25). In humans, AT1 receptor is widely 
expressed at relatively constant levels in adults, while AT2 receptor is 
mainly present during foetal development and decreases rapidly after 
birth in most tissues (26).  
 
Figure 5. Schematic overview of the renin–angiotensin-aldosterone system (RAAS) and 
its intervening compounds. ACE: angiotensin converting enzyme; ACE2: angiotensin 
converting enzyme; Ang: angiotensin; AT1: Angiotensin II type 1 receptor; AT2: 
angiotensin II type 2 receptor; MAS: Mas receptor. 
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Ang II levels are also controlled by the recently identified angiotensin-
converting enzyme 2 (ACE2), which is responsible for the conversion of 
Ang II to angiotensin (1–7), acting as a negative regulator of Ang II 
production. Angiotensin-(1-7), produced through hydrolysis of Ang II, 
interacts with the Mas receptor triggering vasodilator, anti-
proliferative, anti-fibrotic, and anti-thrombotic effects (27). Thus, the 
balance between ACE and ACE2 is important in the regulation of Ang 
II levels (28). 
 
The classical concept of RAAS is of a blood hormonal cascade, whose 
final product, Ang II, plays an endocrine role in the maintenance of BP 
and electrolyte, as well as, fluid balance (29).  
 
1.2.2. ENDOTHELIAL FUNCTION 
The endothelium is a multifunctional endocrine organ which is 
part of the tunica intima, placed between the vessel walls and the 
circulating blood, and has a key role in vascular homeostasis (30). The 
endothelium controls the fluidity and coagulation of the blood through 
releasing factors that regulate platelet activity, the clotting cascade, 
and the fibrinolytic system (31).  Additionally, the endothelium has the 
capacity to produce cytokines and adhesion molecules that regulate 
the inflammatory process. However, its main action is to regulate the 
peripheral vasomotor tone and BP through the release of several 
vasodilatory factors, such as NO or PGI2, and vasoconstrictor factors 
including ET-1, among others (32). In Figure 6 shows the most 
important endothelium-derived factors.  
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Figure 6. Endothelial-derived vasoactive factors. ACE: angiotensin converting enzyme; 
Ang: angiotensin; AT1: Angiotensin II type 1 receptor; AT2: Angiotensin II type 2 
receptor; cAMP: cyclic adenosine monophosphate; cGMP: cyclic guanosine 
monophosphate; COX: cyclooxygenase; ECE: endothelin converting enzyme; EDHF: 
endothelial-derived hyperpolarizing factors; ET: endothelin; ETA: endothelin receptor 
A; ETB: endothelin receptor B; eNOS: endothelial nitric oxide synthase; L-Arg: L-
arginine; NADPH ox: nicotinamide adenine dinucleotide phosphate-oxidase; NO: nitric 
oxide; PGI2: prostaglandin I2 or prostacyclin; PGI2S: Prostaglandin I2 synthase; ROS: 
reactive oxygen species; Sirt-1: Sirtuin-1; KLF-2, Krupple like factor 2.   
 
1.2.2.1. ENDOTHELIAL NITRIC OXIDE 
Endothelial NO is considered the most important endothelium-
dependent factor which plays a key role in vasodilation, inflammation 
and oxidative stress (33). Moreover, NO has a number of other 
beneficial roles in the vessel wall, including inhibition of vascular 
smooth muscle proliferation, reduction of platelet aggregation, 
reduction of expression of adhesion molecules, inhibition of lipid 
oxidation and regulation of apoptosis (34). 
 
In mammals, NO can be generated by three different isoforms of the 
enzyme NO synthase (NOS): neuronal NOS, inducible NOS and by 
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endothelial NOS (eNOS) (35). All NOs isoforms use L-arginine as the 
substrate and molecular oxygen and nicotinamide adenine 
dinucleotide phosphate (NADPH) as co-substrates to produce NO. 
Flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and 
(6R-)5,6,7,8-tetrahydro- L-biopterin are cofactors of all isozymes (36).  
 
Regarding eNOS, this isozyme is mainly expressed in EC, although it 
has also been described in cardiac myocytes, platelets, certain neurons 
of the brain, in syncytio-trophoblasts of the human placenta and in 
kidney tubular epithelial cells (37).  
 
eNOS is synthetized as an inactive form which is bound to the protein 
caveolin in small invaginations of the cell membrane. Under different 
stimuli, including an increase in intracellular Ca2+, eNOS can be 
activated to produce NO. Thus, rises in intracellular Ca2+ induce 
structural changes in calmodulin that allows its binding to eNOS. 
eNOS can be also activated by NO agonists, such as BK, acetylcholine, 
adenosine tri-phosphate or di-phosphate, which can influence the 
detachment of eNOS from caveolin by releasing Ca2+ from the 
endoplasmic reticulum (10). 
 
As mentioned, eNOS can also be activated by other stimuli than a rise 
in intracellular Ca2+. In this sense, the shear stress, which results from 
increased blood flow in the vessel, also results in the activation of 
eNOS. This activation is mediated by protein kinase A, which produces 
the activation of eNOS through the phosphorylation eNOS residue Ser-
1177 (38). In addition, shear stress can also activates specialised Ca2+-
activated K+ channels on the endothelial cell surface, causing K+ efflux 
and Ca2+ influx into the cell (39).  
UNIVERSITAT ROVIRA I VIRGILI 
HYDROLYSATES AND PEPTIDES FROM CHICKEN FOOT PROTEINS TO MANAGE HYPERTENSION 
Anna Mas Capdevila 
 
36 
 
Once eNOS is active, it transfers electrons from NADPH, via the flavins 
FAD and FMN, and substrate L-arginine is oxidized to L-citrulline and 
NO (40). The released NO diffuses to the surrounding VSMC and can 
act on a number of target enzymes and proteins. The most important 
physiological signalling pathway stimulated by NO is the activation of 
soluble guanylyl cyclase and the generation of cyclic guanosine 
monophosphate (cGMP). This molecule activates protein kinase G, the 
primary downstream target, which activates the myosin light-chain 
phosphatase. Myosin light-chain phosphatase dephosphorylates 
smooth muscle myosin leading to the relaxation of muscle layer and 
consequent vasodilatation (35,41).  
 
Although it is appropriate to refer to eNOS as constitutive in the 
endothelium, maintaining basal level of eNOS protein, their expression 
is subjected to modest, but likely important, degrees of regulation. 
mRNA eNOS expression can be modulated by shear stress and by 
transforming growth factor-beta 1, among others (34). In this sense, 
deacetylase Sirtuin 1 (Sirt-1) has also been shown to regulate vascular 
tone via the activation of eNOS (42). Similarly, the transcription factor 
Krupple like factor 2 (Klf-2) is known to upregulate eNOS (43).   
 
Regulation of NO production in the endothelium 
As mentioned above, the production of NO through eNOS can be 
modulated by different molecular mechanisms. One of the most 
relevant is the Sirt-1 pathway. Sirt-1 is a nicotinamide adenine 
dincleotide-dependent deacetylase, highly expressed in the 
endothelium, involved in the regulation of aging, cell cycle regulation, 
apoptosis and inflammation (44). Sirt-1 plays a fundamental role in 
regulating endothelial NO and endothelium-dependent vascular tone 
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by eNOS deacetylation. In addition, many studies have demonstrated 
that Sirt-1 may inhibit endothelial apoptosis and improve vascular 
endothelial function by increasing eNOS expression, thereby exerting 
anti-atherosclerotic effects (45,46).  
 
Despite the described Sirt-1 protective effects, the molecular 
mechanisms involved in these protective effects remain largely 
unknown. However, studies with resveratrol demonstrated that Klf-2 is 
crucial for the activation of Sirt-1. In this regard, it has been 
demonstrated that Klf-2 is essential in the shear stress-induced 
upregulation of eNOS (47). In fact, this transcription factor is 
considered a nuclear effector of the favourable effects of flow on 
endothelial gene expression and function (48).  
Given the important role of Sirt-1 in maintaining vascular endothelial 
homeostasis, Sirt-1 and their activators have been investigated 
considering their potential as a target in pharmacological therapies for 
CVD treatment (49).  
1.2.2.2. PROSTACYCLIN 
 
Another known vasodilator factor is PGI2 which is produced by 
cyclooxygenase (COX) enzyme in the EC. There are two isoforms of 
COX, the endothelial-constitutive COX-1 and COX-2, only expressed 
when the endothelium is damaged and exposed to inflammatory 
cytokines (50). PGI2 is released under similar stimuli than those 
producing NO release. Under these stimuli, exogenous and 
endogenous arachidonic acid is transformed by COX to prostaglandin 
H2, which is then transformed into PGI2 by prostacyclin synthase (51). 
PGI2 binds to the prostacyclin receptors located in VSMC and 
produces de activation of adenylate cyclase which induces the 
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synthesis of cyclic adenosine monophosphate (cAMP). This molecule 
activates protein kinase A triggering the relaxation of the smooth 
muscle in the same way as it does for NO (52).  
1.2.2.3.  ENDOTHELIN-1 
ET-1 is a potent vasoconstrictor peptide which is expressed in EC. ET-1 
is produced by endothelin converting enzyme under stimuli produced 
by inflammatory cells, such as interleukins and tumour necrosis factor 
α, among others (53). Contrary, its production is decreased in response 
to NO or PGI2 (54). ET-1 mediates vasoconstriction and proliferation by 
interacting with G protein-coupled membrane- bound ET-1 type A 
(ETA) and ET-1 type B2 (ETB2) receptors on VSMC. When ET-1 binds to 
ETA or ETB2 receptors, smooth muscle Ca2+ channels open, allowing 
the entrance extracellular Ca2+ into the cell which causes 
vasoconstriction. Interestingly, EC also present ET-1 receptors, in this 
case ETB1. Activation of the ETB1 receptor on endothelium induces 
vasodilation by inducing eNOS. In consequence, there are a release of 
NO and an activation of PGI2 synthesis (54). Thus, ET-1 effect is 
determined on the receptor localisation and the balance between ETA 
and ETB (1 and 2) receptors. Nevertheless, under physiological 
conditions, ET-1 main effect is vasoconstriction mediated by the ETA 
receptor, which is partly counteracted by ETB1 receptor-mediated NO 
release (55). In addition of ET-1 vasoactive effects, ET-1 also causes 
inflammation and VSMC proliferation in the vessels (56). 
 
Therefore, a healthy endothelium is characterised to maintain normal 
vasculature tone and blood fluidity through a balance in the secretion 
of these endothelium-derived relaxing and contracting factors and 
presenting low production of pro-inflammatory factors (57,58). 
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1.2.3. ENDOTHELIAL DYSFUNCTION 
The endothelium homeostasis can be altered under CV risk 
factors including smoking, aging, hypercholesterolemia, 
hyperglycaemia or HTN. The presence of these risk factors could result 
in a chronic inflammatory process, the loss of anti-thrombotic factors 
and the increase of vasoconstrictor and pro-thrombotic factors leading 
to the development of endothelial dysfunction (59). Thus, endothelial 
dysfunction is mainly characterized by the reduction of the 
bioavailability of vasodilators, particularly NO, and/or an increase in 
endothelium-derived contracting factors, such as ET-1. In this regard, 
the reduction in NO bioavailability it is known to be due to reduced 
eNOS protein levels, reduced eNOS enzymatic activity and the 
uncoupling of eNOS activity leading to enhanced production of 
superoxide, among others (60). In addition, in endothelial dysfunction, 
elevated reactive oxygen species (ROS) levels, deriving both from 
mitochondria and NADPH oxidase (NOX) activity, contribute to the 
reduction in NO bioavailability. This reduction is partly caused by the 
reaction of ROS with NO to form peroxynitrite, a key molecule which 
can initiate many pro-atherogenic events (61,62). 
 
Moreover, it has been described that in endothelial dysfunction the 
individuals present an upregulation in ETB2 receptors in VSMC while 
ETB1 receptors on the EC are downregulated, resulting in an enhance 
in ET-1 mediated vasoconstriction (63).  
 
As mentioned, increased ROS production is one of the main factors 
that contribute to the development of endothelial dysfunction. 
Multiple ROS are produced in the vascular wall, such as O
.
−2, H2O2 and 
.
OH, being the mitochondria the major source. However, in the 
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endothelium, NOX are the main ROS source. These enzymes, under 
physiological concentrations, have important functions including host 
defence, post-translational processing of proteins, cellular signalling, 
regulation of gene expression, and cell differentiation (64). However, 
under pathological conditions these enzymes can cause cellular injury 
and death. Pathological states lead NOX to produce an excess of ROS 
that can injure vascular tissue by multiple mechanisms. For example, 
ROS can react with vasoactive substances and impair responses to 
vasodilators (65). 
 
ROS generation is generally a cascade of reactions that starts with the 
production of the free radical superoxide anion (O2
·
) which is the 
responsible of the formation of other reactive species. In the 
endothelium, NOX catalyse the reduction of molecular oxygen to O2
·
 
by using NADPH as electron donor (64). In particular, from the five 
NOX isoforms described, NOX2 and NOX4 are those producing ROS in 
the endothelium, being NOX4 the most abundant isoform (66). NOX4 
appears to generate H2O2, although the primary product is probably 
O2·−, which is rapidly dismutated to H2O2. This isoform produces 
moderate levels of ROS that are required for normal redox signalling. 
However, under pathological conditions, NOX4 can promote the 
formation of a pro-thrombogenic endothelial phenotype. Therefore, 
NOX4-mediated ROS production can contribute both to vascular 
homeostasis or to vascular injury depending on the intracellular 
conditions (67).  
 
Although the pathological role of NOX4 still remains unclear, its 
implication in HTN has been demonstrated, suggesting that the 
UNIVERSITAT ROVIRA I VIRGILI 
HYDROLYSATES AND PEPTIDES FROM CHICKEN FOOT PROTEINS TO MANAGE HYPERTENSION 
Anna Mas Capdevila 
 
41 
 
increase in Ang II could be the responsible of the overactivation of 
NOX4 and consequent increased ROS production (68).  In this sense, 
Nishiyama et al. described significant increased NOX4 mRNA levels in 
spontaneously hypertensive rats (SHR) when compared to  
normotensive Wistar-Kyoto rats (WKY) (69). 
 
Nevertheless, recent studies demonstrated that NOX4 could also 
present protective effects, possibly through NOX4-derived H2O2, 
which may act as a vasodilator in some vascular beds (66). In addition, 
a vasoprotective effect of NOX4 has been reported by enhancing 
eNOS and, consequently, NO availability (70). Thus, NOX4 has a 
relevant role in the endothelium due to its high level of expression and 
its constitutive activity in the vascular homeostasis. However, the 
physiological and pathophysiological roles of NOX4 are still on debate 
(71). 
 
Therefore, the presence of CV risk factors impair the balance in the 
vasodilation and vasoconstrictors release, resulting in a dysfunctional 
endothelium which has pathophysiologic importance in the 
atherosclerotic process and in CV diseases including HTN (72).  
 
2. HYPERTENSION 
HTN or high BP (values over 140/90 mmHg) is a leading global 
health risk and is the most important preventable cause of heart 
disease and stroke. According to the latest reports, globally, 874 
million adults have HTN which approximately represents that one in 
four adults suffer from HTN (1). Furthermore, 3.5 billion suffer from 
prehypertension (1). Thus, considering this epidemiological data, 
researchers have predicted the relative increase of 24 % in the 
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prevalence of HTN in developed countries and of 80 % in developing 
countries from 2000 to 2025 (73). Remarkably, the overall sex- and 
age-adjusted prevalence of HTN was higher in the European countries 
(44 %) than in the two North American countries (Canada and EEUU) 
(28 %) (74). Regarding Spain, the prevalence of HTN is high, around 40 
% and HTN illness doubled the number of deaths from 2005 to 2015 
(75). Interestingly, around 38 % of HTN patients have still not been 
diagnosed (76). In this regard, the lack of symptoms in early HTN states 
is often the reason why HTN patients are not aware of their condition. 
Indeed HTN is often referred to as the ‘silent killer’ (77).  
This rapid increase in HTN prevalence will lead to dramatic rises in the 
incidence of CVD and their consequences, resulting in an 
overwhelmed health care system. The increase in HTN prevalence is 
attributed to an unprecedented increase in obesity and lifestyle 
changes in developed countries (78). From this prevalence, it is evident 
that HTN is an important public health challenge considering that their 
complications represent the major causes of morbidity and mortality.  
HTN development is due to specific causes in a small fraction of cases 
(known as secondary HTN), but in around 90 % of patients, its etiology 
is unknown (essential HTN) (2). HTN is considered a multifactorial 
disease resulting from the combination of genetic, environmental, and 
behavioural factors. The HTN genetic predisposition in combination 
with environmental factors such as smoking or drinking, unhealthy 
diet, physical inactivity or obesity and overweight contribute to the 
pathogenesis of this disease’s increase (79). In addition, ethnicity, age, 
gender or family history of high BP are considered non modifiable risk 
factors for essential HTN (80) (Figure 7).  
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Figure 7. Representation of modifiable risk factor and non-modifiable risk factors 
contributing to the HTN development.  
 
Although HTN consequences differ depending on its severity, the 
patient age and global medical condition, this pathology is considered 
chronic and in the long-term could cause end-organ damage. Thus, 
HTN related end-organ damage include CVDs such as stroke, 
accelerated coronary and systemic atherosclerosis, heart failure or 
chronic kidney disease which result in the most severe situations, in 
increased morbidity and mortality (81).  
Therefore, the ultimate goal of HTN treatment is CVD risk reduction. 
Currently, the strategy to reduce CVD risk in HTN patient include 
lifestyle modifications (healthy diet and low-salt diet, exercise) and, 
depending on HTN stage, appropriate drug therapy (82).  In addition, in 
diet derived-HTN or HTN associated with MetS, its treatment has 
demonstrated to result in a significant reduction of CV risk and to 
improve other MetS comorbidities (83).   
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2.1. HYPERTENSION ASSOCIATED TO METABOLIC SYNDROME 
The MetS is defined as the simultaneous coexistence of 
metabolic abnormalities including obesity, glucose intolerance, 
dyslipidaemia, and HTN, that result in a marked increase in CV 
morbidity and mortality (84). In fact, High BP is considered one of the 
key features of MetS, and it is present in up to one third of patients 
with MetS (85). In this sense, it has been extensively reported that BP is 
strongly influenced by visceral obesity (86) and insulin resistance (87), 
being these two metabolic alterations described for MetS.  Regarding 
to HTN derived from obestity, the altered production of 
adipocytokines in adipose tissue, the major endocrine organ in the 
production of these inflammatory molecules, is the main cause for the 
development of HTN via different pathways (88). In addition, these 
changes in adipocytokines release, including changes in leptin and 
adiponectin, have also been related to insulin resistance, which also 
contribute to the development of HTN (89). Indeed, insulin resistance 
stimulates renal sodium reabsorption (90), increases circulating ET-1 
levels (91), increase leptin and non-esterified fatty acid levels, leading 
to the activation of the sympathetic nervous and raising BP (92,93). 
The activation of sympathetic nervous system induces the activation of 
RAAS since both systems are linked by a positive feedback relationship 
(94).  
Additionally, it has been reported for obese animals, an upregulation of 
RAAS increasing the release of Ang II, suggesting that this system, 
crucial in BP control, is modulated by food intake (95). Moreover, in 
humans, RAAS is present in adipose tissue and it has been 
demonstrated that the production of Ang II and angiotensinogen in this 
tissue is increased in obese subjects (96). Furthermore, plasmatic 
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aldosterone has been reported to be significantly associated with the 
MetS-derived HTN (97).  
Moreover, in rats, it has been demonstrated that both adiposity and 
insulin resistance are associated with the presence of systemic 
oxidative stress (98). Oxidative stress plays a pivotal role in the 
development of HTN mediating the secretion of inflammatory 
cytokines and inducing endothelial dysfunction (99), mainly through 
reducing NO bioavailability (62). 
Therefore, visceral obesity, insulin resistance, oxidative stress, 
endothelial dysfunction, activated RAAS or increased inflammatory 
mediators have been proposed to be possible factors to develop HTN 
in MetS. All the mechanisms involved in HTN in MetS are simplified in 
Figure 8.  
 
Figure 8. Proposed clinical features leading to the development of HTN in MetS. 
Adapted from Yanai et al. 2008 (100). 
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2.2. HYPERTENSION TREATMENT 
HTN is a leading risk factor for disability and death from CV 
causes, thus, prevention strategies for slowing the progression of BP 
elevation and management strategies for lowering BP are crucial for 
HTN patients  (101). In this sense, it has been reported that a reduction 
of 5 mmHg for DBP and 10 mmHg for SBP significantly decreased the 
risk of all major fatal and non-fatal cardiovascular outcomes (102,103). 
Nevertheless, BP lowering target should be determined according to 
the patients’ global risk and accompanied diseases  (104).  
The treatment of HTN includes non-pharmacologic and pharmacologic 
approaches. For those patients presenting prehypertension and 
presenting less than 10 % of pre-existing CV risk, the implementation 
of lifestyle modifications is the most recurrent method to treat HTN 
(105). For those, presenting HTN or, a pre-existing CV risk of 10% or 
higher, both lifestyle change and medication are recommended (106).  
2.2.1. NON-PHARMACOLOGICAL INTERVENTIONS 
Among non-pharmacological lifestyle interventions, dietary 
changes, low salt diet, weight loss, increased physical activity and 
alcohol restriction, have been shown to reduce BP in several clinical 
studies (107–109). Each of these strategies are likely to reduce SBP by 
3 to 8 mm Hg and DBP by 1 to 4 mmHg and these reductions have been 
associated with an important reduction in mortality caused by stroke 
and coronary heart disease (110).    
Although the beneficial effects of non-pharmacological measures on 
BP have been well documented, it should be remarked that their BP-
lowering effects are lower compared to drug therapy; therefore, these 
measures are suitable for  those patients presenting prehypertension 
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or in patients with severe HTN to enhance the effects of the 
pharmacological interventions (111). 
2.2.2. PHARMACOLOGICAL INTERVENTIONS 
Extensive evidences have demonstrated the effect of 
pharmacological interventions in HTN treatment reducing the elevated 
incidence of cardiovascular morbid and fatal events related to high BP 
(109). The antihypertensive pharmacotherapy includes mainly five 
classes of drugs according their targets: diuretics, beta-blockers, 
calcium-channel blockers, angiotensin II receptor blockers (also known 
as sartans) and ACE inhibitors (112).  
The diuretic therapy increases the excretion of water by inhibiting the 
reabsorption of sodium at different segments of the renal tubular 
system (113). There are three main classes of diuretics, thiazides, loop 
diuretics and carbonic anhydrase inhibitors (114). This therapy is 
effective in reducing the risk of stroke, coronary heart disease and 
total mortality evens at low-dose (81), due to their ability to reduce 
blood volume, cardiac output, and with long-term therapy, systemic 
vascular resistance (115). Some of the most popular diuretic drugs are 
furosemide (loop diuretic) or hydrochlorothiazide (thiazide), among 
others.  
Regarding to the beta blockers, also known as beta-adrenergic 
blocking agents, these are competitive antagonists that block the 
receptors for the catecholamines epinephrine and noreprinephrine in 
the sympathetic nervous system (116), resulting in a reduction in 
cardiac output. Thus, these antihypertensive drugs are specially 
prescribed to reduce CV complications in patients with heart failure 
(117) and several studies recent have questioned the usefulness of beta-
blockers as the primary tools to treat HTN (118). Some authors reported 
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that large evidences for beta-blockers in HTN treatment are based only 
in Atenolol effects, popular beta-blocker drug (119).   
Another popular pharmacological therapy to ameliorate HTN is the use 
of calcium channel blockers. Calcium stimulates the heart to contract 
more forcefully and its limitation through calcium channel blockers 
allow blood vessels to relax and as a result, to lower BP (120,121). In 
addition, calcium channel blockers, including Amlodipine, are also 
used for treating certain types of abnormally rapid heart rhythms (122). 
Besides of the use of blockers for beta-receptors and for calcium 
channels, antagonists for Ang II are also extensively prescribed for 
HTN treatment.  The Ang II receptor antagonists (ARBs), including 
Losartan or Atacand, are the most selective blockers of the RAAS 
currently available (116). ARBs bind selectively block the angiotensin 
AT1 receptors, thereby blocking vasoconstriction and other actions 
typically exhibited by Ang II. Regarding the RAAS system, since 2007 it 
was commercialized Aliskiren, the first antihypertensive drug that 
produce its BP-lowering effect through the inhibition of renin. In 
addition, it appears that Aliskiren is the first of a new class of agents 
that may prove useful in the management of patients with 
nephropathy, heart failure and atherosclerosis in addition to HTN (123).  
Nevertheless, to date, the most used and successful antihypertensive 
drugs reducing morbidity and mortality amongst patients with HTN are 
the ARBs and the ACE inhibitors (124). 
2.2.2.1. ACE INHIBITORS 
Among medications that inhibit components of the RAAS 
including renin inhibitors, ARBs and ACE inhibitors, these last are 
considered first-line antihypertensive drugs (15). The ACE inhibitors are 
a heterogeneous group, both in terms of chemical structure and 
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pharmacokinetics, but they have in common the ability to bind 
competitively with the active binding site of ACE (125). Therefore, the 
inhibition of ACE by these drugs reduces the production of Ang II 
(vasoconstrictor) and increase BK (vasodilator) levels obtaining a 
reduction in BP.  
The first ACE inhibitor, teprotide, was a nonapeptide derived from 
snake venom and it was identified by Ferreira et al. in 1965 (126). 
Nowadays, synthetic derivatives of this ACE inhibitor such as 
captopril, enalapril, lisinopril, ramipril or alacepril are used in the 
treatment of HTN in humans (127,128). Although these drugs show a 
remarkable effect in treating HTN, they can also present adverse side 
effects in some patients, such as dried cough, headache, fever, renal 
impairment, taste disturbances, skin rashes, insomnia, and 
angioneurotic edema allergic reactions (129).  
Nevertheless, as previously mentioned, the number of prehypertensive 
individuals is still higher than the number of HTN individuals (1). 
Therefore, in order to prevent the development of HTN, it is important 
to act at the prehypertensive stage. In this sense, it has been 
demonstrated that beta blockers and diuretics, are not suitable for use 
in prehypertensive patients (3). Indeed, the antihypertensive drugs that 
have demonstrated to potentially fulfil the requirements for 
prehypertensive individuals are the ARBs and some calcium channel 
blocker drugs (3).  
However, in most cases the diagnosed prehypertensive patients are 
not pharmacology treated and life style modifications, including low-
salt diet, weight loss or increased exercise, are the strategies followed 
to decrease BP (130). In addition, the use of natural products found in 
food which inhibit ACE and lower BP have emerged as an alternative 
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therapy for the prevention of HTN development, especially in those 
prehypertensive subjects (131). Indeed, the concept of viewing food as 
a remedy is an ancient concept considering the words of Hippocrates 
who, 2500 years ago, stated: “Let food be your medicine and medicine 
be your food.” In consequence, the approach to the food components 
as potential preventive agents in HTN is nowadays considered a hot 
topic.  
Some natural compounds including polyphenols (132) have 
demonstrated to reduce BP and are considered a promising alternative 
in HTN prevention and treatment. In this sense, the use of bioactive 
peptides derived from food proteins has attracted attention 
considering their potential as ACE inhibitors and as antihypertensive 
compounds (133). Thus, the  scientific community and the food 
industry have incentivized the development of new functional foods or 
nutraceuticals based on these peptides to alleviate or decrease the risk 
to develop HTN in prehypertensive subjects (134).  
3. BIOACTIVE PEPTIDES FOR THE MANAGEMENT OF 
HYPERTENSION 
Bioactive peptides, including antihypertensive peptides, are 
defined as bioactive protein fragments comprised in dietary matrixes 
that beyond the nutritional value, they can affect biological processes 
or substrates and, as a result, have an impact on body function or on 
health conditions (135). Nevertheless, since their increasing relevance 
in food research and in pharmacological field, it has been defined that 
to be considered bioactive, peptides should produce a measurable 
biological effect at a physiologically realistic level and this effect 
should be beneficial for health, excluding from this group those 
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requiring high doses and those exerting potential damaging effects 
(136).  
Bioactive peptides are formed by 3 to 20 amino acids residues (137) 
joined by covalent bonds also known as amide or peptide bonds. Their 
amino acid composition and sequence determine the activity of these 
active peptides once they are released from the precursor protein 
where they are encrypted. These bioactive peptides are usually less 
potent in their health beneficial effect than synthetic pharmaceutical 
drugs, but they are also less likely to accumulate in body tissues or to 
confer serious side effects because these are easily metabolized and 
absorbed or excreted (136).  Bioactive peptides have shown numerous 
activities including opiate, anti-thrombotic, anti-oxidative, 
immunomodulatory, mineral binding, ileum contracting anti-
cariogenic, anti-lipemic, osteoprotective and as mentioned, 
antihypertensive (138–140).  
However, considering that CVD and HTN are considered important 
health public problems of civilization, the research focused in the 
obtainment of antihypertensive peptides has been receiving great 
interest during the past 30 years (134,141–144). In fact, more than 1700 
different antihypertensive peptides have been reported in the AHTPDB 
“Database of Antihypertensive Peptides” database (134).  
3.1. ANTIHYPERTENSIVE PEPTIDES 
Since Maruyama and Suzuki in 1982 (145) reported the 
production of ACE inhibitory peptides by tryptic hydrolysis of casein, a 
great number of ACE inhibitory peptides have already been identified 
from dairy products proteins (146). Nevertheless, considering the 
potential antihypertensive effect of milk-derived peptides, being even 
commercialized as BP-lowering compounds (147–149), protein sources 
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other than dairy have also been explored and used for the obtainment 
of potential antihypertensive peptides (150). In this sense, animal 
derived-proteins from blood, meat, eggs (151,152) or plant derived-
proteins from wheat, maize, soy, rice or pumpkin have been 
demonstrated to be a source of bioactive peptides (153,154). In this 
regard, protein-rich by-products generated by agro-industries have 
emerged as an alternative to obtain compounds with bioactivity, 
mainly as protein hydrolysates (155). These by-products apart from 
creating potential environmental problems, represent a loss of raw 
materials and energy, thus requiring significant investments in 
treatments for pollution control (156). Therefore, their alternative use 
to obtain bioactive peptides with a significant added-value and/or a 
strong economic potential is of great interest.  
Specifically, the most used by-products are marine products. However 
in recent years, the use of chicken by-products have arisen as a 
potential source of bioactive peptides (157). The use of chicken by-
products to produce bioactive peptides with an added-value is 
considered a great strategy for poultry industries, allowing to reduce 
by-product management. Indeed, the production and consumption of 
poultry products have been on the increase globally. In fact, according 
to Food and Agricultural Organization (FAO) (158), poultry meat 
production increased from 13 % in the mid-1960s to 28 % in 2018. Per 
capita consumption increased more than threefold over the same 
period being the most consumed meat in developed countries. With 
this massive production, thousands of tons of organic by-products in 
the form of viscera, head, bones, blood, feathers and feet are 
generated (159) representing an environmental and economic problem 
for the industries.  
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Thus, some studies on chicken have focused on extraction, isolation 
and utilization of their proteins. Indeed, it has been reported that 
chicken by-products are a good source of antihypertensive peptides 
(160–162). Some authors indicated that chicken by-products, including 
skin and leg bones, are a source of antihypertensive peptides 
(163)(164). Interestingly, to date, the use of chicken feet has never been 
used before to obtain antihypertensive peptides.  
Table 1 details the most relevant protein sources used since the early 
2000s for the production of peptides with ACE inhibitory activity that 
have demonstrated antihypertensive effects in SHR. 
Source Sequence 
ACEI 
(IC50 - 
µM) 
Antihypertensive 
activity 
(mm hg) 
Dose 
(mg/kg) 
Reference 
Cuttlefish VELYP 5.22 -20.0 10 (165) 
Tuna 
GDLGKTT
TVSNWSP
PKYKDTP 
11.28 -21.0 10 (166) 
Jellyfish n.i. 1.28* -23.0 
200-
800 
(167) 
Cod n.i. 
0.10-
0.15* 
-40.0 30 (168) 
Oyster 
VVYPWT
QRF 
66 - (10.0-15.0) 20 (169) 
Bovine 
lactoferrin 
DPYKLRP 
LPR 
30.5 
0.35 
- (25.0-30.0) 10 (170) 
Fermented 
milk 
LHLPLP 5.5 -28.5 2 (171) 
 
3.1.1. OBTAINING OF ANTIHYPERTENSIVE PEPTIDES 
The obtainment of antihypertensive peptides usually starts with 
the treatment of the sample in order to solubilize the protein and thus, 
to facilitate enzyme accessibility to the protein. As previously 
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mentioned, bioactive peptides are inactive within the parent protein 
and therefore they require to be released from their precursor proteins 
to exhibit activities. In order to release the peptides from the proteins, 
samples are subjected to protein hydrolysis which can be performed 
following different methods, being the most popular, the microbial 
fermentation (172) and enzymatic hydrolysis (173). 
Microbial fermentation is extensively used by the dairy industry, as the 
peptides and amino acids degraded from milk proteins during 
fermentation contribute to the typical flavor, aroma and texture of the 
products. However, as a result of microbial fermentations, bioactive 
peptide can also be released. In this sense, the fermentation of dairy 
products by Lactobacillus helveticus has been demonstrated to be a 
successful strategy for the obtaining of  antihypertensive peptides 
(174). In a similar way, other lactic bacteria have demonstrated to 
produce antihypertensive peptides from dairy products (175).  
As mentioned, another method extensively used to obtain protein 
hydrolysates or bioactive peptides is the enzymatic hydrolysis. A large 
number of studies have demonstrated the release of antihypertensive 
peptides from food proteins, by hydrolysis using different food-grade 
hydrolytic enzymes (individually or in combination) (176,177). In the 
industry the hydrolytic enzymes flavourzyme, pepsin, alcalase, 
chymotrypsin, trypsin or protamex have been used for the production 
of bioactive peptides (178).  
Nevertheless, other factors than the used hydrolytic enzyme could 
interfere in this proteolytic procedure. In this sense, the type of protein 
pretreatment prior hydrolysis and the followed hydrolysis conditions 
(time, pH, ratio enzyme/substrate), will determine the release of 
bioactive peptides from protein matrixes. Thus, the optimization of the 
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hydrolysis conditions is an important strategy for the obtainment of 
peptides presenting specific activities (179,180), however, few studies 
obtaining bioactive peptides have reported the optimization in the 
hydrolysis conditions. 
Once the protein hydrolysates are obtained they are screened in vitro 
for the specific activity. In this regard, one of the most popular 
strategies to obtain antihypertensive natural compounds is by the 
determination of the ACE inhibitory (ACEI) activity. ACEI  
measurement is considered a useful and economic methodology to 
select potential natural compounds able to reduce BP considering that 
the inhibition of this enzyme is also the target for one of the most used 
antihypertensive drugs, the ACE inhibitors (181).  
Then, to proceed to identify ACEI peptides, the hydrolysates are 
subjected to ultrafiltration and/or fractionation by hydrophobicity and 
molecular weight mainly using reversed phase (RP) high performance 
liquid chromatography (HPLC) procedures. The in vitro ACE inhibitory 
activity is also tested for each fraction obtained to identify the location 
of the bioactive peptides derived from the enzymatic hydrolysis of the 
parent protein. In most instances, a single round of RP-HPLC may not 
be adequate to produce homogeneous peptide fractions; therefore, 
the most active fraction is usually subjected to a second or third round 
of RP-HPLC separation to obtain pure peptides. The obtained 
hydrolysate fraction showing the highest ACEI activity, usually the 
<3000 Da fraction, considering that ACEI peptides are those short in 
sequence, is studied by HPLC-MS to identify the sequences of the 
contained peptides (131). The identified peptides need to be 
synthetized and are required to be subjected to ACEI in vitro screening 
to distinguish those potential antihypertensive peptides. Schematic 
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representation of the process to obtain bioactive antihypertensive 
peptides is explained in Figure 9. 
 
Figure 9. Schematic representation of the production process to obtain 
antihypertensive peptides. 
Therefore, the explained procedure results in the obtainment of ACEI 
protein hydrolysates or peptides. Nevertheless, it is important to 
mention that high ACE inhibition in vitro does not always correspond 
to the same bioactivity in vivo. Thus, their evaluation in an animal 
model of HTN is required to confirm their antihypertensive properties.  
3.1.2. ANIMAL MODELS TO STUDY HYPERTENSION 
Historically, the SHR have been the most used animal model for 
testing the in vivo antihypertensive effects of food protein-derived 
protein hydrolysates and peptides. However, other animal models have 
been reported to be useful for the study of HTN. 
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3.1.2.1. SPONTANEOUSLY HYPERTENSIVE RATS 
The SHR are a well-known establish genetic model to study HTN.  This 
model was developed by Okamoto and Aoki by inbreeding Wistar rats 
with the highest BP values (182). This model of HTN is very similar to 
the HTN found in humans, developing many HTN-derived features 
such as cardiac hypertrophy, cardiac failure and renal dysfunction. 
Nevertheless, they do not present important vascular problems; 
despite of depressed endothelial dependent relaxations, they do not 
have a tendency to develop stroke, atherosclerosis or vascular 
thrombosis (183).  
This animal model is widely used since it requires no surgery or 
pharmacological agent to induce HTN, and it is sensitive to most of the 
clinically active antihypertensive drugs, such as Captopril (184).  
In this sense, in studies evaluating potential antihypertensive 
compounds in SHR, WKY rats, the normotensive controls of SHR, 
being both animal models genetically related, are included to discard 
possible undesirable hypotensive effects (185) 
3.1.2.2. CAFETERIA-DIET FED RATS AS AN ANIMAL MODEL TO 
STUDY MetS 
Considering that HTN frequently coexists with other CV risk 
factors and  obesity is a major cause of HTN (186), cafeteria(CAF)-diet 
fed rats are considered a useful model to study diet-induced HTN. 
CAF-diet fed rats are a robust animal model to study MetS (187). This 
experimental animal model reflects the harmful effects of typical 
highly palatable, energy dense and unhealthy Western diet. The 
consumption of this diet, known as CAF diet, leads to development of 
MetS promoting the voluntary hyperphagia that results in rapid weight 
gain, impaired glucose and lipid homeostasis and HTN (187,188). In 
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particular, it was demonstrated by Pons et al. that after 6-8 weeks of 
CAF diet rats presented obesity and diet-induced HTN (189), similarly 
that what happens in humans (186). Moreover, CAF-diet fed rats also 
present alterations in CV system including cardiac hypertrophy, 
ventricular dilatation, cardiac inflammation, fibrosis, endothelial 
dysfunction and impairment of renal system (190).  
This animal model consists on Wistar rats fed standard (STD) chow diet 
and water, while concurrently offered CAF diet ad libitum. CAF diet 
consists in biscuits with paté, biscuits with cheese, semi cured cheese, 
bacon, ensaïmada (sweetened pastry), carrots and milk with sucrose 
20% (w/v). In general the composition of the CAF diet is 35% fat, 51% 
carbohydrates, 14% protein and 0.2% Na, whereas STD diet is 4% fat, 
76% carbohydrates, 20% protein with 0.3% Na (191). Thus, the main 
nutritional incomes of CAF diet derive from fat and carbohydrates 
while in the STD diet only comes from carbohydrates. Regarding to the 
limitations of this model, it has been reported that in some cases, the 
animals could present special preference for a CAF diet particular food 
(192), but this animal behavior is closer to what happens in humans.  
3.1.2.3. SPRAGUE-DAWLEY RATS 
Sprague-dawley (SD) rats are also used as an animal model to 
study diet induced MetS (193). In this sense, it was reported that diet-
induced obesity in SD rats also leads to the development of mild to 
moderate HTN (98). In addition, this model is also used to study heart 
failure (194). Nevertheless, this animal model is and extensively 
reported in studies evaluating the vascular reactivity of many 
compounds in ex vivo experiments (195–198). SD rats are very useful in 
pharmacological studies to evaluate the mechanisms under the 
antihypertensive effect exerted by specific compound or to perform a 
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screening of vasodilator compounds which are considered to also be 
able to significantly reduce BP in hypertensive animals.   
Thanks to the evaluation of many compounds using different animal 
models, the antihypertensive effect of these compounds can be 
assessed. Nevertheless, once the antihypertensive effect is confirmed, 
it is also important to understand the mechanisms by which this 
compound is able to reduce BP. In this sense, considering that some of 
these natural antihypertensive compounds could be included in 
nutraceuticals or functional foods, the EFSA, European Food Safety 
Authority, encourage scientists to provide data including the evidence 
on the mechanisms by which the food/constituent could exert the 
claimed effect (199).  
 
3.1.3. MECHANISMS OF ACTION  
Bioactive peptides derived from dietary matrixes exhibit 
antihypertensive effects through various mechanisms. Most of these 
antihypertensive peptides have been selected to be ACE inhibitors 
(131). However, given the complexity of BP regulation, it is important to 
mention that other mechanisms than ACE inhibition have been 
involved in BP control exerted by those antihypertensive peptides. In 
this regard, it has been demonstrated that antihypertensive bioactive 
peptides could reduce BP by ameliorating endothelial function, 
modulating sympathetic nervous system through opioid-like activity 
and reducing vascular inflammation (200).  
3.1.3.1. ANTIHYPERTENSIVE PEPTIDES MODULATING RAAS 
FUNCTION 
RAAS system is one of the main target systems for BP control for 
antihypertensive peptides. In this sense, it has been described 
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antihypertensive peptides targeting RAAS components such as AT1 
receptor (201,202), renin (203,204) or endothelin converting enzyme 
(205,206) which plays a vital role in BP regulation by cleaving big 
endothelin to form endothelin ET-1. However, ACE has long been 
investigated as a major physiological target for developing 
antihypertensive drugs and natural products (207). 
The inhibition of ACE produced by those peptides reduce BP through 
inhibiting the production of the vasoconstrictor Ang II and avoiding BK 
degradation (208). Therefore, the role of ACE inhibitors is to maintain 
the balance between the vasoconstrictive and salt-retentive effects of 
Ang-II and vasodilator effects of BK (209).  
In this sense, a large number of studies in animals and/or humans have 
demonstrated that various food-derived peptides could significantly 
produce an antihypertensive effect through ACE inhibition upon either 
intravenous or oral administration (210–215). 
These ACE inhibitory peptides are usually small peptides ranging from 
3 to 12 amino acid residues (144), having hydrophobic and branched-
chain amino acids in their structure (216). In this sense, it was 
demonstrated that the active site of ACE cannot accommodate large 
peptide molecules (217). In addition, it has been reported that the 
amino acid sequence located in the three positions close to the C-
terminal end of the ACEI peptide is important for activity. In this 
regard, the presence of aromatic, positively-charged, and basic amino 
acids in these positions is important for competitive binding to the 
ACEI active site. The most effective ACEI peptides identified contain 
Tyr, Phe, Trp, and/or Pro at the C-terminal (144). However, amino acids 
residues required for ACE inhibition at C-terminal position can be 
different depending on peptide size (218). Regarding to N-terminal 
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position, the presence of branched aliphatic amino acids such as Gly, 
Val, Leu, and Ile have been demonstrated to be a good substrate to 
ACE (219). 
However, as previously mentioned, other mechanisms than ACE 
inhibition can be involved in the BP-lowering effect exerted by 
antihypertensive peptides. 
 
3.1.3.2. ANTIHYPERTENSIVE PEPTIDES AMELIORATING 
ENDOTHELIAL FUNCTION 
 
Some bioactive peptides have demonstrated to reduce BP through 
exerting antioxidant effect (220,221) and improving endothelial 
function (222). In this sense, strong evidences indicate that oxidative 
stress and associated oxidative damage in endothelium are mediators 
in the development of HTN. Under this situation, it has been 
demonstrated an increased production of ROS, a reduced NO 
synthesis and decreased bioavailability of antioxidants (223). Thus, the 
antioxidant action of bioactive peptides operates mainly through the 
scavenging of ROS and by the inactivation of free radicals (224). In this 
regard, the amino acid sequence plays an important role in oxygen-
radical scavenging capacity. Hydrophobicity of amino acid within 
sequences have been considered as key factor in peptide ability to 
scavenge radicals (225). Moreover, antioxidant peptides can exert their 
antioxidant effect by the activation of endogen antioxidant systems 
such as reduced glutathione (GSH) (226,227).  
In addition, some antihypertensive peptides have demonstrated to 
improve endothelial function and thus, contribute to BP reduction. 
These peptides mainly improve endothelial function through 
UNIVERSITAT ROVIRA I VIRGILI 
HYDROLYSATES AND PEPTIDES FROM CHICKEN FOOT PROTEINS TO MANAGE HYPERTENSION 
Anna Mas Capdevila 
 
62 
 
enhancing vasodilatory factors, such as NO by increasing NO 
bioavailability or directly inducing endothelial NO formation through 
activation of eNOS (228,229). In fact, some of antihypertensive 
peptides induce NO-mediated vasorelaxation and this seems to be the 
mechanism underlying the BP-reducing effect (230–232). Finally, some 
of these antihypertensive peptides can improve endothelial 
functionality through the reduction of vasoconstrictor factors including 
ET-1 (233). 
3.1.3.3. ANTIHYPERTENSIVE PEPTIDES WITH OPIOID-LIKE 
ACTIVITY 
 
Interestingly, it has been reported that some antihypertensive peptides 
could also present opioid properties. Opioid peptides are those which 
have affinity for an opiate receptor as well as opiate-like effects. 
Endogenous opioid peptides present the same N-terminal sequence 
(Try-Gly-Gly-Phe) and they are originated from three precursor 
proteins: proopiomelanocortin, proenkephalin and prodynorphin (234). 
Once these peptides bind to opioid receptors, physiological effects are 
triggered. In this sense, opioid peptides and multiple opioid receptors 
are present in brain nuclei involved in cardiovascular control (235–237). 
In addition to the central nervous system, endogenous opioids and 
opioid receptors are present in peripheral tissues, including the 
sympathetic ganglia, adrenal medulla, vascular endothelium and 
gastrointestinal (GI) tract (GIT) (238,239).  
Among all the derived effects triggered by the activation of opioid 
receptors, the stimulation of opioid receptors in the vasculature results 
in NO release (238,240) and thus, induce vasodilation. Indeed, there is 
scientific evidence that certain antihypertensive peptides are able to 
reduce BP through opioid-like activity. These peptides, mainly isolated 
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from milk proteins, interact with opioid receptors, with concomitant 
release of NO, which causes vasodilatation, and so reducing BP 
(241,242). Hérnandez-Ledesma et al. suggested that the interaction 
with opioid receptors is probably involved with the antihypertensive 
effects of the antihypertensive peptide α-lactorphin, considering that 
α-lactorphin antihypertensive effect is abolished by the opioid receptor 
antagonist naloxone (243). 
Therefore, these studies suggest that such opioid peptides may reduce 
BP through receptors expressed in the GIT, implying that no absorption 
is required. 
Nevertheless, most of antihypertensive peptides require reaching their 
target organ in an active form, thus, the study of their bioavailability it 
is important to determine their possible physiological effects in vivo.  
3.1.4. ANTIHYPERTENSIVE PEPTIDES BIOAVAILABILITY 
The antihypertensive effect of bioactive peptides is determined 
by their bioavailability after the oral administration. To exert this 
physiological effect, bioactive peptides have to remain active during GI 
digestion and absorption and reach the cardiovascular system. This 
implies resistance to GI enzymes and brush border membrane 
peptidases, and absorption through the intestinal epithelium (150). In 
this sense, those peptides selected to exert biological effects in vitro 
could undergo fragmentation into shorter peptides that are less or 
more active during the digestion. Therefore, in vitro effect could not 
correlate to the same in vivo effect. It is therefore difficult to determine 
the relationship between in vitro ACEI activity, extensively used to 
select potential antihypertensive sequences, and an in vivo 
hypotensive effect. 
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In fact, bioactive peptides when are orally administered may be 
inactivated by several digestive proteinases and peptidases including 
pepsin in the stomach, and the pancreatic enzymes trypsin, elastase, 
α-chymotrypsin and carboxypeptidase A and B in the small intestine. It 
has been noted that certain protein/peptide structures are resistant to 
GI digestion such as those peptides containing Pro and Hydroxy-pro 
residues. In addition, glycosylated peptides have been shown to be 
resistant to enzyme cleavage (141). Nevertheless, it has been described 
that some potent ACEI peptides can be produced through hydrolysis in 
intestinal epithelium surface by brush border membrane peptidases 
(244). 
In this regard, the use of a cell model, such as Caco-2, a model of 
intestinal barrier (245), allows to study the transport of peptides 
through intestinal barrier and allows to identify the possible peptide 
structural modifications after the GI digestion. 
Peptides can be transported through epithelial cells by various means, 
including passive transport and transcytosis, while di- and tri-peptide 
are transported by a peptide transporter 1 (PepT1) (208). Some 
antihypertensive peptides, such as the lactotripeptides Ile-Pro-Pro and 
Val-Pro-Pro, are demonstrated to be resistance to GI degradation and 
to be absorbed intact across the brush border membrane (246). 
Following the absorption of a peptide into the blood stream, it may 
undergo hydrolysis by serum peptidases. In this sense, it has been 
observed for ACE inhibitory peptides that may need to be able to resist 
serum peptidases hydrolysis in order to reach their target organs intact 
and yield their antihypertensive effect (247). However, these serum 
peptidases can originate potent ACE inhibitors, referred to pro-drug 
type inhibitors of ACE, by the hydrolysis of less potent inhibitors (248).  
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Figure 10 shows a schematic representation of the most representative 
phases in bioactive peptide digestion and absorption.  
Figure 10. Digestion and transport barriers in peptide in vivo administration. 
Nevertheless, not all the antihypertensive peptides require to be 
absorbed in the intestinal epithelium to induce BP-lowering effect. In 
this sense, the current opinion about large peptides is that the majority 
do not pass into the bloodstream in a significant amount and that they 
produce its physiological effects through the interaction with 
receptors on the intestinal wall (139,249). In fact, a local RAAS has 
been reported to be present in the small intestine, with the key 
components being expressed (250). In a similar way, those 
antihypertensive peptides that present opioid properties may lower BP 
through receptors expressed in the GIT, implying that no absorption is 
required. In this sense, the existence of three opioid receptors (µ, δ and 
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ĸ) have been reported in the small intestine, located in the myenteric 
plexus (251).  
Thus, the bioavailability of antihypertensive peptides, especially for 
those inhibiting ACE, is essential for their activity. Several approaches 
to enhance peptide resistance to gastrointestinal digestion are used. 
Therefore, peptides can be modified in order to reduce the rate of 
enzymatic degradation and to increase bioavailability while also in 
some cases enhancing bioactivity (252). These modifications include 
end changes, glycosylation, alkylation and conformational changes.  
In addition, encapsulation via nanoparticles and liposomes is also a 
strategy employed for antihypertensive peptides. Consequently, 
antihypertensive peptides may present higher therapeutic efficacy 
with progressive and controlled release of the drug during the 
degradation of the matrix (155).  
3.1.5. HEALTH RELEVANCE OF ANTIHYPERTENSIVE PEPTIDES: 
INCORPORATION INTO FOODS PRODUCTS 
 
Dietary antihypertensive peptides are promising components 
for the prevention and treatment of CVD including HTN as 
nutraceuticals, incorporated into foods creating functional foods or as 
drugs. Recently, both research centres and industries have increased 
their interest in the research of new sources of antihypertensive 
peptides, their lowering-BP effects and their bioavailability, 
considering their potential use as a pre-treatment for HTN.  
Nevertheless, the commercialisation of antihypertensive food products 
depends on the availability of scientific data from in vivo animal and 
human studies positively demonstrating the BP-lowering of these 
products and the mechanisms involved in the BP-reduction. 
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Furthermore, legislation which governs health claims in relation to 
functional foods needs to be taken into account. In this regard, the 
current European Regulation on nutrition and health claims in the EU 
was created in 2007 (Regulation 1924/2006) and the EFSA (253) is in 
charge of reviewing evidence of health claims made by food 
companies. Interestingly, EFSA has recently approved the safety use of 
shrimp peptide concentrate to the control of BP in subjects with mild 
or moderate hypertension (254). These latest updates in EFSA food 
supplements approvals opening up an opportunity to develop a 
nutraceuticals or functional foods to BP control.  
Nevertheless, some bioactive peptides are nowadays commercialised 
in many countries for the HTN control. Figure 10 shows a graphical 
representation of commercial products containing antihypertensive 
peptides derived from foods including Calpis®, Evolus® both 
containing antihypertensive peptide VPP and IPP (174), Valtyron® 
containing sardine isolated peptide VY (255) and PeptACETM which 
include the peptide LKPNM from bonito (256).  
 
 
 
 
 
 
Figure 11. Commercialized products including antihypertensive peptides. 
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 In recent years it has been extensively demonstrated that dietary 
protein hydrolysis is a successful strategy for the obtaining of peptides 
presenting beneficial effects on human health. In this sense, 
antihypertensive peptides are of great interest since HTN is the principal 
risk of CVD, which in turn is the main cause of mortality in western 
societies. The antihypertensive effect of these peptides is mainly related 
to their capacity to inhibit ACE, a fundamental regulatory enzyme in the 
RAAS with a key role in the physiological regulation of the BP. Indeed, 
the selection of bioactive compounds according their ACE inhibitory 
activities is an important strategy in the research of new 
antihypertensive agents. In this regard, the use of food by-products has 
demonstrated to be a successful strategy for the obtainment of bioactive 
peptides, including ACEI peptides. Additionally, these by-product 
derived peptides can be used as functional ingredients with significant 
added-value and strong economic potential. In this sense, chicken 
processing industries generate large amount of by-products, including 
chicken feet.  Therefore, the hydrolysis of chicken foot proteins could be 
a good strategy to obtain ACEI peptides with antihypertensive 
properties after their oral administration. 
Thus, the main objective of this thesis was to obtain ACEI hydrolysates 
with BP-lowering effect from chicken foot proteins and identify their 
bioactive peptides.   
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In order to assess the established assumption, specific objectives 
were proposed: 
1. To obtain antihypertensive hydrolysates from chicken foot proteins 
(Chapter 1).   
Protein hydrolysis is required to release the potential bioactive peptides 
enclosed in the native proteins. However, hydrolysis conditions such as 
raw material treatment, pH, temperature, type of enzyme and 
enzyme/substrate relation determine the production of different 
peptides and their bioactivities. Thus, the optimization of hydrolysis 
conditions it is important for the obtainment of peptides with high ACEI 
activity, and therefore, potential antihypertensive properties. 
Nevertheless, since in vitro ACEI activity does not always correspond to 
the same in vivo activity, the evaluation of the in vivo antihypertensive 
activity is required. Considering these facts, the following aim was 
proposed.  
a) To determine the optimal hydrolysis conditions to obtain chicken 
foot hydrolysates presenting high ACEI activity and 
antihypertensive effect in SHR [Manuscript 1]. 
 
2. To stablish the most effective dose and the mechanisms involved in 
the BP-lowering effect of the antihypertensive chicken foot 
hydrolysate Hpp11 after acute administration (Chapter 2).  
The study of the most effective dose and mechanisms involved in the 
effect of antihypertensive compounds is essential in the investigation of 
potential functional ingredients for the management of HTN. In addition, 
the BP-lowering effect of antihypertensive agents must be linked to the 
HTN state, discarding possible hypotensive effects under normotensive 
conditions. Thus, the following goal was proposed: 
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a) To determinate the most effective antihypertensive dose of the 
chicken foot hydrolysate Hpp11 after acute administration to 
SHR, establish the mechanisms underlying its antihypertensive 
effect and discard a possible hypotensive effect in normotensive 
WKY rats [Manuscript 2]. 
 
3. To evaluate the effect of long-term administration of chicken foot 
hydrolysate Hpp11 in diet-induced hypertension (Chapter 3). 
However, HTN is considered a chronic pathology requiring chronic 
treatment, which frequently occurs concurrently with many other CV 
risk factors related to lifestyle, such as obesity or impaired glucose 
tolerance, which all contribute to MetS. In this sense, CAF-diet fed rats 
are considered a good model for the study of human diet-induced HTN. 
Therefore, the following aim was proposed.  
a) To investigate the effect of long-term administration of Hpp11 on 
BP and evaluate the mechanisms underlying its antihypertensive 
properties in CAF-diet fed rats presenting diet-induced HTN 
[Manuscript 3]. 
 
4. To identify antihypertensive peptides from Hpp11 (Chapter 4). 
The identification of the bioactive peptides in the antihypertensive 
hydrolysate Hpp11 is important, considering their potential for HTN 
maintenance. Thus, chicken foot hydrolysate Hpp11 peptide profile was 
determined through chromatographic analyses and the potential 
antihypertensive effect of identified peptides was evaluated in SHR.   
[Manuscript 4]. 
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5. To study the bioavailability and the mechanism of action and to 
establish the molecular mechanisms involved in the antihypertensive 
effect of AVFQHNCQE (Chapter 5). 
Antihypertensive peptides could reduce BP through different 
mechanisms than ACE inhibition. In this sense, enhancement of NO 
bioavailability or direct effect on vascular relaxation have been 
described as mechanisms involved in the antihypertensive effect of 
bioactive peptides. In addition, the absorption of bioactive peptides in 
the GIT is generally considered as requisite to exert their functionalities. 
Thus, the mechanisms underlying the antihypertensive effect of chicken 
foot-derived peptide AVFQHNCQE and its bioavailability are needed to 
be evaluated.  
a) To establish the mechanism of action of AVFQHNCQE and to 
study the molecular mechanisms operating in the BP-lowering 
effect of this peptide in SHR. [Manuscript 5] and [Manuscript 6] 
b) To study chicken foot-derived peptide AVFQHNCQE 
bioavailability. [Manuscript 6] 
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 Different experimental designs were used to assess the main 
hypothesis and reach the experimental objectives previously described 
in this thesis.  
1- Obtainment of chicken foot hydrolysates with antihypertensive 
properties. 
The experimental design used to obtain hydrolysates presenting 
antihypertensive properties from chicken foot proteins is described in 
Figure 1. Briefly, chicken feet were disrupted into powder, heat pre-
treated and subjected to proteolytic hydrolysis under conditions (pH, 
time, enzyme...). Optimal hydrolysis conditions were those that allow 
the obtainment of hydrolysates from chicken feet showing high ACE 
inhibitory activity. Nevertheless, considering that high in vitro ACE 
activity does not always correspond to the same activity in vivo, the 
hydrolysates showing potent ACE inhibitory activity were administered 
to SHR and BP was recorded before and 2, 4 ,6 8, 24 and 48 h post-
administration by the Tail cuff method.  
 
 
Figure 1: General procedure to obtain hydrolysates from chicken foot proteins presenting 
antihypertensive activity.  
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2- Chicken foot hydrolysate Hpp11 antihypertensive dose 
optimisation and study of the molecular mechanisms involved 
in its antihypertensive effect and the possible hypotensive 
effect in normotensive state.  
To optimise the dose to administer of chicken foot hydrolysate Hpp11 
to obtain the most effective antihypertensive effect, three different 
doses (85, 55 and 25 mg/kg bw) were acutely administered to SHR and 
BP was registered before and 2, 4, 6 8, 24 and 48 h post-administration 
by the Tail cuff method. In addition, an experiment with WKY rats was 
carried out to discard Hpp11 hypotensive effects in normotensive 
conditions. The molecular mechanisms underlying Hpp11 
antihypertensive effect were studied through the determination of 
plasmatic ACE activity in plasma in SHR after 6 h post-Hpp11 
administration. Moreover, considering that other mechanisms such as 
the RAAS could be involved, the effect of Hpp11 on vascular reactivity 
was also studied in pre-contracted aortic rings preparations from SD 
rats.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Experimental procedure followed to determine Hpp11 optimal dose to obtain the 
maximum antihypertensive effect, to discard possible Hpp11 hypotensive effect and to study the 
mechanisms underlying Hpp11 BP lowering effect.  
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3- Long-term administration effects on blood pressure of chicken 
foot hydrolysate Hpp11 in diet-induced hypertensive rats and 
the mechanisms involved in Hpp11 effect.  
To evaluate the effects of chicken foot hydrolysate Hpp11 in cafeteria-
diet fed rats after long-term administration and to evaluate the 
mechanisms involved in the long term effect of Hpp11 (Figure 3). Rats 
were fed standard or CAF diet for 12 weeks, and during the final 3 
weeks, CAF diet-fed animals were administered vehicle (CAF+VH), 50 
mg/kg bw Captopril (CAF+Captopril) or 55 mg/kg bw of Hpp11 
(CAF+Hpp11). STD group was also administered VH (STD+VH). BP was 
recorded weekly. Body weight and plasmatic lipid and glucose levels 
were determined at the end of the experiment. Moreover, liver GSH 
levels, plasmatic ACE activity and the endothelial gene expression of 
eNOS, KLF-2, Sirt-1, NOX4 and ET-1 were studied to elucidate the 
mechanisms underlying the Hpp11 effect. 
 
Figure 3: Experimental design to evaluate the long term administration effects of chicken foot 
hydrolysate Hpp11 in diet-induced rats and the mechanisms involved in its BP lowering effect. 
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4- Identification of antihypertensive peptides present in chicken 
foot hydrolysate Hpp11. 
Peptide identification was performed in order to identify those 
responsible of the antihypertensive activity exhibited by chicken foot 
hydrolysate Hpp11. Therefore, Hpp11 proteins-peptides were separated 
in fractions according to their molecular size and hydrophobicity. Nine 
novel peptides were identified in the <3KDa fraction from Hpp11. Five 
of them showed an ACE inhibitory activity (IC50) values lower than 100 
µM. The antihypertensive effect of oral administration of the identified 
peptides was evaluated in SHR. 
 
 
Figure 4: Experimental design to identify antihypertensive peptides from chicken foot 
hydrolysate. 
 
5- Evaluation of the NO and PGI2 implication in AVFQHNCQE 
antihypertensive effect. Additionally, evaluation of the 
molecular mechanisms underlying AVFQHNCQE 
antihypertensive effect.  
To elucidate the implication of NO and PGI2 in peptide 
antihypertensive effect, rats administered the peptide (10 mg/kg bw) 
or water were also treated with L-NAME (30 mg/kg bw), an inhibitor of 
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NO synthesis, and indomethacin (5 mg/kg bw), an inhibitor of PGI2 
synthesis. BP was recorded before and 6 h after administration (Figure 
5).  Additional experiment was performed using SHR that were 
administered the peptide (10 mg/kg bw) or water. After 6 h of 
administration rats were sacrificed and plasma, liver and aorta were 
extracted to perform different determinations. Hepatic GSH levels, 
plasmatic ACE activity and the endothelial gene expression of eNOS, 
KLF-2, Sirt-1, NOX4 and ET-1 were studied (Figure 5).  
Figure 5: Experimental procedure followed to determine NO and PGI2 implication in the 
AVFQHNCQE antihypertensive effect. Additional experiment was conducted in SHR to elucidate 
the mechanisms underlying the antihypertensive effect exhibited by AVFQHNCQE.  
 
6- Evaluation of AVFQHNCQE bioavailability after oral 
administration and evaluation of its opioid-like effect.  
 
The peptide was subjected to in vitro and in silico simulated 
gastrointestinal digestion. Samples from in vitro simulated digestion 
were analysed by HPLC-MS. Then, peptide was administered to Wistar 
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rats to study its bioavailability after oral administration. Plasma from 0 
h and plasma from 30, 60 and 90 min post-administration were 
collected and analysed by HPLC-MS. To evaluate the peptide 
transport through intestinal barrier an in vitro with Caco-2 cells was 
used. The content from apical chamber and basolateral chamber from 
the insert were collected and analysed by HPLC-MS.  
Additional experiment was conducted to evaluate the opioid-like effect 
of AVFQHNCQE. Thus, SHR were administered by oral gavage the 
peptide or water and subcutaneously injected naloxone or saline. BP 
was measured in these animals before and 6 h post-peptide 
administration.  
 
 
Figure 6: Experimental procedure followed to study the peptide bioavailability and its possible 
opioid-like effect. 
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                                                              MANUSCRIPT 1 
    Objective 
To determine the optimal hydrolysis conditions to obtain chicken foot 
hydrolysates presenting high ACE inhibitory activity in vitro but also 
presenting antihypertensive effect in vivo when administered to SHR. 
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Abstract 
Purpose: Dietary protein hydrolysis was shown to be a successful 
strategy for producing antihypertensive peptides. The aim of this study 
was to obtain antihypertensive hydrolysates from chicken feet 
proteins.  
Methods: In this study, we optimize the hydrolysis conditions to obtain 
hydrolysates from chicken feet with antihypertensive properties. The 
effects of hydrolysis temperature and time on angiotensin-converting 
enzyme inhibitory (ACEI) activity were determined. Moreover, their 
potential antihypertensive activity was also evaluated in spontaneously 
hypertensive rats (SHR).   
Results: Chicken feet samples heat treatment at 100 ºC and posterior 
enzymatic hydrolysis at 50 ºC with Neutrase and Protamex enzymes 
(0.4 AU/g) were the hydrolysis conditions to produce ACEI 
hydrolysates. The hydrolysates obtained showed low values of 
IC50 (9.56 - 40.37 µg protein/mL). 3 hydrolysates were selected 
according their high ACE inhibition and demonstrated antihypertensive 
effect after their administration (5 mL hydrolysate/kg body weight) to 
SHR. 
Conclusions: Chicken feet are suitable raw materials for producing 
antihypertensive hydrolysates that could be used to formulate 
antihypertensive functional foods and nutraceuticals. The results of 
this research open doors to the use of these hydrolysates to treat 
hypertension avoiding the side effects usually accompanied with the 
treatment with antihypertensive drugs.  
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1. Introduction 
According to the World Health Organization, cardiovascular disease 
(CVD) is the leading cause of death worldwide, and it represented 31 % 
of all deaths in 2015 [1]. One of the most controllable risk factors 
associated with CVD events is hypertension, which affects nearly 45 % 
of the population [2].  
The renin–angiotensin–aldosterone system (RAAS) plays an important 
role in the maintenance of arterial blood pressure (BP) and the 
liquid/electrolyte balance [3, 4]. One of its main components is the 
angiotensin-converting enzyme (ACE) [EC 3.4.15.1]. This glycosylated 
zinc dipeptidyl-carboxypeptidase catalyzes the conversion of 
angiotensin I to the potent vasoconstrictor angiotensin II, which is the 
major bioactive molecule of the RAAS. In addition, ACE inactivates 
bradykinin, a potent vasodilator. Synthetic ACE inhibitors, like 
Captopril and Enalapril, are widely used for the treatment of CVD and 
renal disease. However, some undesirable side effects such as chronic 
cough, taste disturbances, skin rashes, and angioedema were 
described for the ACE inhibitors [5]. Therefore, the investigation of 
new natural product-based ACE inhibitors could greatly benefit 
hypertensive patients. 
Dietary protein hydrolysis has been shown to be a successful strategy 
to produce ACE-inhibitory (ACEI) and/or antihypertensive peptides [6]. 
Several vegetal and animal food proteins such as legumes [7], wheat, 
mushrooms, bitter melon seeds, spinach [8], milk and eggs [9], meat 
muscle [10], fish [11] oyster or squid [12] have been shown to produce 
hydrolysates with high ACEI activity.  
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By-products generated in industrial food processing can also be used 
in the production of hydrolysates with ACEI activity [13]. Every year, 
tons of protein-rich secondary products are disposed of as waste from 
food manufacturing, producing environmental and economic problems 
[14, 15]. To reduce these problems, alternative techniques for revaluing 
these by-products, besides converting them into livestock feed and 
organic fertilizers, are being investigated [13, 15]. Chicken feet, which 
represent 3.5-4.0 % of the live weight [16], are a protein-rich poultry 
by-product that could be used as a source of inexpensive 
antihypertensive hydrolysates. In this sense, this by-product is 
especially rich in collagen (72.5 % of total protein content) [17], and this 
protein is a source of peptides with different bioactivities, including 
ACEI activity [18]. 
In the present study, hydrolysates obtained after an enzymatic 
treatment of chicken feet were selected according to their ACEI 
activity. Moreover, the potential beneficial effects of 3 chosen 
hydrolysates were assessed in an animal model of hypertension.  
2. Materials and methods 
2.1. Chemicals and reagents 
Chicken feet from Gallus gallus domesticus were provided by a local 
farm (Granja Gaià, La Riera de Gaià, Spain). Neutrase® 0.8 L (EC 
3.4.24.28, 0.8 AU-N/g from Bacillus amyloliquefaciens) and Protamex® 
(EC 3.4.21.62 and 3.4.24.28, 1.5 AU/g from Bacillus licheniformis and 
Bacillus amyloliquefaciens) were kindly provided by from Novozymes 
(Lyngby, Denmark). ACE (peptidyl-dipeptidase A, EC 3.4.15.1) and 
picrylsulfonic acid solution (5 %, w/v) were purchased from Sigma 
Chemical (St. Louis, MO, USA), and o-aminobenzoylglicil-p-
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nitrofenilalanilprolina (o-Abz-Gly-p-Phe(NO2)-Pro-OH) was provided by 
Bachem Feinchemikalien (Bubendorf, Switzerland). All other chemicals 
were obtained from common commercial sources and were analytical 
grade. 
2.2. Preparation of chicken feet hydrolysates  
Chicken feet were cleaned, crushed, lyophilized and milled using a 
Fagor BV-850 beater (Fagor Electrodomésticos S. Coop., Mondragón, 
Spain). The obtained powder was sieved using a 2 mm pore size sieve 
to obtain fine chicken feet powder. Samples were prepared dissolving 
chicken feet powder in Milli-Q water at 20 mg/mL and vortexing 
during 1 min. Posteriorly, a heating treatment was carried out at 100 ºC 
and pH 3.0, 7.5, or 10.0 with agitation over 1.5 h. After that, the pH of 
all samples was adjusted to 7.0 with HCl or NaOH 1 M, and the 
hydrolysis enzyme was added at a final concentration of 3.97 µL/mL 
for Neutrase and 2.67 µg/mL for Protamex. The used 
enzyme/substrate ratio for all enzymes was 0.4 AU/g protein. 
Hydrolysis was conducted at pH 7.0 and 250 rpm in a MaxQ Orbital 
Shaker Thermo Scientific (Thermo Fisher Scientific, USA) at a 
controlled temperature of 25 or 50 ºC for 0, 2, 4 or 24 h. At least 
duplicate hydrolysis was carried out in all conditions of hydrolysis. 
Inactivation of enzymes was achieved by heating at 80 ºC for 10 min. 
The hydrolysates were centrifuged at 10,000 xg for 20 min at 4 ºC. The 
supernatants obtained were filtered using 0.45 µm filters and kept at -
20 ºC until used. In addition, samples without chicken feet heating 
treatment and hydrolysis enzymes were also prepared. These samples 
were obtained from chicken feet powder dissolved in Milli-Q water (20 
mg/mL) by vortexing during 1 min, then centrifuged at 10,000 xg for 20 
min at 4 ºC, and filtered using 0.45 µm filters. 
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2.3 Characterization of chicken feet powder and hydrolysates 
Moisture, ash, fat and protein content of chicken feet or hydrolysates 
was determined according to the AOAC methods [19]. Protein content 
was determined by Kjeldahl method, multiplying the determined 
nitrogen content by 6.25. The degree of hydrolysis (DH) was assayed by 
measuring the increase in free amino groups using the trinitro-
benzene-sulfonic acid (TNBS) method according to Adler-Nissen (1979) 
[20]. The total number of amino groups was determined in a sample 
that was 100 % hydrolyzed at 110 ºC for 24 h in 6 M HCl. All 
determinations were carried out in at least duplicate. The data shown 
in Table 2, concerning the protein content and DH, are mean values of 
at least two different hydrolysates in the same conditions. All data are 
expressed as the mean ± standard deviation (SD). 
2.4 Determination of ACE-inhibitory activity  
ACEI activity was measured by fluorescence following the method of 
Sentandreu and Toldrá (2006) with some modifications according to 
Guerrero et al.  [22]. ACE working solution was diluted with 0.15 M Tris 
buffer (pH 8.3) containing 0.1 μM of ZnCl2 with 0.04 U/mL of enzyme 
in the final reaction solution. A total of 40 μL of sample, distilled water 
or this enzyme working solution were added to each microtiter-plate 
well and adjusted to 80 μL by adding distilled water if necessary. The 
enzymatic reaction started by adding 160 μL of 0.45 mM o-Abz-Gly-p-
Phe(NO2)-Pro-OH dissolved in 150 mM Tris-base buffer (pH 8.3), 
containing 1.125 M NaCl, and the mixture was incubated at 37 °C. The 
sample fluorescence was recorded at 30 min using a multi-scan 
microplate fluorimeter (FLUOstar optima, BMG Labtech, Offeuburg, 
Germany). Excitation and emission wavelengths were 360 and 400 nm, 
respectively. The software used to process the data were FLUOstar 
control (version 1.32 R2, BMG Labtech). 
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ACEI activity of all hydrolysates were determined as a percentage of 
inhibition of hydrolysates diluted in Milli Q water (1:1, v:v). Hydrolysates 
with ACEI activity ≥ 90 % were selected, and IC50 was determined. IC50 
is the concentration of each hydrolysate (µL of hydrolysate or µg of 
protein/mL of hydrolysate), which reduces enzyme activity by half.   
The determination of ACEI activity of samples was performed in at 
least duplicate. The data shown are mean values of ACEI activity of at 
least two different hydrolysates in the same conditions. 
2.5 Measurement of arterial blood pressure 
Male SHR rats (17–20-week-old, weighing 300–350 g) were obtained 
from Charles River Laboratories España S.A. (Barcelona, Spain). 
Animals were singly housed in animal quarters at 22 ºC with light/dark 
period of 12 h. They were fed with the standard diet based on chow 
Panlab A04 (Panlab, Barcelona, Spain) and tap water ad libitum.  
Antihypertensive activity of selected hydrolysates was determined by 
the tail-cuff method [23]. The original method for measuring arterial 
blood pressure using the tail cuff provides only systolic blood pressure 
(SBP) values, but the equipment used in this study, LE 5001 (Letica, 
Hospitalet, Barcelona, Spain), has a high-sensitivity pulse transducer 
coupled with an accurate microprocessor program and allows for us to 
distinguish between SBP and diastolic blood pressure (DBP). Before 
starting the experiment, all animals were accustomed to the process 
through a 3 weeks training period. 
The different hydrolysates were acutely administered to the rats by 
gastric intubation between 9 and 10 am. The administered dose of the 
hydrolysates was 5 mL/kg body weight (bw). Negative and positive 
control groups received 1.5 mL of water or Captopril (50 mg/kg bw, 
dissolved in water), respectively. SBP and DBP were measured in the 
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animals before the treatment administration and 2, 4, 6, 8, 24 and 48 h 
post-administration. Changes in SBP and DBP were expressed as the 
differences between the mean values of these variables before and 
after the administration. Data are expressed as the mean values ± 
standard error of the mean (SEM) for a minimum of six experiments. 
The animal protocol followed in this study was approved by the 
Bioethical Committee of Universitat Rovira i Virgili (European 
Comission Directive 86/609) and the Spanish Royal Decree 223/1988.  
2.6 Statistical Analysis 
To assess the effect of chicken feet protein hydrolysis conditions on 
ACEI activity, data were analyzed by Student’s T-test. Data obtained in 
the determination of antihypertensive activity were analyzed using 
two-way ANOVA (Duncan’s test). All analyses were carried out using 
IBM SPSS statistics 20.0 software (SPSS, Inc, Chicago, IL, USA). 
Differences between the means were significant when p < 0.05. 
3. Results and discussion 
Protein-rich by-products from non-mammalian species, such as poultry 
or fish, have received considerable attention in recent years [24]. In this 
study, chicken feet were used as a protein source to obtain 
hydrolysates with ACEI properties. Although other chicken parts have 
been utilized as source of hydrolysates with ACEI activity [25–27] 
chicken feet have never been used as far as we know.  
Protein, fat and moisture content of the used chicken feet were 20.1, 
15.03 and 60.5 %, respectively. These contents were quite similar to 
those previously described for this poultry by-product (17.42, 12.04 and 
62.05 %, respectively) [28]. Processing of raw feet to powder resulted 
in a homogeneous material composed of small particles that was more 
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accessibility to the proteases and enriched in protein (44.3 vs 20.1 %). 
Similar protein content values were reported for chicken essence 
residues used as raw material by Chen et al. [29] to obtain 
antihypertensive hydrolysates. ACEI activity of the supernatant 
obtained by centrifugation of chicken feet powder dissolved in water 
was 28.62 %, similar to those reported previously by chicken bone or 
leg protein solutions [27, 30].  
The accessibility of proteases to proteins and therefore peptide 
releasing can be modulated by many factors like their solubilization 
and native or denatured state, which depends on environmental 
factors (i.e., pH, temperature). In this regard, in this study, a heating 
treatment at 100 ºC before hydrolysis was applied to the chicken feet 
powder dissolved in water. Heat pretreatment of chicken breast and 
thigh in water in the obtaining of hydrolysates with ACEI activity has 
been previously used [31]. In addition, since protein solubilization is 
depending on pH, the samples were subjected to different pH prior 
hydrolysis treatment.  
The effect of hydrolysis temperature of 25 and 50 ºC on ACEI activity 
was studied. Hydrolysate ACEI activity, expressed as a percentage did 
not show significant differences associated with hydrolysis 
temperatures. However, IC50, expressed as volume (µL), was lower in 
the hydrolysates prepared at 50 ºC than at 25 ºC (Table 1). It is known 
that the lower IC50 value, the higher the ACE inhibitory activity. 
Therefore, 50 ºC was chosen as optimal temperature to perform the 
chicken feet hydrolysis. In addition, hydrolysis times shorter than 24 h 
(2 and 4 h) were studied. Protein content, DH and ACEI activity of the 
hydrolysates were determined (Table 2). It was observed that only the 
samples at 0 h (without hydrolysis) showed an ACEI activity of less 
than 90 %. These results demonstrated that the use of these hydrolysis 
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conditions (time, temperature) is a great strategy to obtain 
hydrolysates presenting high ACEI activity. In addition, the IC50 value 
was determined for each hydrolysate and expressed as the volume and 
protein concentration. The expression of this value in volume indicates 
the necessary hydrolysate volume to inhibit the enzyme by 50 % under 
the assay conditions. Therefore, this value is indicative of the 
pharmacological potency, given that the lower the IC50, expressed in 
volume, the higher the potency of ACEI of the hydrolysate assayed 
[32]. All hydrolysates showed a strong ACEI activity, although 
differences in the IC50 values between the different hydrolysates can 
be noted (Table 2). ACEI activities of hydrolysates ranged among 0.5 ± 
0.0 and 1.4 ± 0.0 µL. These inhibitory potencies are comparable to 
others obtained from milk fermented with Enterococcus faecalis [33]. 
Moreover, IC50 was also expressed in protein concentration (µg/mL). It 
is an indicator of the pharmacological specificity or the specificity of 
the obtained peptide mixture against ACE, regardless of the protein 
concentration of the fraction [33]. ACEI activities ranged among 9.6 ± 
3.1 and 40.4 ± 0.5 µg/mL (Figure 1). These results clearly reveal 
important ACEI potency in chicken foot hydrolysates. Chicken legs 
have been previously reported as a source of ACEI hydrolysates, but 
the hydrolysates obtained showed higher IC50 than ones obtained in 
this study from chicken feet. In fact, Indonesian native boneless 
chicken leg proteins hydrolyzed with different Bacillus cereus enzymes 
and broiler chicken leg bones hydrolyzed with Alcalse showed IC50 
ranging from 945 to 2580 µg/mL [34, 35]. In addition, hydrolysates 
with ACEI activity from other chicken by-products have also been 
obtained. In this sense, hydrolysates derived from spent hen meat 
proteins treated with Pepsin or Pepsin-Pancreatin showed IC50 values 
of 646 and 424 µg/mL, respectively [36], and hydrolysates obtained 
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from skin proteins of thigh or breast treated with Alcalase or Pepsin-
Pancreatin, respectively, showed IC50 values of 550 and 640 µg/mL, 
respectively [37]. Moreover, chicken blood proteins treated with 
Alcalase showed ACEI properties, but the IC50 value reported for this 
by-product (340 µg/mL) was higher than the obtained in this study. 
However, in vitro ACEI activity is not always accompanied with in vivo 
antihypertensive effect [38]. In fact, some bioactive peptides can be 
hydrolyzed and transformed into inactive peptides during 
gastrointestinal digestion [39]. In this study, the antihypertensive effect 
of 3 different chicken foot hydrolysates (Hpp8, Hpp11 and Hpp23) was 
tested in SHR, the experimental animal model that best mimics 
essential hypertension in humans [40]. Figure 2 shows the in vitro ACEI 
activity of these hydrolysates expressed in percentage versus the 
volume of hydrolysate.  
Prior to the administration of the different hydrolysates, SHR 
presented SBP and DBP values of 202 ± 7.5 and 174 ± 9.3 mmHg, 
respectively. Neither SBP nor DBP of SHR administered water changed 
significantly during the 48 h of experiment duration (Figure 3). As 
expected, the administration of Captopril produced an important 
decrease in SBP and DBP of SHR reaching the maximum decrease at 4 
and 6 h post-administration. These variables returned to baseline 48 h 
after Captopril administration. In addition, oral administration of the 
selected chicken feet hydrolysates caused a significant decrease in 
both SBP and DBP compared to water group (p ≤ 0.05). These results 
indicate that the ACEI peptides present in the chicken feet 
hydrolysates, or shorter forms generated by gastrointestinal digestion, 
can be efficiently absorbed through the intestine of the animals in an 
active form. In this sense, the maximum SBP decreases caused by the 
administration of the hydrolysates (-20.3 ± 0.5, -18.4 ± 2.8, and -27.1 ± 
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4.8 mmHg for Hpp8, Hpp11 and Hpp23, respectively) to SHR, were 
similar to the decrease produced after the administration of Captopril 
(-26.7 ± 2.1 mmHg) (p >0.05) (Figure 3A). Similar maximum SBP 
decreases were reported in a previous study carried out with a 
comparable dose of a hydrolysate obtained from chicken leg bone with 
Alcalase [30]. In addition, a comparable decrease in SBP was reported 
after oral administration of spent hen meat proteins hydrolyzed with 
Pepsin and Pepsin-Pancreatin, but a 4-fold higher dose was 
administered in this study [36]. Regarding DBP, rats given the tested 
hydrolysates reached similar values compared to those reported for 
normotensive animals [41].  
Curiously, the tested hydrolysates presented different decreasing 
patterns, while Hpp8 and Hpp11 presented the maximum decrease in 
SBP 6 h post-administration, and Hpp23 showed its maximum 
antihypertensive effect at 8 h post-administration. Moreover, the 
antihypertensive effect of Hpp23 was more prolonged over time, 
remaining at least 24 h post-administration. In addition, the 
antihypertensive effect of Hpp8 and Hpp11 on DBP was again very 
similar, presenting both hydrolysates a main decrease 6 h post-
administration. However, the maximum decrease in DBP caused by the 
Hpp23 was 2 h before, at 4 h post-administration. Values of DBP 
returned to initial values, 24 or 48 h post-administration of Hpp8 and 
Hpp11 or Hpp23, respectively. Therefore, these findings indicate that 
the peptides responsible of antihypertensive effect could be different 
in the different hydrolysates since the antihypertensive effect pattern 
is not the same for all them. In fact, Hpp8 and Hpp11 peptides exert 
quicker antihypertensive effects than Hpp23 peptides, and they are 
rapidly metabolized into inactive products leading to the subsequent 
reduction in activity. 
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4. Conclusions 
This study shows that chicken feet are suitable raw materials for 
producing antihypertensive hydrolysates that could be used to 
formulate antihypertensive functional foods and nutraceuticals. 
Moreover, their use will enhance the revalorization of these waste 
products and make slaughterhouses more environmentally friendly. 
Further studies to identify the peptides responsible for these activities 
are in progress.  
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TABLES 
 
Table 1. ACEI activity represented as percentage or IC50 (µL) of 
hydrolysates obtained from chicken feet powder solutions with 
Neutrase or Protamex at 25 or 50 ºC during 24 h.   
Heat 
treatment 
conditionsa 
Hydrolysis conditions 
Enzyme Time (h) 
Temperature 
25 ºC 50 ºC 
pH 
ACEI 
activityb 
 (%) 
IC50 (µL) 
ACEI 
activityb (%) 
IC50 (µL) 
3.0 
Neutrase 24 
87.9 ± 3.0 1.5 ± 0.7 91.0 ± 1.8 0.9 ± 0.0 
7.5 91.5 ± 1.2 1.4 ± 0.7 93.0 ± 0.5 0.8 ± 0.3 
10.0 91.5 ± 7.9 1.7 ± 1.4 93.1 ± 3.9 1.2 ± 0.1 
3.0 
Protamex 24 
92.3 ± 1.4 1.1 ± 0.2 93.1 ± 0.6 0.5 ± 0.0** 
7.5 90.1 ± 5.8 1.1 ± 0.3 95.7 ± 3.5 0.5 ± 0.0** 
10.0 96.4 ± 3.0 1.0 ± 0.6 97.4 ± 1.4 0.5 ± 0.1** 
 
a Chicken feet powder solutions were treated at 100 ºC prior hydrolysis at 
different pH conditions.  
b Angiotensin-converting enzyme-inhibitory activity of 50 % diluted 
hydrolysate. 
The data shown are mean values ± SD of ACEI activity of at least two different 
hydrolysates elaborated in the same conditions.  
** Differences between the IC50 (µL) of the hydrolysates elaborated under different 
hydrolysis temperature (25 or 50 ºC) (Student’s t test. p < 0.01).  
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Table 2. Degree of hydrolysis (DH), protein content and ACEI activity of 
hydrolysates obtained from chicken feet powder solutions treated at 
100 ºC and pH 3.0, 7.5 or 10.0 during 1.5 h and subsequent hydrolysis 
with Neutrase or Protamex at 50 ºC, pH 7.0.  
Samples pHa 
Hydrolysis 
conditions 
DH (%) 
Proteinb 
(%) 
ACEI activity 
Enzyme 
Time 
(h) 
Inhibitionc 
(%) 
IC50d (µL) 
Hpp1e 3.0 
Neutrase 0 
10.1 ± 0.4 0.4 ± 0.0 83.0 ± 2.5 2.7 ± 0.1 
Hpp2e 7.5 9.7 ± 0.2 0.3 ± 0.0 71.0 ± 3.5 3.4 ± 0.1 
Hpp3e 10.0 
10.9 ± 
0.2 
0.3 ± 0.0 80.8 ± 1.1 2.0 ± 0.3 
Hpp4e 3.0 
Protamex 0 
13.8 ± 0.1 0.5 ± 0.0 81.6 ± 5.5 4.1 ± 0.4 
Hpp5e 7.5 14.9 ± 0.1 0.4 ± 0.0 82.6 ± 1.6 2.6 ± 0.4 
Hpp6e 10.0 
14.9 ± 
0.2 
0.4 ± 0.0 85.2 ± 2.8 3.1 ± 0.1 
Hpp7 3.0 
Neutrase 2 
17.7 ± 1.6 0.6 ± 0.0 93.8 ± 1.6 0.9 ± 0.1 
Hpp8 7.5 
20.0 ± 
1.7 
0.6 ± 0.0 93.8 ± 1.0 0.9 ± 0.1 
Hpp9 10.0 
21.4 ± 
5.8 
0.6 ± 0.0 94.0 ± 1.5 1.0 ± 0.0 
Hpp10 3.0 
Protamex 2 
23.1 ± 2.2 0.7 ± 0.0 94.8 ± 0.8 0.8 ± 0.2 
Hpp11 7.5 
20.8 ± 
1.5 
0.7 ± 0.0 93.9 ± 1.7 0.6 ± 0.0 
Hpp12 10.0 
22.0 ± 
0.4 
0.7 ± 0.0 94.8 ± 3.5 0.7 ± 0.2 
Hpp13 3.0 
Neutrase 4 
20.5 ± 
2.0 
0.6 ± 0.0 101.6 ± 2.5 1.0 ± 0.0 
Hpp14 7.5 
23.4 ± 
0.9 
0.6 ± 0.0 91.4 ± 2.0 1.3 ± 0.1 
Hpp15 10.0 27.1 ± 2.2 0.7 ± 0.0 91.8 ± 2.2 1.4 ± 0.0 
Hpp16 3.0 
Protamex 4 
25.0 ± 
2.4 
0.7 ± 0.0 94.6 ± 0.1 0.7 ± 0.1 
Hpp17 7.5 
24.5 ± 
1.6 
0.7 ± 0.0 95.8 ± 2.7 0.6 ± 0.0 
Hpp18 10.0 
24.1 ± 
0.2 
0.7 ± 0.0 96.5 ± 4.9 0.6 ± 0.0 
Hpp19 3.0 
Neutrase 24 
20.4 ± 
0.4 
0.7 ± 0.0 91.0 ± 1.8 1.0 ± 0.0 
Hpp20 7.5 
22.9 ± 
0.1 
0.7 ± 0.1 93.0 ± 0.5 0.8 ± 0.3 
Hpp21 10.0 
35.3 ± 
3.9 
0.6 ± 0.0 93.1 ± 3.9 1.3 ± 0.1 
Hpp22 3.0 Protamex 24 
33.7 ± 
0.8 
0.7 ± 0.0 93.1 ± 0.7 0.5 ± 0.0 
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a pH used in the heat treatment (100 ºC) of chicken feet powder dissolved in water 
prior to hydrolysis. 
b Protein was measured by Kjeldahl method. 
c Angiotensin converting enzyme inhibitory activity of 50 % diluted hydrolysate.  
d Volume of hydrolysate needed to give the 50 % of inhibition. 
e Chicken feet powder solution treated at 100 ºC and different pH and posteriorly 
added the corresponding enzyme but without hydrolysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hpp23 7.5 
28.5 ± 
0.2 
0.7 ± 0.0 95.8 ± 3.5 0.5 ± 0.0 
Hpp24 10.0 
28.8 ± 
0.7 
0.7 ± 0.0 97.4 ± 1.4 0.5 ± 0.1 
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FIGURES 
Figure 1. Graphical representation of the IC50, concentration of protein 
(µg/mL of hydrolysate) required to inhibit 50 % angiotensin-converting 
enzyme activity, of the 24 hydrolysates obtained in this study. Values 
are the average of two replicates ± SD. Nomenclature of the 
hydrolysates is as described in Table 2. 
 
Figure 2. Dose–response curves (effect as a function of the dose in 
microliters) for the three selected hydrolysates. Values are the average 
of two replicates. Nomenclature of the hydrolysates is as described in 
Table 2. 
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Figure 3. Decrease in systolic blood pressure (SBP) (A) and diastolic 
blood pressure (DBP) (B) caused in spontaneously hypertensive rats by 
the administration of water, Captopril (50 mg/kg bw), and the 3 
selected hydrolysates obtained from chicken feet proteins (5 mL/kg 
bw): Hpp8, Hpp11 and Hpp23. The data represent mean values ± SEM 
for a minimum of 6 rats. Different letters represent significant 
differences (p < 0.01) between hydrolysate administered group and 
water (a) or differences between hydrolysate administered group and 
captopril group (b) (Two-way ANOVA, Duncan post hoc test).  
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acute dose and the mechanisms 
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                                                                MANUSCRIPT 2 
    Objective 
To determinate the most effective acute dose of a chicken foot 
hydrolysate Hpp11 to reduce BP in SHR, to discard a possible 
hypotensive effect in normotensive animals WKY rats                                                                               
and to establish the mechanisms underlying the antihypertensive effect 
of Hpp11 in SHR. 
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    CHAPTER 3 
To evaluate the effect of long-term 
administration of chicken foot hydrolysate Hpp11 
in diet-induced hypertension 
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                                                                 MANUSCRIPT 3 
    Objective 
To investigate the long-term administration effect of chicken foot 
hydrolysate Hpp11 in diet-induced hypertension and to elucidate the 
molecular mechanisms involved in its chronic antihypertensive effect. 
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Abstract 
The aim of this study was to evaluate the effect of long-term 
administration of the protein hydrolysate from chicken feet Hpp11 in 
diet-induced hypertensive rats. Rats were fed standard or cafeteria 
(CAF) diets for 12 weeks, and during the final 3 weeks, CAF animals 
were administered vehicle, Captopril or Hpp11. Systolic blood pressure 
(SBP) was recorded weekly. Body weight and plasmatic lipid and 
glucose levels were determined. Moreover, liver-reduced glutathione 
(GSH) levels, plasmatic angiotensin converting enzyme (ACE) activity 
and the endothelial gene expression of eNOS, KLF-2, Sirt-1, NOX4 and 
ET-1 were studied. A definite decrease in SBP was recorded in the rats 
that were administered Hpp11. Hpp11 downregulated gene expression 
of the vasoconstrictor ET-1 and induced the upregulation of NOX4 and 
NO enhancer Sirt-1, suggesting the vasoprotective effect of Hpp11. 
Moreover, Hp11 increased hepatic GSH. The present findings suggest 
that Hpp11 is a good candidate to ameliorate diet-induced 
hypertension. 
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1. Introduction 
Hypertension (HTN) is a common risk factor for cardiovascular disease 
(CVD) and a major global public health problem. It affects nearly 45% 
of the world population and results in over ten million deaths annually 
[1]. Remarkably, HTN frequently occurs concurrently with other CVD 
risk factors related to lifestyle, such as obesity, dyslipidemia and 
impaired glucose tolerance (hyperglycemia), resulting in metabolic 
syndrome (MetS) [2]. Rats fed a cafeteria (CAF) diet receive highly 
palatable, energy dense and unhealthy human food ad libitum, while 
they have free access to standard (STD) chow diet and water. These 
animals are considered a robust model of human MetS, displaying 
increased body weight (BW), increased abdominal fat, 
hyperinsulinemia, hyperglycemia, and hepatic steatosis [3]. The 
development of HTN in CAF diet-fed rats has also been reported [4]. 
The treatment of MetS is still a medical challenge, considering the 
complexity of this multifactorial disease [5]. In this sense, interest in 
the research of new therapies for MetS treatment is increasing, and 
the use of bioactive natural ingredients has emerged as a possible 
alternative in the prevention and treatment of this disease.  
The hydrolysis of food proteins is considered a potential source of 
peptides with different bioactivities [6]. Among all these bioactivities, 
highlights the capacity of different peptides to inhibit angiotensin-
converting enzyme (ACE), key-enzyme in blood pressure (BP) control. 
Different protein sources have been reported to release 
antihypertensive peptides such as milk and egg [7] or meat muscle [8], 
among others. In this sense, the interest of proteins derived from food 
by-products for this purpose has increased [9, 10]. The use of food by-
products allows revalorizing this waste materials, making the food and 
agricultural industries more environmentally friendly [11]. In this regard, 
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our group has used chicken foot, a poultry industry by-product, to 
obtain protein hydrolysates presenting antihypertensive effect after 
acute administration [12]. The involvement of ACE inhibition in the 
antihypertensive effect of one of the obtained hydrolysates (Hpp11), 
was confirmed 6 h after its administration in hypertensive rats [12]. 
However, HTN is a chronic pathology requiring chronic treatment; 
thus, the evaluation of the effect of chronic administration of Hpp11 is 
required to evaluate its potential as an antihypertensive agent. In 
addition, the involvement of other mechanisms in the benefits of Hpp11 
hydrolysate on HTN has not already been elucidated. 
Indeed, other mechanisms of action, beyond ACE inhibition, have been 
reported to explain antihypertensive effects of biologically active 
peptides from different food sources [13]. A reduction in BP by 
restoring the endothelium-derived factors production homeostasis and 
by reducing oxidative stress has been reported for some bioactive 
peptides [14]. Endothelial tissue regulates vascular tone and exerts 
finely tuned control over cardiovascular homeostasis, including nitric 
oxide (NO), one of the best characterized vasodilator endothelial 
factors, and endothelin-1 (ET-1), one of the strongest known 
vasoconstrictors [15]. NO is synthesized in the endothelial cells by an 
isoform of the enzyme NO synthase (eNOS) [16], which in turn is 
regulated by eNOS-promoter transcription factor Krüpple like factor 2 
(KLF-2). KLF-2 can inhibit the expression of ET-1 [17], which is 
overexpressed in the vasculature in different hypertensive models [18]. 
KLF-2 activation is also regulated by Sirtuin-1 (Sirt-1), which is mainly 
known as an eNOS promoter (Pons, Margalef, Bravo, Arola-Arnal, & 
Muguerza, 2016). In turn, Sirt-1 promotes the inhibition of NADPH 
oxidase (NOX) activity, which is known to be a reactive oxygen species 
(ROS) producer [20]. 
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Furthermore, besides the imbalance between the production of 
vasodilators and vasoconstrictors, an increase in oxidative stress due 
to the presence of different pathological conditions can also lead to 
the development of endothelial dysfunction and, as a result, can 
induce an increase in BP [21]. In this sense, it has been reported that 
some protein hydrolysates present antioxidant effects and reduce 
oxidative stress. Udenigwe et al. [22] reported that an increase in the 
production of reduced glutathione (GSH), an endogen antioxidant 
system, is one of the antioxidant mechanisms exerted by these 
hydrolysates. 
Therefore, the principal aim of the present study was to evaluate the 
SBP-lowering effect caused by Hpp11 after 3 weeks of administration in 
an animal model of HTN associated with MetS. To reach this objective, 
CAF diet-fed rats were used in this study. Moreover, the molecular 
mechanisms underlying the long-term effects of Hpp11 were studied in 
these animals. 
2. Materials and methods 
2.1. Chemicals and reagents 
Chicken feet from Gallus gallus domesticus were provided by a local 
farm (Granja Gaià, La Riera de Gaià, Spain). Protamex® (EC 3.4.21.62 
and 3.4.24.28, 1.5 AU/g from Bacillus licheniformis and Bacillus 
amyloliquefaciens), was kindly provided by Novozymes (Lyngby, 
Denmark). ACE (angiotensin converting enzyme, EC 3.4.15.1), N-
Hippuryl-His-Leu (Hip-His-Leu), monochlorobimane and glutathione-S 
transferase from horse liver were purchased from Sigma-Aldrich 
(Madrid, Spain). Captopril was provided by Santa Cruz Biotechnology 
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(Dallas, TX, United States). All other chemical solvents used were of 
analytical grade.  
2.2. Preparation and characterization of the chicken foot 
hydrolysate Hpp11  
Hpp11 was obtained following the method described by Bravo et al. 
[23]. Briefly, chicken feet powder mixed with distilled water was 
pretreated for 1.5 h in a water bath set at 100 ºC, 100 rpm. 
Subsequently, an enzymatic solution of Protamex® was added at a final 
concentration of 2.67 µg/mL (enzyme/substrate ratio, 0.4 AU/g 
protein). Hydrolysis was carried out at 50 ºC for 2 h at pH 7.0 in a 
MaxQ Orbital Shaker Thermo Scientific (Thermo Fisher Scientific, 
USA). At the end of reaction, the enzyme was heat inactivated (80 ºC, 
10 min) in a water bath. Then, hydrolysate was centrifuged at 10,000×g 
for 20 min at 4 ºC, and supernatant filtered through a 0.45 μm 
membrane was collected and lyophilized.  
Total protein content was determined by the Kjeldahl method 
according to AOAC methods [24] (total nitrogen content was 
multiplied by 6.25). The degree of hydrolysis (DH) was obtained 
following the TNBS method according to Adler-Nissen [25], in which 
free α-amino groups were determined. A leucine calibration curve was 
used. In addition, amino acid profile of the hydrolysate was 
determinate in this hydrolysate in duplicate.  The identification and 
quantification of the amino acid content was performed by following 
the method described by Dahl-Lassen et al. [26] with some 
modifications. Thus, an acidic hydrolysis using 6 N HCl, under 
increasing temperatures until 150 º C for 1.5 h, followed by basic 
hydrolysis using 4.2 N NaOH under the same conditions used in the 
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acidic hydrolysis. Then, samples were analyzed by UHPLC-QToF/MS 
to identify and quantify amino acid profile in Hpp11.  
ACEI activity was determined according to Guerrero et al. [27] with 
some modifications. ACE working solution was diluted with 0.15 M Tris 
buffer (pH 8.3) containing 0.1 μM ZnCl2 with 0.04 U/mL of enzyme in 
the final reaction solution. A total of 40 μL of sample, distilled water or 
this enzyme working solution were added to each microtiter-plate well 
and were adjusted to 80 μL by adding distilled water if it was 
necessary. The enzymatic reaction started by adding 160 μL of 
0.45 mM o-Abz-Gly-p-Phe(NO2)-Pro-OH dissolved in 150 mM Tris-base 
buffer (pH 8.3), containing 1.125 M NaCl, and the mixture was 
incubated at 37 °C. The sample fluorescence was recorded at 30 min 
using a multiscan microplate fluorimeter (FLUOstar optima, BMG 
Labtech, Offeuburg, Germany). Excitation and emission wavelengths 
were 360 and 400 nm, respectively. The software used to process the 
data were FLUOstar control (version 1.32 R2, BMG Labtech). The ACEI 
activity of Hpp11 was determined as the IC50 (µg of Hpp11 lyophilized). 
The IC50 is the concentration of each hydrolysate (µg of Hpp11 
lyophilized) that reduces the enzyme activity by half. The 
determination of ACEI activity was performed at least in duplicate.  
2.3 Experimental procedure in rats 
Five-week-old male normotensive Wistar rats, Crl:WI were obtained 
from Charles River Laboratories (Barcelona, Spain). The rats were 
maintained at 22 ºC under 12-h light/12-h dark conditions. They 
received STD chow Panlab A04 (Panlab, Barcelona, Spain) and tap 
water ad libitum during the quarantine period (10 days). After that, rats 
were divided into two dietary groups: the STD diet-fed rats, which 
were fed ad libitum STD chow Panlab A04 (Panlab, Barcelona, Spain) 
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and tap water, or CAF diet-fed rats, which were fed fresh CAF diet in 
addition to the STD diet and tap water. CAF diet consisted of biscuits 
with paté, biscuits with cheese, semi cured cheese, bacon, ensaïmada 
(sweetened pastry), carrots and milk with sucrose 20% (w/v) daily. The 
composition of the CAF diet was 35% fat, 51% carbohydrates, 14% 
protein and 0.2% Na, whereas STD diet was 4% fat, 76% 
carbohydrates, 20% protein with 0.3% Na [19]. The different diets were 
administered for 12 weeks. At the 9th week of the experiment, STD diet-
fed rats group were orally administered sweetened milk, containing 
20% sucrose, as vehicle (VH) (n=6 per group; STD+VH). CAF diet-fed 
rats were divided into 3 groups (n=6 per group) and were orally 
administered VH (CAF+VH), VH containing 50 mg/kg body weight 
(bw) of Captopril (CAF+Captopril) or VH containing 55 mg/kg bw of 
Hpp11 (CAF+Hpp11). All compounds were administered daily in a 
volume of 1 mL between 08.00 and 09.00 h for 3 weeks. Systolic blood 
pressure (SBP) was measured weekly during all the experiments by the 
same person to reduce stress-induced variations. SBP was recorded by 
the tail-cuff method [28] at 3 h post administration.  
At the end of the experiment, the rats were fasted for 3 h after the oral 
administration, body weight (BW) was recorded, and then animals 
were killed by live decapitation. Total animal blood was collected into 
tubes containing lithium heparin (Deltalab, Barcelona, Spain) as an 
anticoagulant. The aorta and liver were excised, cleaned and 
immediately frozen in liquid nitrogen and stored at -80 ºC until 
analysis. Plasma was obtained after blood centrifugation at 1500×g for 
15 min at 4 ºC and stored at -80 ºC until their use. The complete 
experimental design is schematized in Figure 1. 
The Animal Ethics Committee of University Rovira i Virgili approved all 
procedures (reference number 7959 by Generalitat de Catalunya). All 
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of the above mentioned experiments were performed as authorized 
(European Directive 86/609/CEE and Royal Decree 223/1988 of the 
Spanish Ministry of Agriculture, Fisheries and Food, Madrid, Spain). 
2.4 Biochemical plasma determinations  
Plasma total cholesterol (TC), triglycerides (TG) and glucose were 
measured using enzymatic colorimetric kits following the 
manufacturer’s protocols (QCA, Barcelona, Spain).  
Plasmatic ACE was measured following the method reported by Pons 
et al. [4]. Briefly, triplicate plasma (3 µL) aliquots were incubated for 
15–90 min at 37 ºC with 40 µL of ACE substrate 5 mM Hip-His-Leu 
(Sigma) assay buffer. Then, 190 µL of 0.35N HCl were added to stop 
the reaction. The generated product, His-Leu, was measured 
fluorometrically following a 10-min incubation with 100 µL of 2% o-
phathaldialdehyde in methanol. The measurements were performed in 
multiscan microplate fluorimeter FLUOstar optima (BMG Labtech) at 
37 ºC, using 350 nm excitation and 520 nm emission filters. 
Commercial ACE at different concentrations was used to obtain a 
calibration curve. ACE activity was expressed as the mean (mU 
ACE/mL of plasma) ± standard error of the mean (SEM) for at least 
three replicates. 
2.5 Reduced glutathione assay 
The GSH assay was performed in liver following the 
monochlorobimane fluorometric method [29]. To evaluate GSH levels, 
90 µL of homogenized supernatant from the liver was mixed with 
monochlorobimane (100 mM) and 10 µL of the catalyst, glutathione S-
transferase solution (1 U/mL). The levels of GSH were quantified using 
a multiscan microplate fluorimeter FLUOstar optima (BMG Labtech) 
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and were expressed as the mean (µmol of reduced glutathione/g tissue 
protein) ± SEM for at least three replicates. 
2.6 RNA extraction and mRNA quantification by real-time qPCR 
RNA extraction was performed in homogenized thoracic aorta using an 
RNeasy Mini Kit following the manufacturer’s protocols (Qiagen, 
Barcelona, Spain). Total extracted RNA was quantified in a Nanodrop 
100 Spectrophotometer (Thermo Scientific). mRNA retrotranscription 
was carried out by using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Madrid, Spain). Quantitative 
PCR amplification and detection were performed in the CFX96 Touch 
Real Time PCR System (Bio-Rad, Barcelona, Spain) using 96-well plates 
and SYBR PCR Premix Reagent Ex Taq™ (Takara, Barcelona, Spain) 
following the commercial protocol.  
Relative mRNA levels of KLF-2, eNOS, Sirt-1, NOX4 and ET-1 were 
analyzed by real-time PCR using peptidylprolyl isomerase A (PPIA) as 
the housekeeping gene. Primers used for the different genes are 
shown in Table 2 and were obtained from Biomers (Söflinger, 
Germany). Primer specificity was verified by melting curve analysis, 
and the amplicon size was verified by 3% agarose gel electrophoresis. 
The efficiency of qPCR was calculated by evaluating a 2-fold dilution 
series of aortic cDNA and was calculated by E = 10(1/slope). The results 
were expressed as the logarithm of the cDNA concentration vs the 
obtained Ct. Relative expression was calculated by dividing the ECt of 
the studied gene by the ECt of the housekeeping gene used as the 
control and then divided by the value of the control situation, STD+VH 
group gene expression. Each sample was analyzed in triplicate.  
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2.7 Statistical analysis 
The results were expressed as the mean ± SEM of six animals per 
group. The data were analyzed by one-way ANOVA or two-way 
ANOVA (Tukey’s test) using IBM SPSS Statistics 20.0 software (SPSS, 
Inc, Chicago, IL, USA). Outliers were identified and eliminated by using 
Grubbs’ test. The comparisons were considered significant at p < 0.05. 
 
3. Results 
3.1 Hpp11 characterization 
Hpp11 was produced and characterized before its administration to 
CAF-diet rats.  The Hpp11 protein content was 62.62 ± 0.00 % (w/w), 
the DH was 19.62 ± 0.76 %. The amino acid profile, expressed as mg of 
amino acid residue per g of lyophilized chicken foot hydrolysate, 
showed that the most abundant amino acid residues Leucine (41.07 ± 
1.26 mg/g), Isoleucine (28.18 ± 0.85 mg/g) and Proline (22.20 mg/g ±  
0.53 mg/g) (Table 1). The ACE inhibitory activity, expressed as the IC50, 
was 8.89 ± 0.93 µg of Hpp11. 
3.2 Effect of Hpp11 on blood pressure 
Figure 2 shows the changes in SBP in the CAF diet-fed rats 
administered VH, Captopril (50 mg/kg bw) or Hpp11 (55 mg/kg bw) for 
3 weeks. The rats fed the CAF diet developed hypertension between 
the 6th and 8th week of diet consumption, reaching values of 142 ± 2 
mmHg for SBP. At the 9th week of diet consumption, supplementation 
of the CAF diet with VH, Captopril or Hpp11 was carried out. It was 
observed that while SBP from the CAF+VH group increased as the 
experiment progressed, reaching values of 149 ± 5 mmHg, the groups 
administered Captopril (CAF+Captoril) or Hpp11 (CAF+Hpp11) 
presented a significant decrease in SBP, showing values of 114 ± 3 and 
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131 ± 1 mmHg, respectively, at the end of the experiment. It is 
important to mention that since the first week of administration, Hpp11 
was able to reduce SBP, showing a similar decrease to that produced 
by Captopril (-9 ± 1 and -10 ± 2 mmHg, respectively). The Hpp11-
induced decrease in SBP was sustained for the three weeks of 
supplementation, showing that the values of this group were close to 
130 mmHg during the three weeks of treatment. However, Captopril 
produced a more pronounced decrease in SBP that was able to restore 
initial values of SBP (117 ± 2 mmHg) at the end of the experiment.  
3.3 Effect of Hpp11 on other cardiometabolic risk factors associated 
with the MetS 
BW and the plasmatic TG, cholesterol and glucose values at the end of 
the experiment are shown in Table 1. The values of BW, plasmatic TG, 
plasmatic cholesterol and plasmatic glucose were significantly higher 
in the groups fed the CAF diet (CAF+VH, CAF+Captopril, CAF+Hpp11) 
than in the group fed standard diet (STD+VH). 
3.4 Effects of Hpp11 on plasmatic ACE, the endogen antioxidant 
system and endothelial function-associated genes  
Figure 3 shows the plasmatic ACE activity values. No differences were 
observed between the STD+VH and CAF groups administered VH and 
Hpp11. However, the CAF diet group administered Captopril presented 
significantly higher values in this parameter.  
The Hpp11 effect was evaluated by the production of GSH in liver. It 
was observed that Hpp11 administration to CAF diet-fed rats produced 
a significant increase in GSH production compared to the CAF groups 
administered Captopril or VH and compared to the STD+VH group 
(Figure 4). 
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Finally, the Hpp11 effect on endothelial function-associated genes was 
studied in the aorta to determine whether the antihypertensive effect 
of long-term administration of Hpp11 could be related to the 
improvement of endothelial function (Figure 5). It was observed that 
Hpp11 significantly increased the mRNA expression of Sirt-1. KLF-2 was 
also increased in the Hpp11 group; however, there were no significant 
differences compared to STD+VH group or CAF+VH group. No 
differences in mRNA eNOS expression were observed in the group 
administered Hpp11 either.  
Additionally, mRNA expression of NOX4 was upregulated in the 
CAF+Hpp11 group, while it was observed that Hpp11 produced a 
significant decrease in ET-1 expression.  
4. Discussion 
HTN is considered one of the most relevant risk factors for MetS, and 
its control clearly reduces the incidence of CVD [30, 31]. High BP is 
typically controlled by the chronic administration of antihypertensive 
drugs. Moreover, BW reduction and improving the plasmatic lipid 
profile have also been demonstrated to be essential for HTN control, 
especially when HTN is associated with MetS [32]. The chicken foot 
hydrolysate Hpp11 has recently been demonstrated to exhibit 
antihypertensive properties after acute administration in SHR [23]. 
Nevertheless, because HTN is a chronic pathology that requires 
chronic treatment [33], the evaluation of the potential antihypertensive 
effect of Hpp11 after chronic administration is crucial. To assess this 
objective, CAF diet-fed rats were used in this study. These animals are 
considered as a robust model for human MetS that provides an 
exceptional tool for screening antihypertensive agents for diet-induced 
HTN [34]. 
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The results of this study show that the administration of Hpp11 at 55 
mg/kg bw for 3 weeks produced a clear decrease in the SBP of CAF-
diet rats compared to their counterpart animals administered VH, 
demonstrating the chronic antihypertensive properties of Hpp11 in this 
animal model. In this sense, while Hpp11 produced a significant 
decrease in SBP from the 1st week of administration, the SBP of the 
CAF+VH group continued to increase as the experiment progressed, 
reaching final SBP values close to 150 mmHg. These findings 
demonstrate that Hpp11 produces an antihypertensive preventive 
effect in CAF diet-fed rats by preventing the continuous increase in 
SBP triggered by CAF-diet intake. Interestingly, at the 1st week of Hpp11 
administration, this hydrolysate was able to reduce SBP as much as 
Captopril decreased SBP (-19 ± 2 mmHg and -20 ± 3 mmHg, 
respectively). Moreover, Hpp11 showed a sustained antihypertensive 
effect from the 1st week of administration until the end of the 
experiment. Other studies have reported the long-term 
antihypertensive effects of other protein hydrolysates in SHR [35, 36]. 
However, the SHR model, which presents an important genetic 
component, is very different from the CAF-diet fed rats used in this 
study. As was mentioned previously, the CAF-diet fed rat model is a 
model of diet-induced HTN. Moreover, HTN in these animals is 
associated with other cardiometabolic risk factors. In the present study 
it was observed that after 8 weeks of diet consumption, CAF diet-fed 
rats presented with obesity, impaired glucose homeostasis and 
hypertriglyceridemia, in addition to HTN. These findings agree with 
those reported by Pons [34]. In this sense, since previous studies have 
reported that some protein hydrolysates derived from other food 
matrixes, such as fish or soy, affect other cardiometabolic risk factors, 
such as plasmatic cholesterol [37] or BW [38], the Hpp11 administration 
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effect was also evaluated on these altered cardiometabolic factors in 
CAF diet-fed rats. Nevertheless, no changes in BW, glucose 
homeostasis, plasmatic TG or plasmatic total cholesterol were 
observed after Hpp11 administration for 3 weeks with respect to the 
CAF diet-fed rat administered vehicle. Similar results were observed 
for the CAF rats that were administered Captopril, with no observed 
improvements in these parameters compared to the CAF group 
receiving VH. 
In addition, in the present study, we researched the mechanisms 
underlying the long-term antihypertensive effect observed after Hpp11 
supplementation in CAF diet-fed rats. One of the mechanisms involved 
in endothelial damage and the control of BP is oxidative stress. In this 
sense, in obesity, as a consequence of an alteration in the production 
of inflammatory cytokines, there is an increase in oxidative stress and 
in the development of endothelial dysfunction. This endothelial 
dysfunction is characterized by the increase in the contractibility of the 
vascular smooth muscle, the scavenging of the vasodilator NO or the 
stimulation in the production of vasoconstrictors and pro-inflammatory 
agents [39]. Liver concentration of GSH is a known biomarker for the 
global oxidative stress status in the body. GSH is considered a key 
antioxidant that reduces oxidative stress by removing ROS from the 
system [40]. In this study, Hpp11 clearly produced an increase in the 
production of hepatic GSH, which indicates an improvement in 
oxidative stress. In agreement, Liu et al. found that antioxidant effects 
induced by waste proteins of Mactra veneriformis also enhanced the 
activity of GSH [41]. In addition, other studies revealed antioxidant 
properties for proteins and peptides that improved oxidative stress by 
multiple pathways [42].  
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The renin angiotensin aldosterone system is a key factor in the 
maintenance of arterial BP, and one of its main components is ACE. 
Hpp11 was previously reported to inhibit ACE activity after acute 
administration in SHR [43]. However, we did not find significant 
changes in the plasmatic ACE activity after long-term Hpp11 
administration. Nevertheless, it has also been reported that long-term 
treatment with ACE-inhibitors can produce an increase in plasmatic 
ACE concentration in both humans [44] and rats [45]. In agreement, we 
found that the CAF rats administered the ACE inhibitor Captopril 
presented an increase in plasmatic ACE activity. Miguel et al. also 
reported an increase in plasmatic ACE after long-term administration 
of egg white hydrolysate in SHR [35]. An increase in ACE gene 
transcription during HTN treatment with ACE inhibitors seems to be 
responsible for the resulting plasmatic ACE increase [46]. This increase 
could be an adaptive response to the inhibition of ACE; however, it 
does not seem to reduce the effectiveness of these drugs.  
Furthermore, a potential vasoprotective effect of Hpp11 was studied 
through the expression of key genes implicated in endothelial function. 
In this sense, Sanchez et al. reported that the milk casein peptides VPP 
and IPP reduced BP through ACE inhibition and an increase in eNOS 
mRNA expression and through the resulting increase in NO availability 
[36]. However, no changes in the expression of eNOS were obtained 
after Hpp11 administration, and no changes in the transcription factor 
KLF-2, which is a potent inducer of eNOS expression, were observed in 
the rats administered Hpp11. However, Hpp11 produced the 
upregulation of Sirt-1 mRNA expression. Sirt-1 is a NAD-dependent 
deacetylase that induces the deacetylation of eNOS and that, 
consequently, increases NO availability [47]. Therefore, the 
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involvement of NO in the antihypertensive effect of Hpp11 should not 
be ruled out.  
In addition, the effect of Hpp11 on NOX4 mRNA expression was also 
evaluated. NOX is the main producer of free radicals in the vasculature 
[20], and in this study, the mRNA expression of NOX4 was upregulated 
in the animals administered Hpp11. Nevertheless, unlike NOX isoforms 
1 and 2, NOX4 is constitutively active and produces primarily H2O2 
rather than •O2− [38]. In this regard, its pathophysiological role is not 
clear, although high levels of NOX4 have been associated with the 
presence of oxidative stress [48]. However, no differences in mRNA 
expression of NOX4 were found between MetS rats administered the 
CAF diet or the healthy control group administered the STD diet, with 
mRNA NOX4 levels excluded as oxidative stress markers in the present 
study. Additionally, other studies demonstrated that NOX4 might have 
protective effects. In this sense, Drummond et al. reported that NOX4 
exerts vasoprotective effects by increasing NO bioavailability and 
suppressing cell death pathways in arteries from animals with 
experimentally induced hypertension, diabetes, or atherosclerosis [49]. 
In addition, Ray et al. reported that mice with a genetic deletion of 
NOX4 developed exaggerated contractile dysfunction, hypertrophy, 
and cardiac dilatation during exposure to chronic overload, indicating 
that NOX4 enhanced vasodilatation and reduced BP [50]. Therefore, 
we suggest that the significant upregulation of NOX4 after Hpp11 
administration in these animals would result in NOX4-derived 
vasoprotective effects. The effect of NOX4-derived H2O2 as a 
vasodilator in some vascular beds could be one of the mechanisms 
responsible for the beneficial effects of Hpp11 [49]. 
 Finally, it was observed that Hpp11 reduced the mRNA expression of 
ET-1 compared to the CAF+VH group. ET-1 is one of the main 
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vasoconstrictors in the endothelium that has been reported to be 
upregulated in obesity and MetS [51]. In addition, apart from the 
vasoconstrictive action, ET-1 causes fibrosis of the vascular cells and 
stimulates the production of ROS [52]. The results showed that Hpp11 
reduced the expression of ET-1. In this sense, ET-1 release was found to 
be inhibited after the administration of peptide derived from the 
bovine β-lactoglobulin ALPMHIR [53], and Fernández-Mussoles 
reported that lactoferrin hydrolysates inhibited endothelin-converting 
enzyme, a key enzyme for the production of active ET-1 [54].  
5. Conclusions 
Hpp11 administration for 3 weeks significantly reduced BP in animals 
presenting diet-induced HTN. Hpp11 exhibits an antioxidant effect and 
confers a vasoprotective effect on CAF-diet fed rats, downregulating 
the aortic mRNA expression of the main endothelial vasoconstrictor, 
ET-1, and inducing the upregulation of NO-enhancer Sirt-1 mRNA and 
NOX-4 mRNA expression. Therefore, Hpp11 could be a good candidate 
for ameliorating diet-induced HTN. Nevertheless, further studies are 
needed to evaluate its efficiency in humans.  
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TABLES 
Table 1. Amino acid profile of chicken foot hydrolysate Hpp11. 
Amino acid  (mg/g) 
Alanine 20.26 ± 0.53 
Arginine 3.36 ± 0.52 
Asparagine n.d. 
Aspartic acid 5.22 ± 0.29 
Cysteine 0.39 ± 0.05 
Glycine 22.04 ± 0.51 
Glutamic acid 16.84 ± 0.55 
Glutamine n.d. 
Histidine           8.66 ± 0.47 
Lysine 4.42 ± 0.64 
Methionine 5.42 ± 0.03 
Phenylalanine 8.66 ± 0.47 
Proline 22.19 ± 2.29 
Serine 3.03 ± 0.11 
Threonine 2.01 ± 0.29 
Tryptophan 0.97 ± 0.19 
Tyrosine 9.42 ± 0.18 
Valine 9.65 ± 0.29 
Results are presented as mean ± standard deviation. N.D, non-identified. 
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Table 2. Primer list characteristics 
Rat 
primers 
Sequence (5′……3′) 
Size of 
amplicon 
Efficiency 
GenBank 
accession No. 
eNOS Fw GGATTCTGGCAAGACCGATTAC 
159 
2.06 
(100.67%) 
NM_021838.2 
eNOS Rv GGTGAGGACTTGTCCAAACACT 
ET-1 Fw TGATTCTCTTGCCTCTTCTTG 
110 
3.08 
(136.04%) 
NM_012548.2 
ET-1 Rv TATGGAATCTCCTGGCTCTC 
KLF2 Fw GGACGCACACAGGTGAGAA 
186 
2.18 
(107.85%) 
NM_001007684.1 
KLF2 Rv ACATGTGTCGCTTCATGTGC 
Sirt1 Fw TTGGCACCGATCCTCGAA 
217 
2.02 
(97.49%) 
XM_006223877.1 
Sirt1 Rv ACAGAAACCCCAGCTCCA 
NOX4 Fw GTGTCTGCATGGTGGTGGTA 
150 
2.24 
(110.62%) 
NM_053524.1 
NOX4 Rv TCAACAAGCCACCCGAAACA 
Table 3. Body weight and values of triglycerides, cholesterol and glucose in 
plasma in STD-diet rats and CAF-diet rats supplemented with VH (CAF+VH), 
50 mg/kg Captopril (CAF+Captopril) and 55 mg/kg Hpp11 (CAF+Hpp11) at the 
end of the experiment.  
    
STD+VH CAF+VH CAF+Captopril CAF+Hpp11 
    
 
Body weight (g) 431.8 ± 19.64a 517.40 ± 14.66b 501.40 ± 18.30b 537.94 ± 10.34b 
Tryglycerides 
(mmol/L) 0.66 ± 0.11a 1.82 ± 0.08b 2.09 ± 0.37b 2.11 ± 0.20b 
Cholesterol 
(mmol/L) 1.68 ± 0.13a 2.48 ± 0.22b 2.19 ± 0.16b 2.73 ± 0.24b 
Glucose (mg/dL) 176.80 ± 7.68a 257.21 ± 15.77b 238.41 ± 11.06b 249.74 ± 14.75b 
         Data are expressed as the mean of six animals ± SEM. Different letters (a,b) denote significant 
differences between groups by one-way ANOVA followed by Tukey post hoc analysis according 
to Levene’s test. esults are presented as mean ± standard deviation. N.D, non-identified. 
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FIGURES 
 
Figure 1. Graphical representation of the experimental design used in 
this study. STD, standard diet-fed rats; STD+VH, STD-diet rats 
administered vehicle; CAF, cafeteria diet-fed rats; CAF+VH, CAF-diet 
rats administered vehicle; CAF+Captopril, CAF-diet rats administered 
50 mg/kg Captopril; CAF+Hpp11, CAF-diet rats administered 55 mg/kg 
Hpp11. 
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Figure 2. Changes in SBP in rats fed CAF diet for 12 weeks and 
administered VH (CAF+VH), 50 mg/kg bw of Captopril 
(CAF+Captopril) or 55 mg/kg bw of Hpp11 (CAF+Hpp11) the last 3 
weeks of the experiment. Values are means (n=6 animals per group) 
with their standard errors. Different letters represent significant 
differences between groups for the overall effect during the 12 weeks 
of the experiment (two-way ANOVA; p<0.05). 
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Figure 3. Plasmatic ACE values at the end of the experiment in the 
STD+VH, CAF+VH, CAF+Captopril (50 mg/kg bw) or CAF+Hpp11 (55 
mg/kg bw) groups. Values are means (n=6 animals per group) with 
their standard errors. Different letters represent significant differences 
between groups (one-way ANOVA; p<0.05). 
 
 
 
 
Figure 4. Hepatic GSH production in liver in STD+VH rats and CAF rats 
supplemented with VH (CAF+VH), 50 mg/kg bw Captopril 
(CAF+Captopril) or 55 mg/kg Hpp11 (CAF+Hpp11) at the end of the 
experiment. The data shown are means (n=6 animals per group) with 
their standard errors. Different letters represent significant differences 
between groups (one-way ANOVA; p<0.05). 
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Figure 5. Changes in mRNA expression of genes related to endothelial 
function in STD+VH, CAF+VH, CAF+Captopril (50 mg/kg bw) and 
CAF+Hpp11 (55 mg/kg bw) at the end of the experiment. Values are 
means (n=6 animals per group) with their standard errors. Different 
letters represent significant differences between groups (one-way 
ANOVA; p<0.05). 
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 CHAPTER 4  
Identification of antihypertensive 
peptides in chicken foot hydrolysate 
Hpp11 
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antihypertensive properties.  
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Abstract 
Introduction: Chicken foot proteins have recently been demonstrated 
by our group to be a great source of hydrolysates with 
antihypertensive properties. The aim of this study was to isolate and 
identify angiotensin I-converting enzyme inhibitory (ACEI) peptides 
from chicken foot hydrolysate Hpp11 and to test their antihypertensive 
properties.  
 
Materials and methods: Peptides were separated into fractions 
according to their molecular size and hydrophobicity by ultrafiltration 
and RP-HPLC, respectively. Subsequent peptide identification in the 
two fractions that presented the highest ACEI activities was carried 
out by HPLC-MS. Ten of the identified peptides were synthesized and 
five of them showed ACEI (IC50) values lower than 100 µM. The 
antihypertensive effects of these ACEI peptides after oral 
administration was evaluated in spontaneously hypertensive rats.  
 
Results and discussion: The peptides AVFQHNCQE and 
QVGPLIGRYCG exhibited antihypertensive activity when administered 
at an oral dose of 10 mg/kg bw. The maximal decrease in systolic blood 
pressure was recorded 6 h after their administration (25.07 ± 4.21 and 
10.94 ± 1.96 mm Hg, respectively).  
 
Conclusion: These results suggest that AVFQHNCQE and 
QVGPLIGRYCG could be used as functional ingredients with 
antihypertensive effects, although it would be necessary to perform 
bioavailability and clinical studies to demonstrate their efficiency in 
humans. 
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1. Introduction 
In recent years, hypertension has become a public health concern, 
being one of the independent risk factor for developing cardiovascular 
diseases (CVD), the leading global cause of death [1]. It is well known 
that a reduction in blood pressure (BP) is beneficial to prevent CVD. 
One of the main regulatory systems of the BP is the renin-angiotensin-
aldosterone system, being angiotensin I-converting enzyme (ACE, EC 
3.4.15.1) the key enzyme in this system. ACE belongs to a family of zinc 
metallopeptidases and produce the cleavage of the C-terminal 
dipeptide from angiotensin I to release angiotensin II, a potent 
vasoconstrictor [2]. The inhibition of ACE is considered important 
target for treatment of hypertension [3]. However, the administration 
of synthetic ACE inhibitors, such as Captopril, Lisinopril and Enalapril, 
has been reported to have adverse side effects [4]. Thus, there has 
been an increasing interest in development of the natural 
antihypertensive compounds and ACE inhibitors as alternative for 
lowering BP [5].  
In this sense, bioactive peptides from dietary proteins have reported a 
wide range of biological activities [6, 7] including antihypertensive 
effect [8–10]. These peptides are enclosed in the native structure of the 
proteins and a treatment is needed to release these bioactive 
sequences [11].  However, other factors such as the possible structural 
changes performed during the protein digestion and the suitability to 
be absorbed in the gastrointestinal tract could interfere in the peptides 
final bioactivity in vivo [12]. Therefore, although bioactive peptides 
presenting in vitro ACE inhibitory (ACEI) activity has been extensively 
reported [13], the evidence for their beneficial antihypertensive effects 
has to be based on the effect after their administration in animal 
experiments [14].  
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Different protein sources have been demonstrated to release ACEI 
peptides with BP lowering properties after their oral administration [8, 
15, 16], including chicken proteins [17–20]. In this sense, chicken foot 
by-products of the poultry industry, have recently been established by 
our group as an excellent protein source to obtain hydrolysates with 
antihypertensive properties  [21]. In fact, the BP lowering effect after 
short and long-term administration of a low dose of the chicken foot 
hydrolysate Hpp11 have been recently demonstrated in spontaneously 
hypertensive rats (SHR) and cafeteria-diet fed rats [22, 23]. However, 
the chicken food bioactive peptides have not been characterized yet. 
Therefore, the aim of the present study was to isolate and identify the 
ACEI peptides present in Hpp11. The isolation of the peptides was 
performed by ultrafiltration followed by two chromatographic steps 
and their amino acid sequence were identified by mass spectrometry. 
The antihypertensive effect of peptides that exhibited notable ACEI 
activity was posteriorly proved in SHR. 
2. Materials and methods 
2.1. Chemicals and reagents 
Chicken feet (Gallus gallus domesticus) were provided by a local farm 
(Granja Gaià, La Riera de Gaià, Spain). Protamex® (EC 3.4.21.62 and 
3.4.24.28, 1.5 AU/g from Bacillus licheniformis and Bacillus 
amyloliquefaciens) were kindly provided by Novozymes (Bagsværd, 
Denmark). ACE (angiotensin converting enzyme, EC 3.4.15.1) was 
purchased from Sigma-Aldrich (Madrid, Spain), Captopril (PubChem 
CID: 44093) was purchased from Santa Cruz Biotechnology (Dallas, 
TX, USA) and o-aminobenzoylglicil-p-nitrofenilalanilprolina (o-Abz-Gly-
p-Phe(NO2)-Pro-OH) was provided by Bachem Feinchemikalien 
(Bubendorf, Switzerland). The synthesized peptides (LSETVV, 
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LSGPVKF, AVKILP, VRWEPAPGPV, VGKPGARAPMY, QVGPLIGRYCG, 
LGIHPDWQFV, and AVFQHNCQE, purity grade ≥ 90 %) were 
purchased from Caslo Laboratory ApS (Caslo, Kongens Lyngby, 
Denmark). Acetonitrile and trifluoroacetic acid were purchased from 
Sigma-Aldrich. All other chemical solvents used were of analytical 
grade. 
2.2. Preparation of chicken foot hydrolysate  
The chicken foot protein hydrolysate Hpp11 was elaborated using the 
commercial enzymatic solution Protamex® (Novozymes, Bagsværd, 
Denmark) (EC 3.4.21.62 and 3.4.24.28, 1.5 AU/g from Bacillus 
licheniformis and Bacillus amyloliquefaciens) as previously was 
described [21]. Briefly, chicken feet were cleaned, crushed, lyophilized, 
milled and sieved using a 2-mm pore size sieve to obtain a fine chicken 
foot powder. Chicken foot powder (20 mg/mL, w/v) was resuspended 
in distilled water and incubated for 90 min in a water bath set at 100 °C 
at 100 rpm. Subsequently, the Protamex® enzymatic solution was 
added at a final concentration of 2.67 µg/mL (enzyme/substrate ratio, 
0.4 AU/g protein). Hydrolysis was carried out at 50 ºC for 2 h at pH 7.0 
in a MaxQ Orbital Shaker Thermo Scientific (Thermo Fisher Scientific, 
Waltham, MA, USA). At the end of the reaction, the enzyme was heat-
inactivated (80 °C, 10 min) in a water bath. Then, the hydrolysate was 
centrifuged at 10,000 ×g for 20 min at 4 ºC and the supernatant was 
filtered through a 0.45-μm membrane; finally, the filtrate was collected 
for analysis.  
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2.3 Isolation and identification of ACEI peptides from chicken 
foot hydrolysate 
2.3.1. Step I: Protein separation based on protein molecular weight 
Hpp11 was subjected to ultrafiltration through two hydrophilic 
membranes with cut-off values of 3 and 10 kDa cut-off (Centripep, 
Amicon, Inc., Beverly, MA, USA). The obtained fractions (<3 kDa, 3-10 
kDa and >10 kDa) were freeze-dried and kept at -20 ºC until use. The 
protein concentration and ACEI activity were tested for each fraction 
at least in duplicate and used for fraction selection.  
2.3.2. Step II: Peptide separation based on peptide hydrophobicity 
Semipreparative RP-HPLC separations of the <3 kDa fraction were 
performed on an Agilent Series 1260 HPLC equipped with the Agilent 
OpenLab CDS ChemStation Edition for LC & LC/MS systems A.01.04 
software for data acquisition (Agilent Technologies, Santa Clara, CA, 
USA). A Europa peptide C18 column (25x1.0 cm i.d., 5 µm particle size, 
120 A˚ pore size) (Teknokroma) was used. Mobile phase A was a 
mixture of water-trifluoroacetic acid (1000:1) and mobile phase B 
contained a mixture of acetonitrile-trifluoroacetic acid (1000:0.8). 
Elution was performed in gradient mode as follows: initial conditions 0 
% B; 0-40 % B, 0-50 min; 40-45 % B, 50-51 min; 45-90 % B, 51-56 min; 
and 90-0 % B, 56-57 min. A 10 min post-run was required for column 
re-equilibration. The flow rate was set at 4 mL/min and analyses were 
performed at room temperature (RT). Absorbance of the eluent was 
monitored at 214 nm. The sample concentration was 10 mg/mL 
(dissolved in water) and the injection volume was 750 µL. Fractions 
from the HPLC system were freeze-dried and kept at -20 ºC until use. 
The protein concentration and ACEI activity were also tested for each 
fraction at least in duplicate and used for fraction selection.  
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The two fractions showing the most potent ACEI activity, F.3 and F.6, 
were subsequently subjected to a second semipreparative RP-HPLC 
separation. The chromatographic conditions were similar but the 
elution was performed with a linear gradient of solvent B in A, going 
from 10 % to 20 % B over 40 min at RT or from 20 to 30 % B over 40 
min for fractions F.3 and F.6, respectively. A flow rate of 4 mL/min was 
used in both cases. The sample concentration was 10 mg/mL 
(dissolved in water) and the injection volume was 750 µL. The ACEI 
activity and protein concentration were determined in all subfractions 
at least in duplicate and used for subfraction selection.  
2.3.3. Step III: Peptide identification by HPLC-MS 
For peptide identification, the most active hydrolysate subfractions 
(F3.3 and F6.6) obtained in the second RP-HPLC separation were 
diluted in 0.1 % TFA to a 0.1 mg/mL final concentration. A 10 μL aliquot 
of each sample was injected into the linear trap quadrupole (LTQ) 
Orbitrap Velos-PRO (Thermo Scientific). Peptides were loaded onto an 
EASY-Column (2 cm, ID 100 µm, 5 µm, C18-A1 precolumn) (Thermo 
Scientific) and then eluted onto an EASY-Column (10 cm, ID 75 µm, 3 
µm, C18-A2 analytical column) (Thermo Scientific) at a flow rate of 400 
nL/min on a nanoEasy high-performance liquid chromatography 
(HPLC) instrument (Proxeon) coupled to a nanoelectrospray ion source 
(Proxeon). The mobile phases used consisted of 0.1 % formic acid/2 % 
ACN (solvent A) and 0.1 % formic acid in 100 % ACN (solvent B). For 
the F3.3 fraction, the gradient was 0-45 % B over 80 min, from 45-100 
% over 20 min and then 10 min at 100 % B. In contrast, for the F6.6 
fraction, the gradient was from 0-35 % B over 40 min, from 35-100 % 
over 10 min and then 10 min at 100 % B. All mass spectra were acquired 
in positive-ion mode. Full–scan MS spectra were (m/z 50-2000) were 
acquired with a target value of 1000000 at a resolution of 30000 at 
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400 m/z, and the 15 most intense ions were selected for collision-
induced dissociation fragmentation in the LTQ with a target value of 
10000 and a normalized collision energy of 35 %. Precursor ion charge-
state screening and monoisotopic precursor selection were enabled. 
Singly charged ions and unassigned charge states were rejected. 
Dynamic exclusion was enabled with a repeat count of 1 and an 
exclusion duration of 30 s.  
Proteome Discoverer 1.4.288 (Thermo) with MASCOT 2.4.1.0 was used 
to search the IPI_chicken_3.81 fasta database (25992 sequences). The 
following database search parameters were used: peptide tolerance, 
10 ppm; fragment ion tolerance, 0.8 Da; no enzyme and variable 
modification, methionine oxidation. During peptide identification, 
probability scores greater than the score fixed by Mascot were 
considered as significant with a p-value minor than 0.05. The 
automatic decoy database search function in Protein Discover was 
enabled to allow estimation of the false discovery rate (FDR).  
The identified sequences were subsequently chemically synthesized by 
Caslo Laboratory ApS. 
2.4 ACEI activity  
ACEI activity was measured according to Mas-Capdevila et al. [22]. 
The fluorescence measurements were performed after 30 min in a 
multiscan microplate fluorimeter (FLUOstar optima, BMG Labtech, 
Offeuburg, Germany). The excitation and emission wavelengths were 
360 and 400 nm, respectively. The software used to process the data 
was FLUOstar control (version 1.32 R2, BMG Labtech). 
A nonlinear fit was performed on the experimental data to calculate 
the 50 % inhibitory concentration values (IC50) with the PRISM version 
4.02 program for Windows (GraphPad Software, Inc. San Diego, CA, 
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USA). ACEI activity was expressed as a percentage (%) or IC50 (µg /µL 
solution). The determination of the ACEI activity of the samples was 
performed at least in duplicate. Data are represented as a mean value 
± standard deviation (SD).  
Protein content was determined by the bicinchoninic acid method 
using the standard Pierce BCA Protein Assay (ThermoFisher Scientific). 
The assay was conducted according to the manufacturer’s instructions 
in a microplate format. A calibration standard curve was prepared with 
seroalbumin bovine. Determination of the protein content was 
performed at least in duplicate. The results are expressed as the mean 
± SD. 
2.5 Measurement of blood pressure 
Male SHR (17–20 weeks old, weighing 350–400 g) were obtained from 
Charles River Laboratories España S.A. (Barcelona, Spain). The animals 
were singly housed in animal quarters at 22 ºC with a 12 h light/dark 
period. They were fed with a standard diet based on chow Panlab A04 
(Panlab, Barcelona, Spain) and had access to tap water ad libitum.  
SHR systolic and diastolic blood pressure (SBP and DBP, respectively) 
was measured using the tail-cuff method [24] with a noninvasive BP 
system model (Letica, Hospitalet, Barcelona, Spain). The rats were 
given a single dose of 10 mg/kg bw of the synthesized peptides, 
including VGKPGARAPMY, QVGPLIGRYCG, AVFQHNCQE, LSGPVKF 
or AVKILP, dissolved in tap water in a total volume of 1.5 mL. Peptides 
were administered to the SHR by gastric incubation through an acute 
administration between 9 and 10 in the morning.  
Positive control rats received 50 mg/kg bw of Captopril, a known ACE-
inhibitor, also dissolved in 1.5 mL of tap water, and the negative control 
rats received 1.5 mL of tap water. SBP was measured in the rats before 
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peptide administration as well as 2, 4, 6, 8 and 24 h post-
administration. Before the measurement, the animals were kept at 38 
°C for 10 min to detect the pulsations of the tail artery. The changes in 
SBP and DBP were expressed as the differences in these variables 
before and after the administration of the different peptides. Data are 
shown as the mean values ± standard error of the mean (SEM) for a 
minimum of six experiments. Before starting the experiment, all 
animals were accustomed to the process with a 2-week training period. 
The animal protocol followed in this study was approved by Spanish 
Royal Decree 223/1988 and by the Bioethical Committee of Universitat 
Rovira i Virgili (reference number 8868 by Generalitat de Catalunya).  
Differences between treatments were analyzed by two-way analysis of 
variance (two-way ANOVA). All the analyses were performed using 
IBM SPSS Statistics (SPSS, Chicago, IL, US). Outliers were determined 
using Grubbs’ test. Differences between groups were considered 
significant when p< 0.05. 
 
3. Results  
3.1 Identification of ACEI peptides 
Hpp11 was first subjected to ultrafiltration through 3 kDa and 10 kDa 
cut-off membranes to separate the peptides according to their 
molecular size. ACEI activity was determined in the following three 
obtained fractions: <3 kDa, 3-10 kDa and >10 kDa. The percentages of 
inhibition obtained were 95.98 ± 0.72 for the <3 kDa fraction, 13.25 ± 
2.86 for the 3-10 kDa fraction and 30.50 ± 2.24 for the >10 kDa fraction 
at a protein concentration of 74.2, 78.3 and 41.7 µg/mL, respectively. 
The ACEI activity of the <3 kDa fraction was the most active and the 
expressed as IC50 was three and a half times higher than activity found 
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for Hpp11 hydrolysate (3.6 µg/mL vs. 12.6 µg/mL) (Figure 1). These 
results indicate that the ACEI activity of Hpp11 is mainly due to small 
peptides.  
The <3 kDa fraction was subjected to semipreparative RP-HPLC to 
separate the peptides according to their peptide hydrophobicity and 
eluted as described in Section 2.3.2. The base peak chromatogram for 
this fraction can be seen in Figure 2A, showing that the hydrolysate 
was a complex mixture of peptides. Thus, it was divided into 8 
fractions (named from F1 to F8), which were collected and lyophilized, 
and their ACEI activities were measured (Figures 2A and B). Fractions 
F2 to F6 showed high ACEI activity (≥70 %). The ACEI activity of these 
selected fractions was also determined and expressed as IC50 values 
(µg of protein/mL) to identify the fraction with the largest amounts of 
bioactive peptides. Most of the ACEI activity from the <3 kDa fraction 
occurred in fractions 3 and 6 (F3 and F6), which showed IC50 ≤ 2 µg/mL 
(1.99 and 1.24 µg/mL, respectively). These two fractions were further 
purified by a second RP-HPLC step. Figures 3A and B show the RP-
HPLC pattern obtained from F3 and F6. Fraction F3 was subdivided 
into 6 new subfractions (from F3.1 to F3.6) and F6 was subdivided into 
8 new subfractions (from F6.1 to F6.8). All fractions showed a specific 
ACEI activity ≤12 µg/mL (IC50) (Figures 3B, C, D and E). However, 
fractions F3.3 and F6.6 were remarkably the most active, with IC50 
values of 0.83 and 0.86 µg/mL, respectively (Figures 3D and E, 
respectively).  
The analysis of these subfractions by mass spectrometry allowed the 
identification of 772 peptides in fraction F3.3 and 248 peptides in 
fraction F6.6. Eight of these peptides were subsequently selected and 
synthesized. Peptide selection was performed according to their high 
sign intensity, peptide length and amino acid sequence (Table 1). As an 
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example, Figures 4A and 4B show the MS/MS spectrum of ion m/z 
538.2 and 554.3 that matched, corresponding to the sequences 
AVFQHNCQE and VRWEPAPGPV, respectively. The synthesized 
peptides showed a wide range of ACEI activity percentages from 0 to 
92 % (Table 2). From the eight peptides analyzed, only five peptides 
showed ACEI activity higher than 50 %. Their IC50 values were lower 
than 100 µM. Two of these peptides stood out for their high ACEI 
activity, sequences AVKILP and QVGPLIGRYCG, which showed IC50 
values as low as 7.06 and 11.01 µM, respectively.  
3.2 Antihypertensive activity of the synthetic peptides 
The antihypertensive effects of the peptides showing the lowest IC50 
values were evaluated in SHR (Figure 5). Prior to oral administration of 
the different peptides, SHR presented SBP values of 208 ± 8.0 mmHg 
and DBP values of 163.3 ± 4.6 mmHg (n= 6 for each treatment). The 
SBP and DBP of SHR administered water did not significantly change 
during the 48 h duration of the experiment. As expected, the 
administration of Captopril (50 mg/kg bw) resulted in an important 
decrease in the SBP of SHR from 2 h after its administration, with the 
maximum decrease (-33.67 ± 1.94 mmHg) observed at 6 h post-
administration. With respect to DBP, Captopril administration also 
produced a significant reduction, reaching a maximum decrease 4 h 
post-administration (-32.97 ± 8.8 mmHg). The antihypertensive effect 
was maintained to 48 h after Captopril administration.  
From the five peptide sequences administered to SHR, including 
VGKPGARAPMY, QVGPLIGRYCG, AVFQHNCQE, LSGPVKF and 
AVKILP, the peptides AVFQHNCQE and QVGPLIGRYCG exerted 
antihypertensive effects when administered at 10 mg/kg bw to SHR 
(Figures 5A and B). Nevertheless, AVFQHNCQE was the most active 
peptide. The administration of this peptide produced a significant 
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decrease in both the SBP and DBP in SHR (-25.07 ± 4.21 mmHg and –
17.65 ± 3.24 mm Hg, respectively). The maximum decrease in SBP 
caused by AVFQHNCQE was observed 6 h post-administration while 
the maximum decrease in DBP was registered at 2 h. BP returned to 
initial values 24 h after administration. Regarding QVGPLIGRYCG, it 
was also observed that this peptide produced a significant decrease in 
SBP (-10.94 ± 1.96 mm Hg) 6 h post-administration. Nevertheless, no 
significant reduction in DBP was observed when this peptide was 
administered. The BP of SHR after VGKPGARAPMY, LSGPVKF and 
AVKILP administration did not change during the experiment (data not 
shown). 
4. Discussion 
It is well-known that the hydrolysis of dietary proteins generates a 
large number of peptides, including some with potentially bioactive 
activities [25]. In this sense, the hydrolysis of chicken protein from 
byproducts has been reported to be a good source for obtaining ACEI 
and antihypertensive peptides [26]. In a previous study performed by 
our group, chicken feet dissolved in water were heated at 100 ºC and 
hydrolyzed using Protamex to obtain the hydrolysate Hpp11, which was 
able to reduce BP when administered to SHR at low doses [21]. The 
bioactivity of this hydrolysate was assumed to be due to the presence 
of specific peptide sequences in Hpp11. Thus, the aim of this study was 
to identify the antihypertensive peptides present in the hydrolysate 
Hpp11. To assess this objective, Hpp11 was subjected to ultrafiltration 
using hydrophilic membranes with 3 and 10 kDa cut-off values and 
ACEI activity of the different obtained fractions was measured. The 
results showed that the <3 KDa fraction presented the highest ACEI 
activity. This finding attributes the highest ACEI activity to small 
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peptides present in this hydrolysate. Similar results were reported by 
other authors for hydrolysates obtained from other protein sources 
[27–29]. Subsequently, the <3 kDa fraction was subjected to a two-step 
RP-HPLC analysis resulting in obtaining of two subfractions (F3.3 and 
F6.6) selected according to their high ACEI activity. The subsequent 
analysis of subfractions F3.3 and F6.6 by mass spectrometry allowed 
the selection of eight peptides (LSETVV, LSGPVKF, AVKILP, 
VRWEPAPGPV, VGKPGARAPMY, QVGPLIGRYCG, LGIHPDWQFV, 
AVFQHNCQE), which were subsequently synthesized. As far as we 
know, none of these peptides had been previously identified to have 
any bioactivity (search carried out in the BIOPEP database as of 
October 2018, www.uwm.edu.pl/biochemia/index.php/pl/biopep.  
The ACEI activity was lower than 100 µM for five of these identified 
amino acid sequences, indicating their potential roles as ACE 
inhibitors. This finding is based on the fact that all the selected 
peptides comprised between 6-11 amino acids; it has been previously 
reported that peptides presenting high ACEI activity are short in length 
and comprising 3 to 12 amino acids [5]. It has also been previously 
reported that the amino acid composition of the three consecutive C-
terminal positions plays an important role in ACE competitive 
inhibition [30]. However, the amino acid residues required for ACE 
inhibition at the C-terminal position can be different depending on the 
peptide size [31]. In general, the presence of hydrophobic aromatic 
amino acids (Tyr, Phe, or Try), or amino acids with hydrophobic 
branched side chains (Val, Leu, or Ile) lead to an increase in ACE 
inhibitory activity [13]. Additionally, many identified ACE inhibitors 
contain Pro at the C-terminal end [32]. In fact, Pro has a rigid ring 
structure that can lock the carboxyl group into a favorable 
conformation, making it able to interact with positively charged 
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residues in the active site of the enzyme. Regarding the N-terminal 
position, the presence of branched aliphatic amino acids such as Gly, 
Val, Leu, and Ile has been reported as good ACE substrates [33]. Thus, 
the presence of the Pro residue at AVKILP C-terminus, the Tyr residue 
at the C-terminus and the Val residue at the N-terminus in 
VGKPGARAPMY, and the Phe residue at the C-terminus and Leu at the 
N-terminus in LSGPVKF may contribute to their ACEI activity. 
Regarding the peptide AVFQHNCQE, the presence of glutamic acids in 
its sequence may contribute to its ACEI effect. Indeed, it is known that 
glutamic acid may cause a net negative charge, and the interaction of 
negatively charged peptides with ACE could chelate zinc atoms, which 
is a component of the ACE active center [34]. However, the peptide 
sequence for QVGPLIGRYCG, one of the most potent ACE inhibitors 
identified in the Hpp11, did not have any particular structural features 
that could be responsible for its activity. Nevertheless, the presence of 
Tyr at the third position before the final position at the C-terminus or 
its conformation in solution could highly favor its ability to inhibit ACE 
[35]. In this sense, peptide conformation, that is the structure adopted 
in the specific environment of the binding site, has been suggested to 
enhance the inhibitory ability of long-chain peptides [36, 37].  
Additionally, two of the peptides, AVKILP and QVGPLIGRYCG, stood 
out for their high ACEI activities, showing IC50 values as low as 7.06 
and 11.01 µM, respectively. Although the ACEI activity of the drug 
Captopril is higher than that presented by these peptides, the interest 
in dietary bioactive compounds is increasing significantly because they 
present high tissue affinity, specificity and efficiency in promoting 
these health effects [38]. Moreover, the ACEI values of chicken foot-
derived peptides are similar than those observed for known 
antihypertensive peptides, such as the fermented milk-derived 
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peptides IPP, VPP and LHLPLP, which showed similar IC50 values (5, 9 
and 5.5 µM, respectively) [39, 40]. Other byproduct chicken-derived 
peptides have been reported to exert high ACEI activities, but their 
activities ranged from 34 to 254 µM [41, 42].  
Many peptides that present ACEI activities in vitro do not exhibit 
antihypertensive properties. In fact, after their oral administration, the 
peptides may be susceptible to degradation by gastrointestinal 
enzymes and by brush border, blood serum and/or intracellular 
peptidases before being transferred into the bloodstream [13]. 
Additionally, even though some peptides are resistant to digestive 
enzymes, large peptides (>6 amino acid residues) may not be absorbed 
into small intestinal epithelial cells [12]. Therefore, testing the in vivo 
antihypertensive effects of the peptides is necessary for validation. To 
assess their effects in vivo, the ACEI peptides identified in Hpp11 were 
administered to SHR, an experimental animal model that best mimics 
essential hypertension in humans [43].  
The VGKPGARAPMY, LSGPVKF and AVKILP peptides sequences did 
not exhibit BP-lowering effects. Interestingly, the AVKILP peptide, 
which showed the most potent ACEI activity, did not present 
antihypertensive effects when administered to SHR, suggesting that 
modifications incurred during gastrointestinal digestion could 
inactivate this peptide. In contrast, the AVFQHNCQE and 
QVGPLIGRYCG peptides decreased BP after their oral administration 
(-25.07 and -10.94 mm Hg of SBP at 6 h post-administration, 
respectively), with AVFQHNCQE being the most active peptide. 
Interestingly, this peptide was also able to reduce DBP, suggesting its 
huge potential as an antihypertensive agent. Our findings agree with 
those demonstrating the potential antihypertensive properties of 
bioactive peptides from chicken by-products including chicken bone 
UNIVERSITAT ROVIRA I VIRGILI 
HYDROLYSATES AND PEPTIDES FROM CHICKEN FOOT PROTEINS TO MANAGE HYPERTENSION 
Anna Mas Capdevila 
 
 193 
 
[17]. Furthermore, the ACEI peptides IKW, LKP, and IVGRPRHQG, 
which were isolated from chicken muscle, showed similar 
antihypertensive effects as AVFQHNCQE but needed to be 
administered at a higher dose of 60 mg/kg bw [44].  
5. Conclusions 
Novel ACEI peptides have been identified in the chicken foot 
hydrolysate Hpp11. Moreover, the antihypertensive properties of the 
QVGPLIGRYCG and AVFQHNCQE peptides have been demonstrated 
in this study for the first time. The potential of these peptides for use in 
functional foods to mitigate hypertension appears to merit further 
clinical studies in humans. 
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TABLES 
 
Table 1. Identification of the peptides contained in the obtained RP-HPLC 
subfractions showing the highest angiotensin converting enzyme inhibitory 
activities.  
Fraction Sequenceª Theoretical M.W. MH+ (Da) m/zc (Da) Charge 
F3.3 VGKPGARAPmY
b
 1146.4 1162.59 581.80 2 
F3.3 QVGPLIGRYCG 1162.4 1162.61 581.80 2 
F3.3 LGIHPDWQFV 1211.4 1211.62 404.54 3 
F3.3 AVFQHNCQE 1075.2 1075.47 538.24 2 
F6.6 LSETVV 646.7 647.36 324.18 2 
F6.6 LSGPVKF 746.9 747.44 374.22 2 
F6.6 AVKILP 639.8 640.44 320.72 2 
F6.6 VRWEPAPGPV 1107.3 1107.59 554.30 2 
a
 Amino acid residues are designated using their one letter codes. 
b
 m= Oxidation of methionine 
cm/z=mass-to-charge
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Table 2. The angiotensin-converting enzyme inhibitory activities of the 
synthetic peptides expressed as percentages and IC50 values 
(concentration of peptide needed to inhibit 50 % of the original ACE 
activity). 
Fraction Sequence 
Peptide concentration 
(µM) 
ACEI activity 
%* IC50 (µM) 
F3.3 VGKPGARAPmY 174.5 75.8 ± 0.06 29.71 
F3.3 QVGPLIGRYCG 161.4 87.2 ± 0.33 11.01 
F3.3 LGIHPDWQFV 137.6 0.0 ± 0.0 >137.6 
F3.3 AVFQHNCQE 142.8 90.4 ± 0.02 44.75 
F6.6 LSETVV 128.9 12.9 ± 0.71 > 515.4 
F6.6 LSGPVKF 122.7 58.4 ± 4.27 80.91 
F6.6 AVKILP 101.4 91.8 ± 0.03 7.06 
F6.6 VRWEPAPGPV 150.5 21.7 ± 2.30 >150 
      
*Percentage of ACEI activity showed at the indicated protein concentration 
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FIGURES 
 
Figure 1. Determination of the angiotensin-converting enzyme 
inhibitory activity expressed as the IC50 for Hpp11 hydrolysate (A) and 
the Hpp11 hydrolysate <3 kDa fraction (B). The IC50 values were 
determined by curve fitting with a nonlinear regression analysis. The 
experimental data in each graphic correspond to two different assays 
in duplicate. 
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Figure 2. Fractionation by RP-HPLC at a semipreparative scale for the 
<3 kDa fraction obtained from Hpp11 (A). The collected fractions were 
termed with F followed by a number (F1–F8). The angiotensin-
converting enzyme inhibitory activity (ACEI) expressed as the 
percentage of inhibition (B) and IC50 (µg/mL) (C) of the collected 
fractions from the semipreparative RP-HPLC system. The data are 
expressed as the mean ± standard deviation for a minimum of two 
measurements. The protein contents of the fractions were estimated 
using the bicinchoninic acid assay. N.d; Non-determined. 
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Figure 3. Fractionation by RP-HPLC at a semipreparative scale for 
fractions F3 (A) and F6 (B) obtained from the first RP-HPLC separation. 
The collected subfractions are termed with the name of the original 
fraction followed by a point and a number. The angiotensin-converting 
enzyme inhibitory activity (ACEI) expressed as the percentage of 
inhibition (B, C) and IC50 (µg/mL) (D, E) of the subfractions from the 
second separation of F3 and F6, respectively. The data are expressed 
as the mean ± standard deviation for a minimum of two measurements. 
The protein contents of the fractions were estimated using the 
bicinchoninic acid assay. N.d; Non-determined. 
 
 
 
 
 
n.d 
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Figure 4. MS/MS spectrum of the doubled charged ions m/z 538.2 (A) 
and 554.3 (B). Following sequence interpretation and database 
searching, the peptides were identified as AVFQHNCQE and 
VRWEPAPGPV, respectively. The MS/MS spectra were acquired with 
linear trap quadrupole-Orbitrap mass spectrometry. The sequences of 
these peptides are displayed with the fragment ions observed in the 
spectra. 
Figure 5. Decrease in the systolic blood pressure (SBP) in 
spontaneously hypertensive rats after the administration of water, 
Captopril (50 mg/kg bw) or AVFQHNCQE (10 mg/kg bw) (A) or after 
the administration of water and QVGPLIGRYCG (10 mg/kg bw) (B). The 
data are expressed as the mean ± SEM. All of the experimental groups 
include a minimum of 6 animals. Different letters represent significant 
differences (p < 0.05). p was estimated by two-way ANOVA. 
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   CHAPTER 5  
To study the bioavailability and the 
mechanism of action of 
AVFQHNCQE and establish the 
molecular mechanisms involved in its 
blood-pressure lowering effect  
UNIVERSITAT ROVIRA I VIRGILI 
HYDROLYSATES AND PEPTIDES FROM CHICKEN FOOT PROTEINS TO MANAGE HYPERTENSION 
Anna Mas Capdevila 
 
204 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
HYDROLYSATES AND PEPTIDES FROM CHICKEN FOOT PROTEINS TO MANAGE HYPERTENSION 
Anna Mas Capdevila 
 
205 
 
 
 
 
 
 
 
Evidence that nitric oxide is involved in the 
blood pressure lowering effect of AVFQHNCQE 
in spontaneously hypertensive rats 
Anna Mas-Capdevilaa, Lisard Iglesias-Carresa, Anna Arola-Arnala, 
Gerard Aragonèsa, Amaia Aleixandreb, Francisca I Bravoa*, Begoña 
Muguerzaa,c 
a Universitat Rovira i Virgili, Department of Biochemistry and Biotechnology, 
Nutrigenomics Research Group, Tarragona, 43007, Spain.  
b Department of Pharmacology, School of Medicine, Universidad Complutense de 
Madrid, 28040 Madrid, Spain; amaya@med.ucm.es 
c Technological Unit of Nutrition and Health, EURECAT-Technology Centre of 
Catalonia, Reus, 43204, Spain.  
 
Submitted to Food Chemistry 
 
                                                             MANUSCRIPT 5 
    Objective 
To evaluate the involvement of vasodilators nitric oxide (NO) and 
prostacyclin (PGI2) in the peptide antihypertensive effect in spontaneously 
hypertensive rats. Additionally, to evaluate the molecular mechanisms 
under AVFQHNCQE antihypertensive effect. 
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Abstract 
AVFQHNCQE is an antihypertensive nonapeptide obtained from 
chicken foot protein. The present study aims to investigate the 
mechanisms involved in the blood pressure (BP)-lowering effect of the 
peptide. Male (17-20 weeks old) spontaneously hypertensive rats (SHR) 
were used in this study. Rats were divided into two groups and orally 
administered water or 10 mg/kg body weight (bw) AVFQHNCQE. One 
hour post-administration, animals of both groups were 
intraperitoneally treated with 1 mL of saline or with 1 mL of saline 
containing 30 mg/kg bw Nω-nitro-L-arginine methyl ester (L-NAME), 
an inhibitor of nitric oxide (NO) synthesis, or with 1 ml of saline 
containing 5 mg/kg bw indomethacin, inhibitor of prostacyclin 
synthesis (n= 6 per group). Systolic BP (SBP) was recorded before and 
6 h after oral administration. In an additional experiment, SHR were 
administered water or 10 mg/kg bw AVFQHNCQE (n=6 per group) and 
sacrificed 6 h post-administration. The aortic expression levels of 
different genes implicated in endothelial function, activity of plasma 
angiotensin-converting enzyme (ACE) and level of liver reduced 
glutathione (GSH) were evaluated in both groups. Moreover, the 
relaxation caused by AVFQHNCQE in isolated aortic rings from 
Sprague-Dawley rats was evaluated. The BP-lowering effect of the 
peptide was not changed after indomethacin administration but was 
completely abolished by L-NAME, demonstrating that this 
antihypertensive activity is mediated by changes in endothelium-
derived NO availability. In addition, AVFQHNCQE administration 
downregulated aortic gene expression of the vasoconstrictor factor 
endothelin-1 and the endothelial major free radical producer NADPH. 
Moreover, while no changes in plasma ACE activity were observed 
after its administration, liver GSH levels were higher in the peptide-
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treated group than in the water group, demonstrating that 
AVFQHNCQE also presents antioxidant properties. 
 
Keywords: bioactive peptide, endothelial dysfunction, blood pressure, 
bioactivity, nitric oxide. 
Abbreviations: ACE, angiotensin-converting enzyme; HTN, 
hypertension; BP, blood pressure; SD, sprague dawley; SHR, 
spontaneously hypertensive rats; SBP, systolic blood pressure; L-
NAME, Nω-nitro-L-arginine methyl ester; GSH, reduced gluthathione; 
ROS, reactive oxygen species. 
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1. Introduction 
 Hypertension (HTN) is a chronic elevation of systemic arterial 
blood pressure (BP) above certain threshold values. However, the 
elevation in BP is only a manifestation of a progressive disease 
representing an important health problem [1]. HTN is considered the 
most preventable risk factor for cardiovascular disease (CVD), and 
successful HTN prevention and treatment are key to reducing the risk 
of CVD [2]. Thus, the current method to treat HTN is the use of long-
term drug therapy; however, the use of these drugs can result in 
different side effects in some patients, leading to reduced patience 
compliance with the treatment, increased health care costs and 
preventable fatalities [3,4]. In this context, new strategies for treating 
HTN based on natural products could greatly benefit hypertensive 
patients. 
Some studies have demonstrated the antihypertensive properties of 
dietary-derived peptides [5–7]. These bioactive peptides are potential 
modulators of various regulatory processes that control BP. The renin 
angiotensin aldosterone system (RAAS) plays an important role in 
regulating arterial pressure [13]. In RAAS, angiotensin-converting 
enzyme (ACE) is a key enzyme in the control of BP and converts 
angiotensin I to the potent vasoconstrictor angiotensin II [8]. Thus, the 
inhibition of this enzyme has become an important target for drugs 
combating HTN. In fact, the inhibition of this enzyme is the main 
mechanism implied in the antihypertensive effect of dietary peptides 
[9–11]. In addition, endothelial function, which maintains normal 
vascular tone and blood fluidity to maintain normotensive BP values, 
has been demonstrated to be the target for some antihypertensive 
peptides [12–14]. In HTN, endothelial function is impaired, presenting 
decreased presence of vasodilator factors, such as nitric oxide (NO) or 
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prostacyclin (PGI2), and/or increased presence of endothelium-derived 
contracting factors, such as endothelin 1 (ET-1) [15]. In this sense, some 
peptides have been demonstrated to present NO-mediated 
antihypertensive effects [13,16]. NO is synthesized by the enzyme 
endothelial NO synthase (eNOS), which uses arginine as a substrate to 
produce NO. L-arginase (Arg-1), the enzyme that degrades arginine, 
has been demonstrated to play a crucial role in NO production and in 
the development of vascular disease [17]. In contrast, Krüpple-like 
factor 2 (KLF-2) has been demonstrated to be an eNOS promoter [18]. 
KLF-2 can also inhibit the expression of other important genes involved 
in regulating vessel tone, such as ET-1 [19]. KLF-2 activation is 
regulated by Sirtuin-1 (Sirt-1), which is also well known to activate 
eNOS by deacetylation and thereby increases the production of NO 
and promotes endothelial-dependent vasodilatation [20]. In addition, 
Sirt-1 promotes the inhibition of the activity of NADPH oxidase (NOX) 
[21], the major free radical producer in the endothelium, which is 
known to be overexpressed in spontaneously hypertensive rats (SHR) 
linking to the presence of endothelial dysfunction in this animal model 
[22]. Similarly, reactive oxygen species (ROS) have several effects on 
vascular and endothelial function, such as the inactivation of the 
vasodilator NO by O2- [23], contributing to the development of 
endothelial dysfunction [15]. Some studies have demonstrated that 
antihypertensive peptides can also present antioxidant activity by 
enhancing one of the main endogenous antioxidant system, reduced 
glutathione (GSH) [24,25]. 
In a previous study, the peptide sequence AVFQHNCQE was identified 
in the antihypertensive chicken foot hydrolysate Hpp11 [26]. This 
peptide presented in vitro ACE inhibitory (ACEI) activity and exhibited 
antihypertensive activity in SHR at a dose of 10 mg/kg body weight 
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(bw). Nevertheless, the underlying mechanisms involved in the 
antihypertensive effect of AVFQHNCQE are still unknown. Thus, the 
aim of this study was to evaluate the involvement of endothelial-
relaxing factors as possible antihypertensive mechanisms of 
AVFQHNCQE. We used SHR alternatively treated with Nω-nitro-L-
arginine methyl ester (L-NAME), an inhibitor of NO synthesis, or with 
indomethacin, an inhibitor of prostacyclin synthesis. Furthermore, in 
an additional experiment, the concentration of liver GSH, activity of 
plasma ACE and aortic expression levels of different genes implicated 
in endothelial dysfunction were evaluated in AVFQHNCQE-treated 
SHR. 
2. Materials and methods 
2.1. Reagents 
L-NAME, indomethacin, ACE (peptidyl-dipeptidase A, EC 3.4.15.1), N-
hippuryl-His-Leu (Hip-His-Leu), monochlorobimane, glutathione-S 
transferase from horse liver, acetylcholine and methoxamine 
hydrochloride were purchased from Sigma-Aldrich (Madrid, Spain). 
The peptide AVFQHNCQE was synthetized by CASLO Aps (Kongens 
Lyngby, Denmark), and its purity of 98.94% was verified by HPLC–MS. 
Heparin was purchased from DeltaLab (Barcelona, Spain). All other 
chemical solvents used were of analytical grade. 
2.2. Experimental procedure in animals  
Male SHR (17–20 weeks old) weighing 298 ± 2 g were used. All animals 
were obtained from Charles River Laboratories (Barcelona, Spain). The 
animals were maintained at a temperature of 23 ºC with 12 h light/dark 
cycles and consumed tap water and a standard diet (A04 Panlab, 
Barcelona, Spain) ad libitum during the experiments. Animals were 
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administered distilled water or 10 mg/kg bw AVFQHNCQE dissolved in 
tap water by oral gavage between 8 and 9 am. The total volume orally 
administered to the rats was 1 mL in all cases. One hour after the oral 
administration, animals in each group (water or peptide) were 
intraperitoneally administered 1 mL saline solution (water + saline or 
AVFQHNCQE + saline groups, respectively). The remaining rats were 
divided into four groups, two groups that were intraperitoneally 
administered 30 mg/kg bw L-NAME (water + 30 mg/kg L-NAME or 
AVFQHNCQE + 30 mg/kg L-NAME) and two groups that were 
administered 5 mg/kg bw indomethacin (water + 5 mg/kg 
indomethacin or AVFQHNCQE + 5 mg/kg indomethacin groups) (n=6 
for group). L-NAME and indomethacin were dissolved in saline 
solution, and the volume injected into rats was 1 mL in all treatment 
groups. Systolic blood pressure (SBP) was recorded in the rats by the 
tail cuff method [27] before and 6 h after water or peptide 
administration. To guarantee the reliability of the measurements, we 
established a training period of 10 days before the actual trial time, and 
during this period, the rats became accustomed to the procedure. 
Moreover, to minimize stress-induced variations in BP, all 
measurements were taken by the same person in the same peaceful 
environment. Nevertheless, the researcher assigned to carry out the 
measurements did not know the exact treatment of each animal. 
Additional experiment was performed using 17–20-week-old male SHR 
weighing 302 ± 4 g. Housing and diet conditions were the same as 
those described in the previous experiment. Animals were 
administered 1 mL of tap water (n= 6) or 10 mg/kg bw AVFQHNCQE 
dissolved in 1 mL of tap water (n= 6) by oral gavage and sacrificed by 
live decapitation 6 h post-administration. Total blood was collected in 
heparin tubes. Plasma was obtained by blood centrifugation (1,500 x g, 
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15 min, 4 °C), and aorta and liver were excised and immediately frozen 
in liquid nitrogen. Both plasma and tissues were stored at −80 °C until 
further use. 
Figure 1 shows a graphical representation of both experimental designs 
used in this study. 
2.3 Determination of plasmatic ACE activity 
ACE activity was measured in the plasma following the method 
reported by Mas-Capdevila et al. [28]. Commercial ACE at different 
concentrations was used to obtain a calibration curve. Plasma ACE 
activity was expressed (mU ACE/mL) as the mean ± standard error of 
the mean (SEM) of plasma for at least three replicates. 
2.4 Reduced gluthatione assay  
The GSH assay was performed in the liver following the 
monochlorobimane fluorometric method [29]. GSH levels were 
evaluated using 90 µL of homogenized supernatant from the liver 
mixed with monochlorobimane (100 mM) and 10 µL of the catalyst, 
glutathione S-transferase solution (1 U/mL). The levels of GSH were 
quantified using a multiscan microplate fluorimeter (FLUOstar optima, 
BMG Labtech, Offeuburg, Germany) and expressed as the mean ± 
SEM µmol GSH/g tissue protein for at least three replicates. 
2.5 RNA extraction and mRNA quantification by real-time qPCR 
The thoracic aorta was homogenized in TissueLyser (Qiagen, 
Barcelona, Spain), and RNA extraction was performed using the 
RNeasy Mini Kit (Qiagen, Barcelona, Spain). Total extracted RNA was 
quantified in a Nanodrop 100 Spectrophotometer (Thermo Scientific, 
Madrid, Spain). mRNA reverse transcription was carried out by using 
the High Capacity cDNA Reverse Transcription Kit (Applied 
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Biosystems, Madrid, Spain). Quantitative PCR amplification and 
detection were performed in the CFX96 Touch Real Time PCR System 
(Bio-Rad, Barcelona, Spain) using 96-well plates and SYBR PCR Premix 
Reagent Ex Taq™ (Takara, Barcelona, Spain) following the commercial 
protocol. 
Relative mRNA levels of eNOS, Arg-1, Klf-2, Sirt-1, NOX4 and ET-1 were 
analyzed by real-time PCR using glyceraldehyde 3-phosphate 
dehydrogenase (GADPH) as the housekeeping gene. The primers used 
for the different genes are shown in Table 1 and were obtained from 
Biomers (Söflinger, Germany). Primer specificity was verified by 
melting curve analysis, and the amplicon size was verified by 3% 
agarose gel electrophoresis. The efficiency of qPCR was calculated by 
evaluating a 2-fold dilution series of aortic cDNA and calculated by 
E = 10(1/slope). The results were expressed as the logarithm of the cDNA 
concentration vs the obtained Ct. Relative expression was calculated 
by dividing the ECt of the studied gene by the ECt of the housekeeping 
gene used as the control and then divided by the value of control, 
water group gene expression. Each sample was performed in triplicate. 
2.6 Experiments in aortic rings 
Male Sprague-Dawley (SD) rats, 17–22 weeks old and weighing 240–
305 g, were sacrificed by decapitation. To perform the experiment, the 
thoracic aorta was excised from each of the animals, and excess fat 
and connective tissue were removed. To obtain the aortic 
preparations, the tissue was placed in a dissecting dish containing 
Krebs-Henseleit solution (NaCl, 118 mM: KCl, 4.7 mM; CaCl2, 2.5 mM; 
KH2PO4, 1.2 mM; MgSO4, 1.2 mM; NaHCO3, 25 mM; and glucose, 10.0 
mM) and cut into 3–4 mm rings. Aortic rings were mounted between 
two steel hooks in organ baths containing Krebs-Henseleit solution at 
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37 °C and continuously bubbled with a 95 % O2 and 5 % CO2 mixture, 
which gave a pH of 7.4. An optimal tension of 2 g was applied to all the 
aortic rings, and the preparations were adjusted every 15 min during 
the 60–90 min equilibration period before the evaluation of the tested 
compounds. The isometric tension was recorded by using an isometric 
force displacement transducer connected to an acquisition system 
(Protos 5, Panlab). Then, after the equilibration, 80 mM KCl was added 
to verify their functionality, and when the contraction had reached the 
steady state (approximately 15 min after the administration), the 
preparations were washed to recover basal tension. 
The presence of endothelium was confirmed by the relaxation in 
response to the addition of 10 μM acetylcholine of segments previously 
contracted by treatment with 10−5 M methoxamine. A relaxation equal 
to or greater than 80% was considered evidence of the functional 
integrity of the endothelium, and the absence of relaxation in response 
to acetylcholine was considered the absence of endothelium. 
The rings were exposed to 10−5 M methoxamine to obtain steady state 
contraction, and AVFQHNCQE curves (10-8–10-4 M) were assayed in 
the methoxamine-pre-constricted rings. Water, as a negative control, 
was added to the bath at the same volumes used to assay the 
AVFQHNCQE dose-response curve. The relaxation responses were 
expressed as a percentage of the pre-contraction induced by 
methoxamine, which was considered 100 percent. Concentration–
dependent response curves were fitted to a logistic equation, and 
statistical analysis was performed to compare the curves. 
All animal protocols followed in this study were approved by the 
Bioethical Committee of the Universitat Rovira i Virgili (European 
Commission Directive 86/609) and the Spanish Royal Decree 
223/1988. 
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2.7 Statistical analysis 
The results were expressed as the mean ± SEM of six animals per 
group or at least six experiments including the aortic rings extracted 
from 6 different animals in the vascular reactivity study. The data from 
the L-NAME and indomethacin experiments were analyzed by one-way 
ANOVA (Tukey’s test) using IBM SPSS Statistics 20.0 software (SPSS, 
Inc., Chicago, IL, USA). Plasma ACE activity, GSH content and gene 
expression results were analyzed by the unpaired Student’s t test for 
independent samples using IBM SPSS Statistics 20.0 software (SPSS, 
Inc). Differences between concentration–response curves in aortic ring 
experiments were analyzed by two-way analysis of variance (two-way 
ANOVA). Outliers were identified and eliminated by using Grubbs’ 
test. Differences between groups were considered significant when p < 
0.05. 
 
3. Results  
3.1 Effects of AVFQHNCQE on blood pressure in SHR treated 
with L-NAME or indomethacin 
The initial values of SBP in the SHR were 205 ± 1.3 mmHg. Figure 2 and 
Figure 3 show the changes in SBP in SHR groups that were 
administered water or 10 mg/kg bw of the peptide AVFQHNCQE and 
that were treated intraperitoneally with saline solution, L-NAME or 
indomethacin. As expected, the SHR that received water (water + 
saline group) did not experience changes in their SBP values at 6 h 
post-administration; however, the oral administration of 10 mg/kg bw 
of AVFQHNCQE (AVFQHNCQE + saline group) produced a significant 
decrease in SBP (-31.0 ± 2.5 mmHg; p ≤ 0.05) (Figure 2 and Figure 3). 
Nevertheless, when animals receiving the peptide were 
intraperitoneally treated with L-NAME (AVFQHNCQE + 30 mg/kg of L-
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NAME group), the antihypertensive effect of this peptide disappeared 
and even resulted in a significant increase in SBP when compared to 
the SBP in the water + saline group (+ 10.1 ± 2.5 mmHg; p ≤ 0.05). In 
contrast, the antihypertensive effect of the peptide was also observed 
in the animals that were also intraperitoneally injected with 5 mg/kg 
indomethacin (AVFQHNCQE + 5 mg/kg bw of indomethacin group). 
Interestingly, the SBP reduction in the animals administered peptide 
and treated with indomethacin, and the SBP decreases in the animals 
administered peptide and treated with saline were the same: -31.0 ± 1.2 
mmHg and -31.1 ± 1.8 mmHg, respectively. 
 
3.2 Effects of AVFQHNCQE on plasmatic ACE activity, liver 
GSH concentration and endothelial-related gene 
expression 
No differences in plasma ACE activity were found between the group 
administered water and the group administered peptide (Figure 4). 
However, after 6 h, AVFQHNCQE administration produced a marked 
increase in GSH levels when compared to the group that received 
water (Figure 5). Hepatic GSH production was 70.27 % higher in the 
AVFQHNCQE-treated group than in the water-treated group. 
Peptide administration did not produce any significant changes in the 
expression of the eNOS, Arg-1, KLF-2 and Sirt-1 genes (Figure 6A) but 
produced a significant decrease in ET-1 and NOX4 expression (Figure 
6B), showing a reduction of 46.12 % and 93.59 % for ET-1 and NOX4, 
respectively, when compared to the group administered water.  
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3.3 Effects of AVFQHNCQE in aortic rings 
To evaluate the effects of AVFQHNCQE on vascular reactivity, the 
peptide was studied in methoxamine pre-constricted aortic ring 
preparations. Figure 7 shows that AVFQHNCQE did not induce 
relaxation in aortic ring preparations from SD rats. 
4. Discussion 
Dietary proteins have been demonstrated to be a potential source of 
bioactive peptides and to exhibit different bioactivities, including 
antihypertensive activity [30,31]. It has been reported that some 
chicken proteins can yield peptides with ACEI and antihypertensive 
properties [32–34]. In this regard, a previous study carried out by our 
group in SHR [26] demonstrated that treatment with the chicken foot-
derived peptide AVFQHNCQE at a dose of 10 mg/kg bw produced a 
significant decrease in SBP 6 h post-administration. This peptide was 
identified from the chicken foot hydrolysate Hpp11 obtained after 
sample pretreatment (100 ºC, 1.5 h) and hydrolysis (2 h, 50 ºC, pH=7) 
with the proteolytic enzyme Protamex [26]. 
Antihypertensive peptides mainly target ACE inhibition; however, the 
pathophysiology of HTN is complex, and there are other potential 
targets where these bioactive peptides may exert their specific 
antihypertensive actions [35]. Because the mechanisms involved in the 
antihypertensive effect exerted by the chicken foot-derived peptide 
AVFQHNCQE were unknown, this study aimed to elucidate the 
mechanisms underlying the in vivo antihypertensive effect of the 
peptide. Specifically, this study evaluates the potential participation of 
endothelial-relaxing factors in the antihypertensive effect of 
AVFQHNCQE. Thus, to evaluate the implication of NO in the 
antihypertensive effect of the peptide, L-NAME, an inhibitor of eNOS 
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[36], was administered to SHR. NO induces the production of cAMP 
and consequently increases dilatation and decreases BP [37]. The 
results presented in this study provide clear proof of the participation 
of NO in the BP-lowering effect of AVFQHNCQE, as evidenced by the 
disappearance of its antihypertensive effect in L-NAME-treated rats. 
Similar results were observed by Kouguchi et al. for a chicken collagen 
hydrolysate, demonstrating that collagen-derived peptides can exhibit 
vasoprotective functions via NO production and effectively protect 
against atherogenesis [38]. Additionally, the NO-mediated 
antihypertensive effects of other antihypertensive peptides, including 
those derived from casein or whey proteins, which also exhibited 
antioxidant effects, were previously described [31]. Interestingly, in this 
study, it was demonstrated that AVFQHNCQE also exhibited 
antioxidant effects by increasing the production of hepatic GSH, the 
main endogenous antioxidant that reduces oxidative stress and free 
radical damage [39]. 
In HTN, oxidative stress limits NO bioavailability [2], and the presence 
and possible involvement of oxidative stress in HTN in SHR has been 
reported [40,41]. In fact, free radicals in the endothelium can directly 
scavenge NO and avoid NO-dependent vasodilatation. Thus, 
considering that the antihypertensive effect of the peptide was NO-
mediated, the antioxidant effect produced by this peptide could 
contribute to the reduction of oxidative stress, consequently increasing 
NO bioavailability. Similarly, Dávalos et al. also reported antioxidant 
activity for ACEI egg white protein-derived peptides, suggesting that 
both mechanisms, the inhibition of ACE and the antioxidant effect, 
could contribute to the control of HTN [24].Considering that NO was 
clearly involved in the antihypertensive effect of AVFQHNCQE, 
whether or not the genes involved in NO production pathway were 
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overexpressed in animals that received the peptide was evaluated. 
However, no significant changes in mRNA expression of eNOS, Arg-1, 
Sirt-1 and KLF-2 were observed. In addition, ET-1 and NOX4 mRNA 
expression was evaluated after peptide administration. ET-1 is 
considered the main vasoconstrictor in the endothelium [42], and 
NOX4 is the main producer of free radicals in the vasculature [21]. In 
particular, an increase of NOX4 under stressful conditions was 
previously found to be detrimental [43]. In this study, the 
administration of AVFQHNCQE reduced the expression of ET-1. 
Previous studies have demonstrated that the modulation of endothelial 
ET-1 release was key in the BP-lowering effect of several other 
antihypertensive peptides, including milk-protein derived peptides 
[44]. In addition, Fernández-Musoles et al. reported the capacity of 
lactoferricin B-derived peptides, which demonstrated ACEI properties, 
to inhibit the endothelin-converting enzyme responsible for ET-1 
production [45]. Moreover, AVFQHNCQE was able to reduce the 
expression of NOX4. A reduction in this enzyme is related to a 
reduction in ROS production. In fact, it has been demonstrated that a 
reduction of this enzyme mediates the antihypertensive effect of the 
commonly used antihypertensive drug atorvastatin [46]. Thus, 
considering these findings, improved endothelium function contributes 
to the antihypertensive effect of AVFQHNCQE. 
Considering these findings, which demonstrate that AVFQHNCQE 
decreases BP via NO and reduces the expression of ET-1 and NOX4, 
we expected that this peptide would also be able to induce relaxation 
in aortic ring preparations. However, the peptide did not relax the 
aortic ring preparations. Thus, our in vivo and ex vivo results are not in 
accordance. Nevertheless, we should not forget that the aorta is a 
conduit artery, and resistance arteries determine the arterial BP more 
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than the large vessels [47]. In addition, it should be highlighted that SD 
rats are normotensive animals and AVFQHNCQE could present 
different effects in the arteries of hypertensive animals. Therefore, we 
believe that the vasodilation produced by NO is involved in the 
antihypertensive effect of the peptide, despite that in this experiment 
we could not demonstrate the relaxing properties of the peptide. 
The endothelium also secretes other vasodilator agents than NO such 
as PGI2. Although NO is considered the more important vasodilator in 
endothelium, PGI2 was the first endothelium-derived relaxing 
substance described. This prostaglandin is mainly produced by the 
cyclooxygenase enzyme (COX), which is also released in the 
endothelium and is considered a central cardioprotective hormone 
[48,49]. To evaluate the implication of the vasodilator PGI2 in the BP-
lowering effect of the peptide, the antihypertensive effect was 
evaluated in rats treated with indomethacin, which is a COX inhibitor. 
Although some peptides produce PGI2-mediated antihypertensive 
effects, such as novokinin, a potent antihypertensive peptide designed 
based on the structure of ovokinin [50], in this study, indomethacin 
treatment did not modify the antihypertensive effect of AVFQHNCQE. 
Therefore, considering this result, the participation of PGI2 in the 
antihypertensive effect of AVFQHNCQE could be discarded. 
Finally, considering that AVFQHNCQE has shown in vitro ACEI activity 
[26], the in vivo effect of this peptide on ACE activity was also studied. 
However, the in vitro ACE inhibitory activity of the peptide did not 
correspond to the same bioactivity in vivo because no changes were 
observed in the plasma ACE activity of peptide-treated SHR 6 h post-
administration when compared to the activity in the water-treated 
SHR. Although oral administration of ACE inhibitors has been widely 
used to decrease BP in animal models and humans, it remains unclear 
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which organs these drugs target to achieve their antihypertensive 
effects [51]. Moreover, in contrast to the multitude of studies that have 
addressed the effects of peptide application on BP, a relatively small 
number of studies have quantified ACEI effects of peptides in vivo [52]. 
Nevertheless, the physiological and pharmacological consequences of 
the lack of effectivity on ACE in vivo do not seem to reduce the 
therapeutic effect of these drugs [53]. In fact, increased levels of 
plasma ACE activity have been found in SHR acutely treated with 
captopril, a known ACE inhibitory drug [54]. 
 
5. Conclusions 
In this study with SHR, as represented in Figure 8, we demonstrated 
the participation of NO in the antihypertensive effect exerted by 
chicken foot-derived peptide AVFQHNCQE. This peptide could 
enhance NO availability by reducing oxidative stress. In addition, the 
reduction in ET-1 and NOX4 mRNA expression after peptide 
administration also contributed to improved endothelium functionality 
and therefore reduce BP. 
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TABLES 
Table 1. List of primers characteristics.  
Rat 
primers 
Sequence (5′……3′) 
Size of 
amplicon 
Efficiency 
GenBank 
accession No. 
eNOS Fw GGATTCTGGCAAGACCGATTAC 
159 
2.06 
(100.67%) 
NM_021838.2 
eNOS Rv GGTGAGGACTTGTCCAAACACT 
Arg1 Fw GGCAGTGGCGTTGACCTTGT 
158 
2.14 
(105.64%) 
NM_017134.3 
Arg1 Rv AGCAGCGTTGGCCTGGTTCT 
Sirt1 Fw TTGGCACCGATCCTCGAA 
217 
2.02 
(97.49%) 
NM_001007684.1 
Sirt1 Rv ACAGAAACCCCAGCTCCA 
KLF2 Fw GGACGCACACAGGTGAGAA 
186 
2.18 
(107.85%) 
NM_001007684.1 
KLF2 Rv ACATGTGTCGCTTCATGTGC 
ET-1 Fw TGATTCTCTTGCCTCTTCTTG 
110 
3.08 
(136.04%) 
NM_012548.2 
ET-1 Rv TATGGAATCTCCTGGCTCTC 
NOX4 Fw GTGTCTGCATGGTGGTGGTA 
150 
2.24 
(110.62%) 
NM_053524.1 
NOX4 Rv TCAACAAGCCACCCGAAACA 
GADPH Fw CCATGTTCGTCATGGGTGTG 
91 
1.97 
(98.93 %) 
NM_002046.4 
GADPH Rv GGTGCTAAGCAGTTGGTGGTG 
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FIGURES 
 
Figure 1. Graphical representation of the experimental design for Nω-
nitro-L-arginine methyl ester hydrochloride and indomethacin study in 
spontaneously hypertensive rats (1A) and graphical representation of 
the experimental design used to study the effects of peptide 
administration on the renin-angiotensin-aldosterone system (RAAS), 
endothelial function and oxidative stress in SHR (1B). 
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Figure 2. Changes in systolic blood pressure (SBP) caused in 
spontaneously hypertensive rats after different treatments: oral 
administration of water + intraperitoneal injection of saline (a), oral 
administration of water + intraperitoneal injection of 30 mg/kg bw Nω-
nitro-L-arginine methyl ester hydrochloride (b), oral administration of 
10 mg/kg bw AVFQHNCQE + intraperitoneal injection of saline (c) or 
oral administration of 10 mg/kg bw AVFQHNCQE + intraperitoneal 
injection 30 mg/kg bw Nω-nitro-L-arginine methyl ester hydrochloride 
(b). Data are expressed as the mean ± standard error (SEM) of six 
animals. Different letters represent statistically significant differences 
(p ≤ 0.05). The value of p was estimated by one-way ANOVA. 
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Figure 3. Changes in systolic blood pressure (SBP) caused in 
spontaneously hypertensive rats after different treatments: oral 
administration of water + intraperitoneal injection of saline (a), oral 
administration of water + intraperitoneal injection of 5 mg/kg bw 
Indomethacin (a), oral administration of 10 mg/kg bw AVFQHNCQE + 
intraperitoneal injection of saline (b) or oral administration of 10 mg/kg 
bw AVFQHNCQE + intraperitoneal injection of 5 mg/kg bw 
Indomethacin bw (b). Data are expressed as the mean ± standard error 
(SEM) for six animals. Different letters represent statistically significant 
differences (p ≤ 0.05). The value of p was estimated by one-way 
ANOVA. 
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Figure 4. The effect of the peptide AVFQHNCQE on plasma ACE 
activity 6 h post-administration in spontaneously hypertensive rats. 
Values are means ± SEM (n=6 animals per group). The results were 
analyzed with Student’s t test, and the differences between the means 
were considered significant when p ≤ 0.05. The asterisk indicates 
statistically significant differences. 
 
 
 
 
 
Figure 5. Liver reduced glutathione (GSH) production 6 h post-
administration of the peptide AVFQHNCQE in spontaneously 
hypertensive rats. Data are expressed as the means ± SEM (n=6 
animals per group). The results were analyzed with Student’s t test, 
and the differences between the means were considered significant 
when p ≤ 0.05. The asterisks indicate statistically significant 
differences. 
* 
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Figure 6. The effect of the peptide AVFQHNCQE on the expression of 
genes involved in the nitric oxide pathway (A) and on genes related to 
vasoconstriction and radical oxygen species production (B) in the 
endothelium at 6 h post-administration in spontaneously hypertensive 
rats. Values are means (n=6 animals per group) with their standard 
errors. The results were analyzed with Student’s t test, and the 
differences between the means were considered significant when p ≤ 
0.05. The asterisks indicate statistically significant differences. 
 
 
 
 
 
Figure 7. Cumulative concentration–response curves of AVFQHNCQE 
(10-8 - 10-4 mg/mL) in methoxamine pre-constricted aortic rings from 
Sprague-Dawley rats. Water was employed as a control, adding the 
same volume used to carry out the concentration-response curves of 
the peptide. Data are mean values ± SEM (n=6 animals per group). No 
significant differences were observed between the control group and 
the AVFQHNCQE group. 
* 
* 
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Figure 8. In hypertension endothelial dysfunction is produced. This 
pathological state is characterized by an imbalance between the 
vasodilator (mainly NO) and the vasoconstriction (mainly ET-1) 
endothelial factors. Due to the administration of AVFQHNCQE 
produced NO-mediated antihypertensive effect it was expected an 
increase in NO bioavailability. NOX4 mRNA was found decreased in 
rats administered the peptide leading to a decrease in ROS production 
and thus, increasing NO availability. The mRNA of ET-1, the most 
important endothelial vasoconstrictor factor and inhibitor of NO 
synthesis, was also found decreased. Finally, the peptide increased the 
production of GSH, the main endogen antioxidant system which 
reduces ROS and thus, reduces NO scavenging.  All this findings lead 
to enhance nitric oxide, and therefore, reduce the vasoconstriction 
observed under hypertension conditions. 
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Abstract 
The antihypertensive effect of the peptide AVFQHNCQE in 
spontaneously hypertensive rats (SHR) has been recently 
demonstrated. This study investigates the bioavailability and the 
opioid-like activity of this peptide after its oral administration. 
AVFQHNCQE was administered to male Wistar rats at a dose of 10 
mg/kg body weight. Plasma samples were collected before (0 h) and at 
different time points post-administration. An additional in vitro study 
using Caco-2 monolayer cells was carried out. Peptide and its potential 
fragments were quantified by UHPLC-MS/MS and UHPLC-HRMS. 
Both in vitro and in vivo experiments demonstrated that peptide 
AVFQHNCQE was not absorbed. An additional in vivo experiment 
using SHR was conducted to test if peptide antihypertensive effect 
could be mediated through binding intestinal opioid receptors. 
Naloxone, an opioid antagonist, was intraperitoneal administered to 
block opioid receptors and the blood pressure (BP) lowering properties 
of the peptide were evaluated under these conditions. No changes in 
BP were recorded in rats administered Naloxone, demonstrating that 
AVFQHNCQE antihypertensive effect is mediated through its 
interaction with opioid receptors. AVFQHNCQE opioid-like activity 
would clarify the antihypertensive properties of AVFQHNCQE in spite 
of its lack of absorption. 
 
Keywords: bioactive peptide, endothelial dysfunction, blood pressure, 
bioactivity, nitric oxide. 
Abbreviations: ACE, angiotensin-converting enzyme; HTN, 
hypertension; BP, blood pressure; SHR, spontaneously hypertensive 
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rats; SBP, systolic blood pressure; RAAS, renin angiotensin aldosterone 
system; GI, gastrointestinal. 
Chemical compound studied in this article: Naloxone (PubChem CID: 
5284596), heparin (PubChem CID: ‎ 772) and captopril (PubChem CID: 
44093). 
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1. Introduction 
Bioactive peptides are specific protein fragments released by limited 
proteolysis of their specific precursor proteins, which present 
additional biological activities over and above their expected 
nutritional [1,2]. Different health benefits have been reported for these 
peptides, including antioxidant, antithrombotic, antimicrobial, opioid 
and anticancer  activities [3]. Nevertheless, one of the most important 
biological property attributed to bioactive peptides is their 
antihypertensive effects [4]. These peptides are usually obtained and 
selected by their capacity to inhibit angiotensin-converting enzyme 
(ACE), key enzyme in blood pressure (BP) regulation [5]. Hypertension 
(HTN) is a global public health problem [6] and although its medical 
treatment is well established, it can present side-effects in some 
patients [7]. Thus, the use of antihypertensive peptides as an 
alternative for HTN prevention and treatment is receiving interest 
despite the fact that these inhibitory peptides present lower ACE 
inhibitory (ACEI) activity than the antihypertensive drugs [4].  
Other mechanisms than the inhibition of ACE could be involved in 
bioactive peptide BP-lowering effect, including an improvement in 
endothelial function by the activation of nitric oxide (NO) pathway [8].  
In this sense, NO has also been reported to mediate the endothelium-
dependent vasorelaxation effects of different antihypertensive 
peptides [8]. The antihypertensive peptides that mediate its effect 
through NO could enhance NO production by the activation of 
endothelin NO synthase by phosphorylation at Ser-1177 residue 
consistent [9]. Additionally, some bioactive peptides also present 
antioxidant effects, which in turn would contribute to enhance NO 
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bioavailability and to improve endothelium functionality by reducing 
radical oxygen species, that are known to be NO scavengers [10].    
Peptide in vivo physiological effects depend on their ability to reach 
the target sites in an active form [11]. In this context, gastrointestinal 
(GI) digestion plays a key role in the formation and degradation of 
bioactive peptides [12]. Once ingested, peptides might be subjected to 
hydrolysis by different GI enzymes such as pepsin, trypsin, 
chymotrypsin and peptidases from the surface of epithelial cells, which 
could result in the release of different amino acid sequences [13]. In 
addition to digestion, absorption may also condition peptide 
bioactivity. In this sense, peptides are absorbed depending on their 
size and structure. Di- and tri-peptides are frequently transported 
through PepT1 peptide transporter [14], while larger peptides can be 
absorbed by passive diffusion [15]. Moreover, water-soluble large 
peptides can cross via the tight junctions between cells and highly 
lipid-soluble peptides appear to be able to diffuse via the transcellular 
route [14].  
However, some bioactive peptides might mediate their physiological 
effects through its binding to receptors present in the intestinal wall, 
implying that their absorption is not required [13]. In fact, it has been 
demonstrated that some opioid peptides are not absorbed and can 
produce their biological effects by the interaction with opioid 
receptors (μ, δ and κ), which have been described in several tissues 
including in GI tract [15,16]. In this regard, some opioid peptides have 
demonstrated to regulate BP and produce its BP-lowering effect 
through the binding to opioid receptors present in the GI tract [17]. 
Nurminen et al. [18] evidenced the involvement of opioid receptors in 
the antihypertensive effect of the peptide α-lactorphin (YGLF), since its 
BP-lowering effect was abolished by the administration of  the non-
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selective opioid receptor antagonist, Naloxone [19]. Furthermore, 
Sipola et al. [20] demonstrated α-lactorphin produced its opioid-
mediated antihypertensive effect through NO release.  
AVFQHNCQE is a nonapeptide initially identify in the chicken foot 
hydrolysate Hpp11, which exhibited antihypertensive properties after 
its oral administration to spontaneously hypertensive rats (SHR) [21]. 
However, AVFQHNCQE vulnerability to GI enzymes and posterior 
absorption has not been studied yet. Thus, the aim of this study was to 
investigate the bioavailability of the antihypertensive peptide 
AVFQHNCQE after its oral administration. For this purpose, in silico 
and in vitro approaches were used to study the peptide susceptibility 
to GI digestion. In addition, AVFQHNCQE absorption was studied both 
in vitro by using Caco-2 cell monolayers and in vivo evaluating peptide 
presence in plasma from Wistar rats [14]. Finally, a potential 
involvement of opioid receptors in the BP-lowering effect of 
AVFQHNCQE was studied in presence of opioid receptors-antagonist 
Naloxone.  
 
2. Materials and methods 
 
2.1. Materials 
The peptide AVFQHNCQE was synthetized by CASLO Aps. (Kongens 
Lyngby, Denmark) and its purity was 98.94 %. Captopril was provided 
by Santa Cruz Biotechnology (Dallas, TX, United States). Pepsin, bile 
salts mixture, trypsin, α-chymotrypsin, porcine pancreatic lipase, 
colipase, trifluoroacetic acid (TFA), formic acid (FA) LC-MS grade and 
bovine serum albumin (BSA) were obtained from Sigma-Aldrich 
(Madrid, Spain). Acetonitrile and methanol LC-MS grade were 
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purchased from Merck (Darmstadt, Germany). The synthetic 
isotopically labelled peptide IFV*TGQDYNDK (V*= Val-13C5,15N) was 
obtained from Biomatik (Ontario, Canada) and used as internal 
standard (IS) for MS experiments. Chicken foot hydrolysate Hpp11 was 
obtained by our group following the procedure described by Bravo et 
al. [21,22] . All other chemical solvents used were of analytical grade.  
2.2. In silico and in vitro simulated digestion 
In silico simulated peptide digestion was carried out using the 
programs ExPASy PeptideCutter, available at 
http://web.expasy.org/peptide_cutter. This approach can predict the 
hydrolysis of a protein sequence obtained from a protein database 
using the known enzymatic cleavage sites. The digestive enzymes 
pepsin, chymotrypsin, trypsin, lipase and colipase were used to predict 
the protein fragments generated in GI digestion of AVFQHNCQE.  
For the in vitro simulated peptide GI digestion, two-stage hydrolysis 
process were carried out according to Martos et al. [23]. AVFQHNCQE 
was dissolved in simulated gastric fluid (35 mM NaCl at pH 2 for 15 
min) and posteriorly subjected to digestion by porcine pepsin (E.C. 
3.4.23.1, 3440 units/mg) at an enzyme/substrate ratio of 1:20 w/w at 37 
ºC for 60 min. Gastric digestion with pepsin was stopped by adding 1 
M NaHCO3 and pH was adjusted to 7.0 with NaOH 1 M (final protein 
concentration of 5 mg/mL). Aliquots of this gastric digest was 
collected (G60) and stored at -20 °C until analysis. Duodenal 
digestions were performed by using, as the starting material, the 
obtained gastric digests, with the addition of 1M CaCl2, 0.25M bis-Tris 
pH 6.5, 0.25 M bis-Tris pH 6.5, and a 0.125 M bile salts mixture 
containing equimolar quantities of sodium taurocholate and 
glycodeoxycholic acid. Posteriorly, the duodenal enzymes trypsin (EC 
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232-650-8, 10100 BAEE units/mg protein), α-chymotrypsin (EC 232-671-
2; 55 units/mg protein), porcine pancreatic lipase (EC 232-619-9) and 
colipase (EC 259-490-1), prepared in 35 mM NaCl adjusted to pH 7, 
were added to the solution. The duodenal digestion was carried out at 
pH 7, 37 ºC during 60 (D60). Then, enzymes were inactivated by 
heating at 95 °C for 10 min in a water bath, followed by cooling to 
room temperature. A triplicate of aliquots at each time point were 
collected and stored at -20 °C until analysis.  
 
2.3. Peptide bioavailability studies 
2.3.1. In vivo experiment   
Male Wistar rats (17-20 weeks-old, weighting between 230 and 250 g) 
were obtained from Charles River Laboratories (Barcelona, Spain). 
Animals were maintained in pairs, at 22 ºC with light/dark cycles of 12 
h and were fed standard chow diet (AO4, Panlab, Barcelona, Spain) ad 
libitum during all the experiment. Animals were randomly divided and 
administered tap water (control group, n = 6) or 10 mg/kg body weight 
(bw) peptide (AVFQHNCQE group, n = 6) by gastric intubation after a 
starvation of 12 h. The total volume of water or AVFQHNCQE orally 
administered to the rats was 1 mL. Blood samples were collected via 
saphenous vein extraction by use of heparin vials (Starsted, Barcelona, 
Spain) before the water or peptide administration and 30 min and 60 
min post-administration. Plasma samples were obtained by blood 
centrifugation (2,000 x g, 15 min, 4 ºC) and were pooled (n= 6 per 
treatment group) to perform UHPLC-MS/MS analysis. Plasma was 
stored at –80 ºC until the analysis.  
 
 
UNIVERSITAT ROVIRA I VIRGILI 
HYDROLYSATES AND PEPTIDES FROM CHICKEN FOOT PROTEINS TO MANAGE HYPERTENSION 
Anna Mas Capdevila 
 
245 
 
2.3.2. In vitro experiment  
 
Caco-2 cells were obtained from Sigma-Aldrich and were grown 
Dulbecco’s modified minimum essential medium (DMEM), 
supplemented with 20 % fetal bovine serum (FBS), 2 mmol/mL L-
glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin at 37 ºC in 
and 5 % CO2. Cells were seeded onto Transwell inserts permeable 
membrane support (0.4 µm pore, 24 mm diameter, 4.7 cm2 grown 
surface from, Merck Co., Bedford, MA) placed in six-well plates. The 
seeding density was 12,000 cell/cm2. Medium was replaced every 2-3 
days and cells were growing for 21 days. At 21st day of the procedure, 
the integrity of the Caco-2 monolayer was assessed by the 
measurement of transepithelial electrical resistance (TEER) using a 
Millicell ERS-2 voltammeter (EMD Millipore, Darmstadt, Germany) 
selecting the ones with TEER values higher than 200 Ω/cm2. 
For the transport study, Caco-2 cells, maintained in DMEM, were 
gently rinsed with Hank’s balanced salt solution (HBSS) and 
equilibrated for 20 min at 37 ºC prior to the transport study. Then, it 
was evaluated the transepithelial transport of the peptide 
AVFQHNCQE (1mM) dissolved in HBSS and the digests obtained in the 
in vitro simulated digestion (G60 and D60). AVFQHNCQE or the 
peptide digests G60 and D60 were added to the apical (AP) chamber 
and were incubated for 1 h at 37 ºC. After this time, triplicates of the 
AP chamber content and the basolateral (BL) chamber content were 
taken and stored at –80 ºC until UHPLC-HRMS analyses.  
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2.4. Peptide analysis by UHPLC-MS/MS and UHPLC-HRMS 
2.4.1 Optimisation of peptide extraction in plasma 
In order to efficiently extract the peptide or peptide fragments from 
plasma after AVFQHNCQE administration in Wistar rats, three 
different extraction methods were assayed.  
Solid phase extraction (SPE): plasma samples (150 µL) were mixed with 
25 µL of IFV*TGQDYNDK (IS) (10 ppm) and 800 µL of H2O (1% TFA). 
Then, these solutions were heated at 95 ºC for 2 min to denature 
plasma proteins. After cooling down, samples were centrifuged 
(15,000 rpm, 15 min, 4 ºC) and loaded to Oasis HLB (30 mg, 1 mL) 
cartridges (Waters, Barcelona, Spain), which were sequentially pre-
conditioned with 1 mL acetonitrile: water 0.1% FA (75:25, v/v) and 1 mL 
water 0.1% FA. Loaded cartridges were washed with 1 mL water 0.1% 
FA and dried. Retained peptides were eluted with 2 sequential 
additions of 250 µL acetonitrile: water 0.1% FA (75:25, v/v). Eluted 
samples were totally dried in a speed-vac concentrator (Thermo Fisher, 
Waltham, Massachusetts), USA), reconstituted in 100 µL of water (0.1 
% FA and 0.1 % BSA) and analyzed by UHPLC-MS/MS. The extraction 
was performed in triplicate.  
Protein precipitation by TFA: 150 µL of plasma were mixed with 25 µL 
of IS (10 ppm) and 40 µL of water (10% TFA) and heated for 2 min at 95 
ºC to precipitate plasma proteins. After cooling down, samples were 
centrifuged (15,000 rpm, 15 min, 4 ºC) and supernatants were analyzed 
by UHPLC-MS/MS. The extraction was performed in triplicate. 
Protein precipitation by TFA and SPE: plasma samples (150 µL) were 
mixed with 25 µL of IS (10 ppm) and 40 µL of water (10% TFA) and 
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heated at 95 ºC for 2 min. After cooling down, samples were 
centrifuged (15,000 rpm, 15 min, 4 ºC) and supernatants were purified 
using Oasis HLB (30 mg, 1 mL) cartridges (Waters) with the same 
procedure described before and analyzed by UHPLC-MS/MS. The 
extraction was performed in triplicate. 
2.4.2. Peptide extractions from in vitro digestions and Caco-2 
monolayers 
Samples obtained from in vitro peptide simulated digestion and Caco-2 
monolayers were diluted 10 times with water (0.1% FA) and centrifuged 
(15,000 rpm, 15 min, 4ºC). Supernatants were directly analyzed by 
UHPLC-HRMS to avoid the loss of polar peptide fragments. Extensive 
clean-up or pre-concentration procedures were not necessary due to 
the high concentration of peptide and low matrix complexity than 
plasma samples. 
2.4.3. Analysis by UHPLC-MS/MS and UHPLC-HRMS 
The obtained purified solutions from plasma and peptide digests G60 
and D60 and from AP and BL chambers in Caco-2 experiment were 
analysed using an UHPLC 1290 Infinity II Series coupled to a QqQ 6490 
Series (Agilent Technologies, Santa Clara, CA, USA) for tandem mass 
experiments or a qTOF 6550 Series (Agilent Technologies) for high-
resolution mass spectrometry experiments. Chromatographic 
separation of peptide or their fragments were performed using a 
Kinetex 2.6 µm EVO C18 column (150×2.1 mm, 2.7 µm) from 
(Phenomenex, Torrance, USA) as stationary phase and water 
containing 0.1% formic acid (solvent A) and acetonitrile (solvent B) as 
mobile phase. Separation was performed in gradient elution as follows: 
isocratic; 0–0.5 min, 2 % B; 0.5–1 min, 2- 6% B; 1– 5 min, 6- 15% B; 5– 6 
min, 15- 35 % B; 6- 10 min, 35-98 % B; 10- 12 min, 98 % B isocratic; 12- 
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12.10, 98- 2% B. For all runs, 10 μL of sample (4 ºC) was injected, and 
flow rate was 0.350 mL/min and column temperature was 25 ºC.  
Peptide ionisation was performed in positive electrospray ionization 
(ESI) and source parameters were as follows and the same for both 
mass spectrometer instruments:  gas temperature 150 °C; gas flow 13 
L/min, sheath gas temperature 250 ºC; sheath gas flow 11 L/min; 
nebulizer pressure 40 psi capillary voltage 3000 V and nozzle voltage 
500 V. For plasma samples, QqQ instrument was used to quantify 
AVFQHNCQE peptide because low concentration was expected. The 
mass spectrometer was operated in multiple reaction monitoring 
(MRM) mode and optimized transitions were 538.4 > 928.9 (10 eV) for 
quantification and 538.4 > 758.5 (10 eV) and 538.4 > 453.4 (10 eV) for 
confirmation (RT = 4.25 min) of AVFQHNCQE and 653.4 > 940.8 (20 
eV) for quantification and 653.4 > 1046.0 (20 ev) and 653.4 > 839.7 (25 
eV) for confirmation (CE = 20 eV, RT = 6.15 min) of IFV*TGQDYNDK 
(IS). Peptide quantification was performed by an internal standard 
calibration curve using the pure standard of AVFQHNCQE peptide 
with a limit of detection of  0.05 ppb and limit of quantification of 
0.130 ppb in plasma and a linear range up to 166 ppb (r2>0.9999). 
For in vitro simulated digestion experiments and Caco-2 monolayer 
samples, qTOF instrument was used to investigate the presence of 
unknown peptide fragments and previously in silico predicted peptide 
fragments by means of its accurate mass. Peptide and its fragments 
were semi-quantified using the chromatographic peak area observed in 
the extracted ion chromatograms using a 20 ppm mass window.  
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2.5. Evaluation of the opioid-like activity of AVFQHNCQE in SHR  
Male, 17–20-week-old, SHR, weighing 286 ± 4 g were used in this 
study. All these animals were obtained from Charles River Laboratories 
Spain. The SHR were housed at a temperature of 23 ºC with 12 h 
light/dark cycles, and had free access to tap water and a standard diet 
(A04 Panlab). Before the experiments, rats were submitted to a training 
period of 10 days to guarantee the reliability of the measurements. To 
evaluate if AVFQHNCQE presented opioid-mediated effect, SHR 
received via subcutaneous Naloxone (3 mg/kg bw), and afterwards a 
single oral dose (1 mL) of AVFQHNCQE (10 mg/kg bw). Additionally, 
water, Captopril (50 mg/kg bw), known antihypertensive drug, and 
chicken foot hydrolysate Hpp11 (55 mg/kg bw), were administered as 
controls. Captopril and Hpp11 are able to inhibit ACE in vivo. All 
treatments were administered by oral gavage between 8:00 and 9:00 h 
a.m. The total volume orally administered to the rats for all treatments 
was of 1 mL. Systolic blood pressure (SBP) was recorded in the rats by 
the tail cuff method [24] before and 2, 4 and 6 h post-administration. 
All measurements were taken by the same person in the same peaceful 
environment.  
The Animal Ethics Committee of University Rovira i Virgili approved all 
procedures (reference number 8868 by Generalitat de Catalunya). All 
the above-mentioned experiments were performed as authorised 
(European Directive 86/609/CEE and Royal Decree 223/1988 of the 
Spanish Ministry of Agriculture, Fisheries and Food, Madrid, Spain).  
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2.6. Statistical analysis 
Results from transepithelial transport studies are presented as means ± 
standard error mean (SEM). Means were compared using Student's t-
test. The results for the experiments investigating the participation of 
opioid receptors in the AVFQHNCQE, Captopril and Hpp11 
antihypertensive effect were expressed as the mean ± SEM of six 
animals per group (heterogeneity was tested by Levene’s test) and 
were analysed by one-way ANOVA (Tukey’s test) using IBM SPSS 
Statistics 20.0 software. Outliers were identified and eliminated by 
using Grubbs’ test. Differences between groups were considered 
significant when p < 0.05. 
3. Results and discussion 
Food proteins contain specific peptide sequences that are inactive as 
long as they remain bonded to other amino acids within the primary 
protein structure, which might be released by protein hydrolysis [25]. 
These peptides can present a wide range of bioactivities including 
ACEI and antihypertensive activity [25]. In this sense, it has been 
demonstrated that the hydrolysis of chicken foot proteins is a good 
strategy for the obtaining of bioactive peptides able to reduce BP 
[21,22]. In fact, the antihypertensive effect of the peptide AVFQHNCQE 
(10 mg/kg bw), identified initially in the chicken foot hydrolysate 
Hpp11, has been previously demonstrated in SHR [21]. Nevertheless, it 
is unknown if this peptide sequence is susceptible to GI digestion, 
resulting in new peptide fragments which might be the responsible of 
the AVFQHNCQE bioactivity. Therefore, the peptide fragmentation 
under GI digestion of the antihypertensive peptide was investigated 
using in silico and in vitro approaches. Simulated in silico digestion 
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considers the primary structure of peptides and the known cleavage 
specificity of the GI tract enzymes, predicting the peptide potential to 
release other shorter peptides sequences during digestion. Table 1 
shows the amino acid sequences of peptides predicted to be released 
after AVFQHNCQE gastric and duodenal digestion based on the in 
silico digestion approach. This model predicted a peptide hydrolysed 
only by pepsin and chymotrypsin. Trypsin was also evaluated showing 
no effects on peptide hydrolysis. Although in silico approach is 
important for the identification of the potential bioactive amino acid 
sequences, the results of these studies have to be interpreted with 
caution, since this approach does not consider the tertiary structure of 
the proteins. However, based on the in silico prediction it would 
appear that AVFQHNCQE could release different amino acid 
sequences, which could be involved in its antihypertensive effect.  
Simulated in vitro gastrointestinal digestion model was used to 
investigate the releasing of the amino acid sequences previously 
predicted in the in silico approach. The peptide was sequentially 
digested under physiological conditions and the identification of amino 
acid sequences in samples obtained from both gastric and intestinal 
digestion were performed by UHPLC-HRMS (Table 2). It was observed 
in sample G60 the native peptide and also the presence of different 
peptide fragments. However, the most intense signal corresponded to 
the native peptide, AVFQHNCQE, indicating that this peptide presents 
a high resistance to gastric digestion. In this sense, Ruiz et al. reported 
for the peptides VRYL and KKYNVPQL, derived from Manchego 
cheese, their resistance to GI digestion and their ability to reach their 
target organs as an intact form. Interestingly, KKYNVPQL, such as 
AVFQHNCQE, contains glutamine residue (Q) in the C-terminal, which 
is commonly presented in peptides resisting GI digestion hydrolysis 
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[26]. Regarding to duodenal digests, the most intense signal after 60 
min under simulated intestinal digestion (D60) corresponded to free 
amino acids. Taking into account that most antihypertensive peptides 
require to be absorbed in the intestine to produce their BP-lowering 
effect [11], absorption of the AVFQHNCQE or their potential derived 
fragments should produce before 60 min of intestinal digestion.  
Therefore, an additional in vivo study was carried out in which the 
presence of the AVFQHNCQE or their fragments were evaluated by 
chromatographic analysis in Wistar rats plasma collected before and 
30 and 60 min post-administration of AVFQHNCQE (10 mg/kg bw) or 
water. However, since no specific and optimised peptide extraction 
methodology exist for AVFQHNCQE using plasma samples, this 
procedure was optimised and validated to obtain the maximum 
recovery and reproducibility. Three different extraction methodologies 
(SPE, TFA and SPE+TFA) were evaluated using samples spiked with 1 
ppb of AVFQHNCQE peptide to determine recovery (%), repeatability 
(% RSD) and matrix effect (%). SPE method was demonstrated to be 
the most efficient method for the peptide extraction in plasma 
obtaining a recovery of 92.4 % with good reproducibility (Table 3) and 
negligent matrix effect (less than 20 %). Once the peptide extraction 
method was optimised, rat plasma at 0, 30 and 60 min after peptide 
(10 mg/kg bw) or water oral administration were subjected to SPE 
extraction and analysed by UHPLC-MS/MS for AVFQHNCQE peptide 
quantification or, by UHPLC-HRMS for peptide fragments analysis. 
Interestingly, neither the peptide nor their potential fragments were 
identified in the plasma samples studied, indicating that none of them 
was absorbed.  
In order to verify the lack of absorption of the peptide or their resultant 
fragments in the GI tract an additional study using Caco-2 cells was 
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carried out. The native peptide AVFQHNCQE and the samples 
collected after the simulated gastric and duodenal digestions (G60 and 
D60, respectively) were incubated in Caco-2 monolayer for 1 h. The 
peptide and its resultant fragments were identified in the AP chamber 
from G60 samples, however only a 0.10-0.25 % were transported to 
the BL chamber (Table 4). Therefore, the presence of native 
AVFQHNCQE in AP chamber after 1 h of incubation and the absence of 
the peptide or their fragments in BL chamber demonstrated that it was 
not absorbed through the intestinal monolayer. Similarly, Miguel et al. 
reported for the antihypertensive peptide RADHP the lack of 
transported through Caco-2 monolayer [12].  
The absence of the peptide AVFQHNCQE or their potential derived 
fragments in the mass spectrometry data from the plasma or BL 
chamber samples suggest that AVFQHNCQE can exert its 
antihypertensive effect without requiring to be absorbed, by 
interacting with receptors present in the intestinal tract, as has been 
previously reported for other large peptides [15]. In this sense, it has 
been demonstrated that some antihypertensive peptides that also 
present opioid activity do not require to be absorbed to induce BP 
reduction. These opioid peptides induce antihypertensive effect by 
their interaction with the opioid receptors present in the GI tract [27]. 
The mechanism of action proposed driven by the stimulation of these 
opioid receptors is the subsequent NO release causing vasodilation 
[28–31]. Therefore, considering that AVFQHNCQE was not absorbed, 
an antihypertensive effect mediated by the interaction with opioid 
receptors present in the intestinal tract was investigated. Thus, to 
evaluate the involvement of opioid receptors in the antihypertensive 
properties of AVFQHNCQE, its BP-lowering effect was studied in 
presence of Naloxone, which is an opioid receptor antagonist [32]. 
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Figure 1, 2 and 3 show the changes in SBP 6 h after oral administration 
of the peptide, the chicken foot hydrolysate Hpp11 and Captopril in 
rats previously subcutaneously treated with Naloxone or saline. The 
results of this study showed that the antihypertensive effect of 
AVFQHNCQE was completely abolished in Naloxone-treated rats 
while in the control rats, subcutaneously treated with saline, it was 
observed –31 ± 2 mmHg of SBP decrease when compared to water 
group (Figure 1). Similarly to our results, Nurminen et al. reported for 
the milk-derived peptide α-lactorphin opioid mediated 
antihypertensive effect [18]. Therefore, considering the present 
findings, AVFQHNCQE produced its antihypertensive effect through 
the interaction with opioid receptors, clarifying the reason why this 
peptide do not require to be absorbed to produce its physiological 
effect.   
Interestingly, Hpp11 chicken foot hydrolysate, in which was initially 
identify the peptide AVFQHNCQE, and Captopril, an ACEI 
antihypertensive drug [33], were able to reduce BP in both groups, in 
the Naloxone-treated group and saline-treated group indicating that 
their BP-lowering effects were not mediated through the interaction 
with opioid receptors (Figure 2 and Figure 3). According to this, Hpp11 
was demonstrated to produce its antihypertensive effect by reducing 
plasma ACE activity [22], confirming that as ACE inhibitor, such as 
Captopril, its effect is not mediated by opioid receptors and would be 
absorbed and transported to reach the cardiovascular system and to 
inhibit ACE [34].  
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4. Conclusions 
In the present study, it was demonstrated that AVFQHNCQE showed a 
high resistance to gastric digestion but it was totally hydrolysed to free 
amino acids after 60 min in the duodenum. In addition, this peptide did 
not cross through intestinal epithelium, indicating that AVFQHNCQE 
does not require its absorption to produce its BP-lowering effect. 
Indeed, it was demonstrated that the peptide produces its 
antihypertensive effect through their interaction with opioid receptors. 
Future studies are required to demonstrate its antihypertensive effect 
in humans. Nevertheless, this study represents a valuable contribution 
to clarify the mechanisms implicated in the antihypertensive effect of 
AVFQHNCQE.  
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TABLES 
  
     Table 1. In silico simulated digestion of the peptide AVFQHNCQE 
Original sequence Enzymea Digestion stage Final sequence 
AVFQHNCQE Pepsin Gastric  VFQHNCQE 
AVFQHNCQE Pepsin Gastric  AV 
AVFQHNCQE Pepsin Gastric  FQHNCQE 
VFQHNCQE Chymotrypsin Duodenal VF 
VFQHNCQE Chymotrypsin Duodenal QHNCQE 
QHNCQE Chymotrypsin Duodenal VFQH 
QHNCQE Chymotrypsin Duodenal NCQE 
VFQHNCQE Chymotrypsin Duodenal QHNCQE 
VFQHNCQE Chymotrypsin Duodenal FQHNCQE 
FQHNCQE Chymotrypsin Duodenal QHNCQE 
FQHNCQE Chymotrypsin Duodenal FQH 
FQHNCQE Chymotrypsin Duodenal NCQE 
FQHNCQE Chymotrypsin Duodenal QH 
FQHNCQE Chymotrypsin Duodenal NCQE 
In silico simulated digestion of peptide AVFQHNCQE using the bioinformatics tool, Peptide 
Cutter from Expasy®. 
a
 Pepsin and chymotrypsin were the enzymes that hydrolyzed the 
peptide in gastric and duodenal stage, respectively. Trypsin, lipase and colipase were also 
evaluated showing no effects on peptide hydrolysis.  
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Table 2. Identified sequences from in vitro digestion of the peptide 
AVFQHNCQE 
Peptide sequencea m/zb 
Mass 
monoisotopic 
(Da) 
RTc Charge Area D0d Area D60e 
AVFQHNCQE 538.233 1,074.451 4.86 2 5,236,186 13,652 
AVFQHNCQE(S-
S)AVFQHNCQE 
537.730 2,146.887 
5.24 
 
4 605,812 - 
AVF 336.191 335.183 5.83 1 200,712 - 
AVFQHNC 409.683 817.350 4.72 2 220,051 - 
AVFQHN 358.179 714.343 4.24 2 685,482 - 
AVFQHNCQE(S-
S)QHNCQE 
458.436 1,829.715 4.11 4 136,056 - 
AVFQH 301.158 600.300 4.34 2 155,533 - 
AVFQHNCQE(S-
S)CQE 
484.526 1,450.554 4.25 3 93,694 - 
QHNCQE 379.647 757.279 
1.23 
 
2 288,536 335,871 
NCQE 493.169 492.161 1.27 1 - 57,009 
a
 Amino acid residues are designated using their one letter codes. 
b m/z=mass-to-charge 
c RT= retention time 
d G60= samples from 60 min of gastric digestion 
e D60= samples from 60 min of duodenal digestion. 
 
SPE, plasma + solid phase extraction; TFA, plasma + trifluoroacetic acid; TFA + SPE, 
trifluoroacetic acid + solid phase extraction. a Average percent recovery of the 
peptides by the described method. b Repeatability (RSD—relative standard 
deviations—of peak response and retention time). 
 
 
 
 
 
 
      Table 3. Recovery and reproducibility of the evaluated extraction 
methods 
Method Rec. (%, n=3)a RSD (%, n=3)b 
SPE 92.4 2.5 
TFA 48.2 28.3 
TFA + SPE 37.8 26.5 
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Table 4. Transport of peptide and fragments from D0 through Caco-2 
monolayer 
Peptide sequencea m/zb 
Mass 
monoisotopic 
(Da) 
RTc Charge 
D0 % 
transportd 
AVFQHNCQE 538.233 1,074.451 4.86 2 0.25 
AVFQHNCQE(S-
S)AVFQHNCQE 
537.730 2,146.887 5.24 4 0.11 
AVF 336.191 335.183 5.83 1 0.15 
AVFQHNC 409.683 817.350 4.72 2 0.60 
AVFQHN 358.179 714.343 4.24 2 0.10 
AVFQHNCQE(S-
S)QHNCQE 
458.436 1,829.715 4.11 4 0.15 
AVFQH 301.158 600.300 4.34 2 0.17 
AVFQHNCQE(S-S)CQE 484.526 1,450.554 4.25 3 0.15 
QHNCQE 379.647 757.279 1.23 2 N.D 
NCQE 493.169 492.161 1.27 1 N.D 
a
 Amino acid residues are designated using their one letter codes. 
b m/z=mass-to-charge 
c RT= retention time 
d % transport:  percentage of the peptide or peptide fragments content found in 
basolateral chamber in comparison to the apical chamber content. D60= samples from 
60 min of duodenal digestion. 
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FIGURES 
 
Figure 1. Changes in systolic blood pressure (SBP) caused in 
spontaneously hypertensive rats after 6 h post-administration of the 
different treatments: oral administered water + intraperitoneal injected 
saline, oral administered water saline + intraperitoneal injected 3 
mg/kg bw Naloxone, oral administered water 10 mg/kg bw 
AVFQHNCQE + intraperitoneal injected saline or oral administered 
water 10 mg/kg bw AVFQHNCQE + intraperitoneal injected 3 mg/kg 
bw Naloxone. Data are expressed as the mean ± standard errors. The 
experimental groups always had six animals each. Different letters 
represent statistically significant differences (p < 0.05). P was 
estimated by one-way ANOVA. 
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Figure 2. Changes in systolic blood pressure (SBP) caused in 
spontaneously hypertensive rats after 6 h post-administration of the 
different treatments: oral administered water + intraperitoneal injected 
saline, oral administered saline + intraperitoneal injected 3 mg/kg bw 
Naloxone, oral administered 55 mg/kg Hpp11 + intraperitoneal injected 
saline or oral administered 55 mg/kg bw Hpp11 + intraperitoneal 
injected 3 mg/kg bw Naloxone. Data are expressed as the mean ± 
standard errors. The experimental groups always had six animals each. 
Different letters represent statistically significant differences (p < 
0.05). P was estimated by one-way ANOVA. 
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Figure 3. Changes in systolic blood pressure (SBP) caused in 
spontaneously hypertensive rats after 6 h post-administration of the 
different treatments: oral administered water + intraperitoneal injected 
saline, oral administered saline + intraperitoneal injected 3 mg/kg bw 
Naloxone, oral administered 50 mg/kg bw Captopril + intraperitoneal 
injected saline or oral administered 50 mg/kg Captopril + 
intraperitoneal injected 3 mg/kg bw Naloxone. Data are expressed as 
the mean ± standard errors. The experimental groups always had six 
animals each. Different letters represent statistically significant 
differences (p < 0.05). P was estimated by one-way ANOVA. 
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The link between the prevalence of diseases such as CVD or HTN 
to dietary factors has been extensively demonstrated through 
epidemiological evidence (1). Therefore, the use of bioactive compounds 
is emerging in response to the increased perception on the relationship 
between food and health (2). In this sense, dietary proteins have 
demonstrated that they could be considered a potential source of 
bioactive peptides with a wide range of biological activities (3). Among 
these bioactive peptides, those presenting antihypertensive activity 
have attracted great attention due to their potential beneficial effects 
related to HTN and CVD management (4).   
HTN, affecting more than 874 million adults worldwide (5), is the most 
common preventable risk factor for CVD and is considered the leading 
single contributor to all-cause mortality and disability worldwide (6). The 
relationship between high BP values and increased risk of CVD is graded 
and continuous. Thus, a successful prevention and treatment of HTN are 
key to reduce disease-derived problems and to promote longevity in the 
world’s population (7).  Depending on the HTN stage, the intervention 
ranges from lifestyle modifications to pharmacological therapy (8). 
However, the use of antihypertensive drugs, especially ACE-inhibitors, 
could be associated with several negative side effects in some patients 
(9). These undesirable effects lead to reduce patient compliance with 
treatment, increasing health care costs and preventable fatalities. 
Therefore, the research focused on the development of natural protein-
derived compounds that could alleviate or ameliorate HTN is receiving 
great attention (10).   
                                                 GENERAL DISCUSSION 
UNIVERSITAT ROVIRA I VIRGILI 
HYDROLYSATES AND PEPTIDES FROM CHICKEN FOOT PROTEINS TO MANAGE HYPERTENSION 
Anna Mas Capdevila 
 
270 
 
Certain dietary proteins, comprising those from vegetal and animal 
origin have been reported to be a source of bioactive peptides, including 
those with ACEI and antihypertensive activity. Accordingly, chicken 
proteins have been demonstrated to be a source of ACEI peptides and 
also antihypertensive peptides (11–13). Considering that tones of chicken 
by-products are generated every year, representing economic and 
environmental problem for the poultry industries, the obtainment of 
bioactive peptides from these chicken by-products has emerged as a 
potential alternative use of these products allowing to their 
revalorization (14). Indeed, some chicken by-products including skin (12), 
bone (15) or blood (16) have been reported to be a source of ACEI and 
antihypertensive peptides. However, as far as we know, chicken feet, 
also a poultry by-product, has never been used before. Considering this, 
chicken feet, subjected to specific proteolytic treatment, could be a 
source of peptides presenting ACEI activity and antihypertensive 
activity. Thus, the objective of this Thesis was to obtain and to identify 
from chicken feet proteins ACEI peptides presenting antihypertensive 
properties and to study the bioavailability and the mechanisms involved 
in the possible BP-lowering effect.  
Therefore, the first objective was to explore the use of chicken feet 
proteins to obtain hydrolysates with ACEI activity and antihypertensive 
activity under optimized hydrolysis conditions [Manuscript 1].  Thus, 
chicken feet processed into a powder, diluted in water and heated at 100 
ºC, was subjected to a hydrolysis procedure. Prior hydrolysis, since 
protein solubilisation is depending on pH, different conditions of this 
parameter were evaluated. Then, different hydrolysis conditions, 
including two enzymes (Neutrase and Protamex), two temperatures (25 
and 50 ºC) and different times were assayed. The ACEI activity was 
determined in the obtained hydrolysates as selection criteria for the best 
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hydrolysis conditions to obtain hydrolysates with ACEI activity higher 
than 90 %. It was observed that 50 ºC was the optimal temperature to 
obtain chicken foot protein hydrolysates presenting more than 90 % of 
ACE inhibition. Indeed, only the samples obtained at time 0 h of 
hydrolysis showed ACEI activity of less than 90 %. In fact, the 
pharmacology potency of these eighteen hydrolysates was 
demonstrated by their low IC50 values, similar than those reported for 
milk proteins currently commercialised as antihypertensive ingredients 
(17). However, since high in vitro ACEI activity does not correlate to in 
vivo antihypertensive activity (18), the evaluation of the in vivo 
antihypertensive effect in SHR is required. Hence, three hydrolysates 
obtained under different hydrolysis conditions and presenting the lowest 
IC50 values were administered to SHR at dose of 5 mL/kg body weight 
(bw). The evaluated hydrolysates showed antihypertensive effects after 
their administration to SHR. These results confirm the great 
antihypertensive potential of chicken feet proteins and could be used to 
formulate antihypertensive functional foods or nutraceuticals.  
Posteriorly, considering the therapeutic applicability of this chicken foot 
hydrolysate in HTN maintenance, a dose optimisation study was 
performed using the antihypertensive chicken foot hydrolysate 11 
(Hpp11), obtained after 2 h 50 ºC hydrolysis with protamex [Manuscript 
2]. Three different low doses 85, 55 and 25 mg/kg bw were administered 
to SHR to identify the dose with the maximum antihypertensive effect. 
Administered doses, 85 and 55 mg/kg, showed similar antihypertensive 
effect. Remarkably, both doses exhibited a BP decrease similar to that 
caused by the antihypertensive drug Captopril, confirming the great 
antihypertensive potential of Hpp11. Moreover, the dose of 55 mg/kg 
maintained the antihypertensive effect 8 h post-administration. On the 
other hand, a possible undesirable hypotensive effect of chicken foot 
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hydrolysate Hpp11 was rule out when administered to the normotensive 
control of SHR, WKY rats, linking Hpp11 effect to pathogenic state. 
Furthermore, it was demonstrated that Hpp11 competitively binds to 
ACE, a key enzyme in BP control. Other ACE inhibitory peptides, 
competitively block the binding of Ang I to ACE, thereby inhibiting the 
formation of Ang II and thus, reducing the vasoconstriction (19). In 
addition, Hpp11 reduced ACE activity in plasma, indicating that this can 
be the mechanism involved in Hpp11 antihypertensive effect. 
Nevertheless, it is known that antihypertensive peptides can reduce BP 
through other mechanisms than ACE inhibition. In this sense, the effect 
of Hpp11 on vascular reactivity was also studied in pre-contracted aortic 
rings preparations. However, Hpp11 did not produce vasorelaxation 
effect in aortic ring preparations. Therefore, these results confirmed that 
the optimal dose of chicken foot hydrolysate was 55 mg/kg, showing 
similar antihypertensive effect than this produced by Captopril and link 
the effect of this hydrolysate to the presence of HTN.   
Nevertheless, considering that HTN is a chronic disease requiring 
chronic treatment (20), we aimed to evaluate the antihypertensive effect 
of the long-term administration of Hpp11 in cafeteria-diet-fed rats 
[Manuscript 3]. This dietary model is an exceptional tool to study MetS 
(21) including diet-induced HTN (22). Agreeing to previous reported, in 
this study, after 8 weeks of CAF diet rats developed diet-induced HTN. 
Since 9th week and for 3 weeks rats fed CAF diet received a daily oral 
dose of Hpp11 (55 mg/kg bw) which was able to decrease BP since the 
first week of administration. Contrary, the untreated rats increased BP 
as CAF diet weeks progressed. Remarkably, at the end of the 
experiment, Hpp11 produced an important decrease in BP of -20 mmHg 
compared to the untreated group. These results confirm the potent 
antihypertensive effect of Hpp11 and their benefits in CVD, considering 
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that, a reduction of 10-12 mmHg in SBP may reduce the risk of stroke by 
40 %, coronary heart disease by 16 % and all-cause mortality by 13 % 
(23). Other protein hydrolysates reported antihypertensive effect after 
long-term administration in SHR (24,25) nevertheless, to our knowledge, 
this is the first study demonstrating the antihypertensive effect of a 
protein hydrolysate in CAF-diet fed rats. These results are relevant 
considering that CAF-diet fed rats, such as most HTN patients, present 
besides of HTN, the associated cardiometabolic risk factors. Thus, Hpp11 
antihypertensive effect in this animal model open doors to the use of this 
hydrolysate in diet-induced HTN management.  
Interestingly, long-term administration of Hpp11 not only induced 
antihypertensive effect but also demonstrated to exert antioxidant effect 
by enhancing the production of GSH, a key antioxidant system that 
reduces oxidative stress by removing ROS (26). The antioxidant effects 
of certain proteins were already known (27,28). Indeed, antioxidant 
effect of Hpp11 could be involved in the observed BP reduction 
considering that no changes were observed in plasmatic ACE activity. 
Additionally, it seems that the reduction in mRNA expression of the 
vasoconstrictor ET-1 and the increase in mRNA expression of Sirt-1, 
enhancer of NO availability, could contribute to the beneficial effect of 
Hpp11 in diet-induced hypertensive rats improving endothelium 
functionality. In addition, mRNA expression of NOX4 was found 
increased in CAF-diet rats administered Hpp11. This upregulation of 
NOX4 was linked to NOX4 vasoprotective effects considering that 
healthy rats fed STD diet showed similar mRNA expression levels of this 
parameter. NOX4 overexpression could contribute to improve the 
endothelium through enhancing NO bioavailability (29). Therefore, these 
results demonstrated that Hpp11 administered during 3 weeks reduced 
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BP through exerting antioxidant effect and conferring endothelial 
vasoprotective pattern in diet-induced hypertensive rats.  
Considering the previous result,  it was demonstrated that the hydrolysis 
of chicken foot proteins under optimised hydrolysis conditions resulted 
in the obtainment of antihypertensive hydrolysates including the Hpp11. 
In the following study we aimed to identify those antihypertensive 
peptides contained in chicken foot hydrolysate Hpp11 [Manuscript 4]. 
Thus, Hpp11 was subjected to peptide separation according to molecular 
size and hydrophobicity by ultrafiltration and RP-HPLC. The posterior 
selection according to the exerted ACEI allowed to identify the 
hydrolysate fractions presenting the highest ACEI activity. Then, peptide 
identification by HPLC-MS in the fractions showing the high ACEI 
activity resulted in the obtainment of 1020 identified peptides. 
According to their intensity, size and/or sequence eight peptides were 
selected to be synthetized and five of them showed high ACEI activity, 
lower than 100 µM. Interestingly, two of the identified peptides, the 
sequences AVFQHNCQE and QVGPLIGRYCG, also showed 
antihypertensive effect when administered at low dose of 10 mg/kg bw 
to SHR, suggesting that those peptides could be involved in Hpp11 
antihypertensive effect. Interestingly, the antihypertensive effect of 
peptides derived from other chicken proteins was previously reported, 
however the administered doses were very variable, ranging from 10 
mg/kg to 60 mg/kg to obtain similar BP decrease (15,30). Although other 
identified peptides in Hpp11 showed high ACEI activity than the peptide 
AVFQHNCQE, this peptide was also demonstrated to present 
antihypertensive effect. These findings demonstrate that high in vitro 
ACE inhibitory activity does not always correlates to potent 
antihypertensive effect.  
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In order to evaluate the participation of endothelial-related relaxing 
factors the peptide antihypertensive effect different experiments were 
carried out. In this sense, to evaluate if peptide antihypertensive effect 
was dependent of the vasodilators NO or PGI2, AVFQHNCQE 
antihypertensive effect was studied in SHR also peritoneal injected L-
NAME, inhibitor of NO synthesis, or indomethacin, inhibitor of COX, the 
main responsible of PGI2 synthesis. It was demonstrated that 
AVFQHNCQE produced NO-mediated antihypertensive considering that 
in presence of L-NAME, the peptide antihypertensive effect 
disappeared. This result demonstrated that the vasodilation of the 
vessels induced by NO could be the mechanism underlying the 
antihypertensive effect of the peptide [Manuscript 5]. According with 
that, when it was evaluated the plasmatic ACE activity in the group 
administered the peptide no significant reduction was found, showing 
similar ACE activity values than the group that received water 
demonstrating that ACE inhibition is not involved in peptide BP- 
lowering effect. NO-mediated antihypertensive effect was previously 
reported for antihypertensive peptides (31), especially in those peptides 
showing opioid properties (32) which do not require to be absorbed to 
produce their effects (33). Indeed, in a posterior study evaluating the 
peptide bioavailability in plasma and its transepithelial transport through 
Caco-2 monolayer it was observed that AVFQHNCQE was not absorbed 
through intestinal epithelium [Manuscript 6]. Therefore, the implication 
of the opioid receptors in the peptide antihypertensive effect was 
studied in presence of Naloxone, an opioid receptor antagonist. The 
results showed that in the animals receiving Naloxone, the 
AVFQHNCQE BP-lowering effect disappeared, evidencing that the 
interaction with opioid receptors was crucial to exert an 
antihypertensive effect. In fact, opioid receptors have been described in 
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the GIT (34) and it is extensively demonstrated that their activation could 
interfere in BP regulation (35). Thus, the stimulation of opioid receptors 
by AVFQHNCQE in GIT, without requiring its absorption, could enhance 
NO bioavailability and thus, induce vasodilation and consequently 
reduce BP.  
To evaluate the molecular mechanisms involved in the NO-mediated 
antihypertensive effect of AVFQHNCQE, the implication of endothelial 
genes related to NO-production pathway were evaluated. Nevertheless, 
no significant changes were observed neither in mRNA expression of NO 
producer (eNOS) nor in mRNA expression of NO inducers (Sirt-1, KLF-2 
and Arg-1). Hence, only a decrease in vasocontrictior ET-1 and in NOX4 
was observed leading to an increase NO availability considering that ET-
1 also inhibits NO production and NOX4 in SHR is clearly related with an 
increase in ROS production (36) [Manuscript 5]. Therefore, an 
improvement in endothelial function by reducing ET-1 and NOX4 
expression and thus, increasing NO bioavailability, could be the 
mechanisms underlying the NO-mediated antihypertensive effect of 
AVFQHNCQE.  
Considering all the results of this Thesis, it was demonstrated that the 
hydrolysis of chicken foot proteins under the optimal hydrolysis 
conditions resulted in the release of antihypertensive peptides. Chicken 
foot protein hydrolysate Hpp11 reduced BP after acute administration of 
a low dose of 55 mg/kg. As expected, considering that Hpp11 was 
selected according to their in vitro ACEI activity, it was demonstrated 
that in vivo reduction of plasmatic ACE and the exerted antioxidant 
effect are the main mechanisms involved in Hpp11 acute 
antihypertensive effect. Furthermore, it was demonstrated that its effect 
was linked to the presence of pathogenic state, being not observed in 
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WKY. In addition, long-term administration of Hpp11 presented 
antihypertensive effect in diet model of HTN conferring a vasoprotective 
endothelial pattern. The long-term antihypertensive effect produced by 
Hpp11, reaching a decrement of -18 mmHg when compared to untreated 
group could be directly associated with a reduction in major CVD events 
(37). Therefore, Hpp11 could be a potential alternative in HTN treatment. 
The posterior analysis by HPLC-MS in the Hpp11 most active fractions 
allowed the identification of antihypertensive peptides, including the 
peptide AVFQHNCQE.  
It was demonstrated that the NO-mediated antihypertensive 
AVFQHNCQE produced after acute administration when administered 
to SHR, and this effect is mediated through their interaction with opioid 
receptors in GIT. Opioid peptides do not require its absorption to 
produce their effect (33), this could explain the antihypertensive effect 
of AVFQHNCQE even demonstrated that it was not absorbed. NO-
mediated antihypertensive effect could be explained by the antioxidant 
effect produced by the peptide, reducing NO scavenging and also, by an 
improvement in the endothelial function. The reduction in ET-1 and 
NOX4 expression could contribute to the NO increase considering that 
ET-1 inhibits NO synthesis and NOX4 is known as ROS producer in SHR. 
The present findings clearly indicate that in SHR, AVFQHNCQE 
activates an opioid-mediated, cardiovascular depressor mechanism; 
however, further studies are needed to elucidate which type of opioid 
receptors are activated by AVFQHNCQE and how this opioid-mediated 
activity enhances NO availability and thus, produce the BP reduction. 
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1. The hydrolysis of chicken foot proteins under optimized 
conditions (2 h, 50 ºC, pH=7 hydrolysis with Protamex) results in 
the obtaining of hydrolysates with antihypertensive properties.   
2. The most effective dose of chicken foot hydrolysate Hpp11 was 
55 mg/kg bw showing the maximum antihypertensive effect 6 h 
post-administration to SHR. The BP decrease pattern observed 
in rats administered peptide was similar than the observed in the 
group administered the antihypertensive drug Captopril.  
3. Chicken foot hydrolysate Hpp11 (55 mg/kg bw) did not reduced 
BP in WKY, the normotensive control of the SHR. Therefore, 
Hpp11 effect is linked to hypertension condition.  
4. The reduction of ACE activity was the mechanism underlying 
the chicken foot hydrolysate Hpp11 antihypertensive effect after 
its acute administration. 
5. Long-term administration of chicken foot hydrolysate Hpp11 (55 
mg/kg bw) significantly reduced BP in diet-induced 
hypertensive rats.  
6. Chicken foot hydrolysate Hpp11 reduced BP in diet-induced 
hypertensive rats through exhibiting antioxidant effect and 
improving endothelial function, enhancing the expression of 
Sirt-1 and NOX4 and decreasing the expression of ET-1. 
7. AVFQHNCQE and QVGPLIGRYCG, were the antihypertensive 
peptides identified in chicken foot hydrolysate Hpp11.  
8. AVFQHNCQE produced a NO-mediated antihypertensive effect. 
AVFQHNCQE contributed to enhance NO availability by 
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exhibiting antioxidant effect and reducing the expression of NO 
scavengers, such as ET-1 and NOX4.  
9. AVFQHNCQE produced its antihypertensive effect through the 
interaction with opioid receptors and therefore, its absorption 
through the intestinal epithelium was not required. 
The hydrolysis of chicken foot proteins under optimized conditions is a 
good strategy for the obtainment of antihypertensive hydrolysates and 
peptides. One of the obtained hydrolysates, the Hpp11, reduced BP after 
its acute and chronic administration by reducing ACE activity and by 
improving endothelial function. The antihypertensive peptides identified 
in Hpp11, QVGPLIGRYCG and AVFQHNCQE, which was demonstrated 
to exert its effect through the interaction with opioid receptors in GIT, 
could contribute to Hpp11 antihypertensive effect.   
Thus, the obtained antihypertensive hydrolysate and peptides could be 
good candidates to be used as nutraceuticals or to be included in a 
functional food for the mitigation and the prevention of HTN.  
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Hypertension is considered one of the most important public health 
problems in our society. The treatment of this pathology is based 
on lifestyle modifications and pharmacology treatment. However, 
for those patients developing hypertension, whose blood pressure 
is not high enough to warrant pharmacology treatment, the use 
nutraceuticals or functional foods with antihypertensive properties 
have attracted considerable interest as good strategy to avoid the 
development of hypertension.
In this regard, this thesis aims to obtain antihypertensive peptides 
through the hydrolysis of chicken foot proteins, a by-product 
from poultry industries. Thus, through the hydrolysis of chicken 
foot proteins, it was obtained an hydrolysate, Hpp11, exerting 
antihypertensive effect after acute and chronic administration. 
Hpp11 administered acutely produced antihypertensive effect by 
reducing the activity of angiotensin converting enzyme, while when 
administered chronically the antihypertensive effect was mediated 
by an improvement in the endothelial function. Additionally the 
peptides contained in Hpp11 were characterised and two of them, 
AVFQHNCQE and QVGPLIGRYCG, showed antihypertensive effect. 
In particular, the peptide AVFQHNCQE was not absorbed and 
produced its antihypertensive effect through the interaction with 
opioid receptors from the gastrointestinal tract. The interaction with 
those receptors leaded to a nitric oxide-mediated antihypertensive 
effect. Moreover, the peptide contributed to enhance nitric oxide 
by exhibiting antioxidant effect and improving endothelial function. 
The results of this thesis open the doors to the use of the 
antihypertensive hydrolysate and peptides in functional foods or 
nutraceuticals for the control and prevention of hypertension.
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